---
document_datetime: 2023-09-21 18:54:13
document_pages: 74
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/toujeo-h-c-309-x-0079-g-epar-assessment-report-variation_en.pdf
document_name: toujeo-h-c-309-x-0079-g-epar-assessment-report-variation_en.pdf
version: success
processing_time: 66.7857195
conversion_datetime: 2025-12-17 22:39:46.944865
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

26 February 2015 EMA/157145/2015 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Toujeo

International non-proprietary name:

insulin glargine

Procedure No. EMEA/H/C/000309/X/0079/G

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................5                                  |                                                                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier .....................................................................................5       |                                                                                                         |
| 1.2. Steps taken for the assessment of the product                                                                          | ........................................................5                                               |
| 2. Scientific discussion ................................................................................7                  |                                                                                                         |
| 2.1. Introduction ........................................................................................................7 |                                                                                                         |
| 2.2. Quality aspects....................................................................................................8   |                                                                                                         |
| 2.2.1. Introduction                                                                                                         | .....................................................................................................8  |
| 2.2.2. Active Substance...............................................................................................8     |                                                                                                         |
| 2.2.3. Finished Medicinal Product..................................................................................8        |                                                                                                         |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects                                                        | ...............................9                                                                        |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                   | ........................9                                                                               |
| 2.3. Non-clinical aspects..............................................................................................9    |                                                                                                         |
| 2.3.1. Introduction, Pharmacology and Pharmacokinetics ................................................9                    |                                                                                                         |
| 2.3.2. Toxicology......................................................................................................     | 10                                                                                                      |
| 2.3.3. Ecotoxicity/environmental risk assessment.........................................................                   | 10                                                                                                      |
| 2.3.4. Discussion on non-clinical aspects .....................................................................             | 10                                                                                                      |
| 2.3.5. Conclusion on the non-clinical aspects ...............................................................               | 10                                                                                                      |
| 2.4. Clinical aspects..................................................................................................     | 10                                                                                                      |
| 2.4.1. Introduction ...................................................................................................     | 10                                                                                                      |
| 2.4.2. Pharmacokinetics ............................................................................................        | 12                                                                                                      |
| 2.4.3. Pharmacodynamics..........................................................................................           | 14                                                                                                      |
| 2.4.4. Discussion on clinical pharmacology ..................................................................               | 16                                                                                                      |
| 2.4.5. Conclusions on clinical pharmacology.................................................................                | 16                                                                                                      |
| 2.5. Clinical efficacy..................................................................................................    | 17                                                                                                      |
| 2.5.1. Main studies ...................................................................................................     | 17                                                                                                      |
| 2.5.2. Discussion on clinical efficacy............................................................................          | 48                                                                                                      |
| 2.5.3. Conclusions on the clinical efficacy ....................................................................            | 54                                                                                                      |
| 2.6. Clinical safety                                                                                                        | .................................................................................................... 54 |
| 2.6.1. Discussion on clinical safety..............................................................................          | 65                                                                                                      |
| 2.6.2. Conclusions on the clinical safety ......................................................................            | 66                                                                                                      |
| 2.7. Pharmacovigilance                                                                                                      | ............................................................................................. 67        |
| 2.8. Risk Management Plan........................................................................................           | 67                                                                                                      |
| 2.9. Product information............................................................................................        | 69                                                                                                      |
| 2.9.1. User consultation                                                                                                    | ............................................................................................ 69         |
| 3. Benefit-Risk Balance                                                                                                     | .............................................................................69                         |
| 4. Recommendations.................................................................................73                       |                                                                                                         |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| AE            | adverse event                                                                                                          |
|---------------|------------------------------------------------------------------------------------------------------------------------|
| AHA           | antihyperglycaemic agents                                                                                              |
| AIA           | anti-insulin antibody                                                                                                  |
| ATC           | anatomical therapeutic chemical                                                                                        |
| BG            | blood glucose                                                                                                          |
| BMI           | body mass index                                                                                                        |
| CGM           | continuous glucose monitoring                                                                                          |
| CHMP          | Committee for Medicinal Products for Human Use                                                                         |
| CI            | confidence interval                                                                                                    |
| CV            | cardiovascular                                                                                                         |
| DCCT          | Diabetes Control and Complications Trial                                                                               |
| DTSQs         | Diabetes Treatment Satisfaction Questionnaire (status)                                                                 |
| e-CRF         | electronic case report form                                                                                            |
| EMA           | European Medicines Agency                                                                                              |
| FDA           | Food and Drug Administration                                                                                           |
| FPG           | fasting plasma glucose                                                                                                 |
| GCP           | Good Clinical Practice                                                                                                 |
| GFR           | glomerular filtration rate                                                                                             |
| GIR-AUC 0-24h | area under the body weight standardized glucose infusion rate versus time curve from time zero to 24 hours post dosing |
| GIR-AUC 0-36h | area under the body weight standardized glucose infusion rate versus time curve from time zero to 36 hours post dosing |
| GIR max       | maximum glucose infusion rate                                                                                          |
| GLP-1         | glucagon-like peptide-1                                                                                                |
| ICH           | International Conference on Harmonization                                                                              |
| IMP           | investigational medicinal product                                                                                      |
| IND           | Investigational New Drug                                                                                               |
| INS-AUC 0-24  | area under the serum insulin glargine concentration versus time curve from time zero to 24 hours post dosing           |
| INS-AUC 0-36  | area under the serum insulin glargine concentration versus time curve from time zero to 36 hours post dosing           |
| IVRS/IWRS     | interactive voice/web response system                                                                                  |
| LC-MS/MS      | liquid chromatography tandem mass spectrometry                                                                         |

<div style=\"page-break-after: always\"></div>

| LOCF   | last observation carried forward                 |
|--------|--------------------------------------------------|
| LS     | least square                                     |
| MDRD   | modification of diet in renal disease formula    |
| MedDRA | Medical Dictionary for Regulatory Activities     |
| MMRM   | mixed model for repeated measurements            |
| NDA    | New Drug Application                             |
| NGSP   | National Glycohemoglobin Standardization Program |
| NIMP   | non-investigational medicinal product            |
| NPH    | neutral protamine Hagedorn                       |
| OAD    | oral antihyperglycaemic drug                     |
| PCSA   | potentially clinically significant abnormality   |
| PD     | pharmacodynamic                                  |
| PK     | pharmacokinetic                                  |
| PSP    | Paediatric Study Plan                            |
| PT     | preferred term                                   |
| RR     | relative risk                                    |
| SAE    | serious adverse event                            |
| SE     | standard error                                   |
| SHRB   | Severe Hypoglycaemia Review Board                |
| SMPG   | self-monitored plasma glucose                    |
| SMQ    | standardized MedDRA query                        |
| SOC    | system organ class                               |
| SUSAR  | suspected unexpected serious adverse reaction    |
| T1DM   | type 1 diabetes mellitus                         |
| T2DM   | type 2 diabetes mellitus                         |
| TEAE   | treatment-emergent adverse event                 |
| U100   | Insulin glargine 100 U/ml (HOE901-U100 )         |
| U300   | Insulin glargine 300 U/ml (HOE901-U300)          |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Sanofi-aventis Deutschland GmbH submitted to the European Medicines Agency on 25 April 2014 an extension of the existing marketing authorisation of Optisulin to register an additional form 300 units/ml grouped with a Type IAIN variation to change the invented name from Optisulin to Toujeo.

The applicant applied for an addition of a new strength/potency (300 units/ml), grouped with a change in the (invented) name of the medicinal product (Toujeo). The applicant applied initially for the following indication for the new strength/potency: Treatment of diabetes mellitus in adults.

## The legal basis for this application refers to:

Annex I of Regulation (EC) No 1234/2008, point (c) - Extensions of marketing authorisations

Article 7.2 of Commission Regulation (EC) No 1234/2008 - Group of variations

## Information on Paediatric requirements

Not applicable

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000,  the  applicant  did  not  submit  a  critical  report  addressing  the  possible  similarity  with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific Advice

The applicant did not seek scientific advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Pieter de Graeff

Co-Rapporteur:   Kristina Dunder

CHMP Peer reviewer: n/a

- The application was received by the EMA on 25 April 2014.
- The procedure started on 28 May 2014.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 15 August 2014. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 18 August 2014.
- PRAC RMP Advice and assessment overview adopted by PRAC on 11 September 2014
- During the meeting on 25 September 2014, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the

<div style=\"page-break-after: always\"></div>

applicant on 26 September 2014.

- The applicant submitted the responses to the CHMP consolidated List of Questions on 20 November 2014.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 30 December 2014.
- PRAC RMP Advice and assessment overview adopted by PRAC on 9 January 2015.
- During the CHMP meeting on 22 January 2015, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant.
- The applicant submitted the responses to the CHMP List of Outstanding Issues on 26 January 2015.
- PRAC RMP Advice and assessment overview adopted by PRAC on 12 February 2015.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 11 February 2015.
- During the meeting on 26 February 2015, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting an extension of the Marketing Authorisation for Toujeo.

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## Background

Diabetes  mellitus  is  a  chronic  disease  characterized  by  hyperglycaemia  from  defects  in  insulin secretion, insulin action, or both.

Type 1 diabetes mellitus (T1DM) usually begins at a young age (&lt;20 years) and is mainly due to autoimmune destruction of the pancreatic ß-cells that produce insulin. As a result, patients  with T1DM require lifelong insulin supplementation for survival.

In type 2 diabetes mellitus (T2DM),, the most common form of diabetes accounting for over 90% of all diabetes cases , the combined impact of impaired insulin secretion and insulin resistance results in elevated blood glucose (BG) levels. Due to the latter, hyperglycaemia may prevail despite plasma insulin  levels  exceeding  those  in  non-diabetic  individuals.  Treatment  initially  involves  changes  in lifestyle (diet, exercise), with oral antihyperglycaemic drugs (OADs) added as necessary to maintain adequate BG control. Other injectable therapeutic agents, such as the glucagon-like peptide-1 (GLP-1) receptor agonists may be an option before or in addition to insulin in some patients. Ultimately, due to  the  progressive β-cell  failure  in  T2DM,  insulin  replacement  is  indicated in  patients  to  manage hyperglycaemia. As many patients with T2DM maintain some residual endogenous insulin secretion, the insulin treatment regimen in T2DM may be less complex than in T1DM .

It has been established in T1DM and T2DM that uncontrolled, high levels of BG are a factor for chronic microvascular  and  macrovascular  complications  that  can  result  in  retinopathy,  nephropathy, neuropathy and premature cardiovascular (CV) morbidity and mortality. Studies have shown that improving the control of BG levels in both T1DM , and T2DM  reduces the risk of these complications.

## About the product

Insulin is the most effective available glucose-lowering treatment. Insulin preparations differing both in their time of onset and duration of action are available for insulin substitution therapy. Of the different  therapeutic  options,  basal-bolus  regimens  try  to  closely  mimic  physiological  insulin concentrations by injections of long-acting insulin products for basal insulin supply (comprising insulin glargine,  insulin  detemir,  degludec      or  human  insulin  [neutral  protamine  Hagedorn-insulin; NPH-insulin]) and premeal (bolus) injections of short- or short- and rapid-acting insulin products (comprising human insulin or human insulin analogues aspart, lispro or glulisine). The combined time-action profiles of the basal insulin dose(s) and the short-acting insulin products are to match fasting  and  prandial  glucose  load;  inappropriately  high  or  low  insulin  levels  may  lead  to hypoglycaemia or hyperglycaemia.

Insulin glargine is a recombinant analogue of human insulin.

Toujeo (Insulin glargine 300 U/mL, HOE901-U300 in this document: U300).) is indicated in diabetes mellitus where treatment with insulin is required. U300 has the same composition as Lantus and Optisulin, which were the commercial formulations of insulin glargine 100 U/mL available when the studies included in this dossier were performed, except for adjustment of 3 times the amount of active pharmaceutical ingredient and corresponding zinc content.

Insulin  glargine  as  Lantus  [EMEA/H/C/000284]  and  Optisulin  [EMEA/H/C/000309]  has  been authorised in the EU since June 2006. The efficacy and safety of insulin glargine are well known through  extensive  data  collection  involving  over  200  000  patients  included  in  clinical  trials  and observational studies.

<div style=\"page-break-after: always\"></div>

In  the  subsequent  text  insulin  glargine  100  U/mL  is  also  referred  to  as  U100  or  as  Lantus  (a commercial formulation of insulin glargine 100 U/mL available when the studies included in this dossier were performed).

## 2.2. Quality aspects

## 2.2.1. Introduction

The U300 pen injector is a multiple-dose, disposable insulin pen injection system for single patient use. Insulin  glargine  is  available  as  solution  for  injection  containing  10.91  mg/mL  insulin  glargine [equivalent  to  300  U  (units)  of  insulin  glargine/mL].  The  finished  product  is  to  be  administered subcutaneously. The total content of the 1.5 ml cartridge is 450 insulin units. The injection system provides a maximum of 80 units in one dosing. The dose for injection is adjusted in 1U increments.

## 2.2.2. Active Substance

## General information

Insulin glargine, is a known active substance used for the approved solution for injection containing 100 U/mL. No further data was provided regarding the active substance for this line extension application as the active substance has been approved for manufacturing 100 U/mL solution for injection finished product preparations. The active substance used in this formulation is of the same quality as that used for the manufacture of the already approved 100 U/mL solution for injection, thus no new information or assessment is required.

## 2.2.3. Finished Medicinal Product

## Description of the product and pharmaceutical development

The 300U pen contains 1.5 mL of solution for injection, which is equivalent to 450 Units (450U is indicated on the pen). Each mL contains 300 Units insulin glargine (equivalent to 10.91 mg).

The registered Insulin glargine 100U/mL solution for injection is a 3 mL cartridge containing 100U/mL. Compared to the 100U/mL presentation, the 300U/mL presentation contains a threefold amount of insulin glargine as well as a threefold amount of zinc chloride per mL.  The amounts of other excipients are similar to the 100U/mL composition.

The insulin glargine finished product is contained in a sealed cartridge assembled into a pen injector. The pen injector is operated fully mechanically and does not contain electronics. The construction of the U300 pen injector is based on SoloStar®, an insulin injection device which is marketed world-wide by Sanofi since 2007.

## Manufacture of the product and process controls

The manufacturing process and the process controls correspond to those approved for the marketed insulin glargine solution for injection 100 U/mL process. During development only minor changes were made in the manufacturing procedure to adapt the process to the scaled up batch sizes. The presentation was changed from a 3 mL to a 1.5 mL cartridge.

The manufacturing process is described in detail.  The critical process controls in place are deemed sufficient.

No animal and/or human derived material is used. No novel excipients are used.

## Product specification

Overall  the  finished  product  is  considered  sufficiently  controlled.  The  analytical  procedures  are sufficiently described and appropriately validated.

<div style=\"page-break-after: always\"></div>

The end of shelf life specifications are brought in line with the specifications for the 100U/ml presentation.

## Stability of the product

Overall the stability (and in-use stability) of Insulin Glargine (300U/ml) filled in the 1.5 ml cartridge has been sufficiently demonstrated for its intended use. The stability data provided supports the proposed shelf life of 30 months at +2°C to 8°C and an in-use period of 4 weeks at up to 30°C.

## Adventitious agents

No materials of human or animal origin are used during manufacture. There is no viral safety risk since  the  same  active  substance  is  used  as  for  the  approved  insulin  glargine  100U/mL  and  the manufacturing process and the process controls of the insulin glargine 300 U/mL correspond to insulin glargine 100U/mL.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on composition, pharmaceutical development and manufacture has been presented in a satisfactory manner.

Compared to  the  registered  100U/mL  insulin  glargine  presentation,  the  300U/mL  line  extension contains a threefold amount of insulin glargine as well as a threefold amount of zinc chloride per mL. The amounts of other excipients remain the same. No further development has been performed.

The  manufacturing  process  is  deemed  sufficiently  described  and  validated.  Overall,  the  finished product is well controlled. The list of specification tests, their limits and justifications, the validation of the methods as well as the characterization of impurities are considered appropriate.

The company presents the 300U pen injector as a 1U-80U dosing system and the accuracy of the 1U-80U dosing is suited for its purpose.

Overall the stability (and in-use stability) of Insulin Glargine (300U/mL) filled in the 1.5 mL cartridge is sufficiently demonstrated for its intended use. The results generated during the stability studies support the proposed shelf life and storage conditions as defined in the SmPC.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

Overall,  information  on  development,  manufacture  and  control  of  the  finished  product  has  been presented in a satisfactory manner. The results of tests carried out indicate satisfactory consistency and uniformity of important quality characteristics.

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC.

## 2.3. Non-clinical aspects

## 2.3.1. Introduction, Pharmacology and Pharmacokinetics

Given the drug substance is the same in HOE901-U100 formulation and HOE901-U300 formulation, the  nonclinical  profile  of  insulin  glargine  has  been  well  characterized.  Therefore,  no  additional nonclinical studies were performed with the HOE901-U300 formulation, except for a local tolerance study.

<div style=\"page-break-after: always\"></div>

## 2.3.2. Toxicology

## Local Tolerance

Both HOE901 formulations (100 U/mL and 300 U/mL), did not cause any local effects at the injection sites different from saline solution-treated injection sites. The U300 formulation showed the same good local tolerability as the U100 formulation following subcutaneous administration, which is the intended route of clinical use. Following intramuscular, intravenous and paravenous administration, representing the potential false administration routes, also a good tolerability was seen.

## 2.3.3. Ecotoxicity/environmental risk assessment

Insuline glargine is a protein which will rapidly be degraded in the environment.

Furthermore,  insulin  glargine  is  already  used  in  existing  marketed  products  and  no  significant increase in environmental exposure is anticipated, since patients who switch to a different strength will not start using more insulin glargine.

Therefore insulin glargine is not expected to pose a risk to the environment.

## 2.3.4. Discussion on non-clinical aspects

Repeat-dose toxicity of insulin glargine (HOE901-U100) has been studied in the mouse (up to 20 U/kg/day), rat (up to 50 U/kg/day) and dog (up to 5 U/kg/day) previously. The carcinogenic potential was  evaluated  up  to  12.5  U/kg/day  in  mice  and  rats.  In  all  studies  HOE901  was  administered subcutaneously.  In  all  species  the  toxicological  profile  was  dominated  by  the  exaggerated pharmacological, blood glucose lowering activity of HOE901. Since the drug substance is the same for both formulations, HOE 901-U100 and HOE901-U300, no differences in the nonclinical profile are expected for HOE901-U300.

Given the drug substance is the same in HOE901-U100 formulation and HOE901-U300 formulation, the nonclinical profile of insulin glargine has been well characterized. Because there is already a wealth of human safety experience, the applicant believes that the results of the nonclinical studies conducted with HOE901-U100 and submitted to the original marketing authorization applications and subsequent  submissions  for  the  authorized  product  also  apply  to  HOE901-U300.  Therefore,  no additional nonclinical studies were performed or are planned with the HOE901-U300 formulation, which was found to be acceptable.

The additional evaluation of local tolerability in one dedicated study conducted in rabbits with the HOE901-U300 formulation to compare this formulation with the HOE 901-U100 formulation was considered to be sufficient by CHMP to complete the nonclinical program for insulin glargine and to support the use of the HOE901-U300 formulation in patients.

## 2.3.5. Conclusion on the non-clinical aspects

From  a  non-clinical  point  of  view  there  were  no  objections  against  extending  the  Marketing Authorisation of the product.

## 2.4. Clinical aspects

## 2.4.1. Introduction

In  the  subsequent  text,  insulin  glargine  100  U/mL  is  also  referred  to  as  U100  or  as  Lantus  (a commercial formulation of insulin glargine 100 U/mL available when the studies included in this dossier were performed).

<div style=\"page-break-after: always\"></div>

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The  applicant  has  provided  a  statement  to  the  effect  that  clinical  trials  conducted  outside  the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

In the HOE901-U300 clinical development program, a total of 1686 patients received at least one dose of U300, 1546 patients were randomized and treated with U300 in the 6-month main study periods of the Phase 3 studies and the 16-week exploratory Phase 2 study.

Table 1- Number of subjects/patients who received at least 1 dose of study treatment (all completed studies)

| Phase / Study                 | Treatment duration   | U300   | U100(Lantus)   | Total   |
|-------------------------------|----------------------|--------|----------------|---------|
| Phase 1 program               |                      |        |                |         |
| Healthy subjects              |                      | 23     | 24             | 24      |
| T1DM                          |                      | 140    | 91             | 142     |
| Total Phase 1                 |                      | 163    | 115            | 166     |
| Phase 2/3 program             |                      |        |                |         |
| Studies in T1DM               |                      |        |                |         |
| PDY12777                      | 16 weeks             | 30     | 29             | 59      |
| EFC12456                      | 6 months             | 274    | 275            | 549     |
| Total T1DM                    |                      | 304    | 304            | 608     |
| Studies in T2DM               |                      |        |                |         |
| EFC11628                      | 6 months             | 404    | 402            | 806     |
| EFC11629                      | 6 months             | 403    | 406            | 809     |
| EFC12347                      | 6 months             | 435    | 438            | 873     |
| Total T2DM                    |                      | 1242   | 1246           | 2488    |
| Total Phase 2/3 T1DM and T2DM |                      | 1546   | 1550           | 3096    |

A total of 6 Phase 1 studies were performed with HOE901-U300 providing clinical pharmacology data in this submission; see Table 2. One single-dose study (PKD10086) was conducted in healthy subjects and  2  single-dose  studies  (PKD11627,  PKD12270)  and  3  multiple  dose  studies  (TDR11626, PDY12335,  and  PKD13560)  were  conducted  in  patients  with  T1DM.  All  studies  employed  the euglycaemic clamp technique, except PDY12335 which used CGM.

Study PKD10086 examined the bioequivalence and equivalent bioefficacy of the insulin glargine 300 U/mL (U300) and 100 U/mL formulations in 24 healthy male and female subjects following 2 single SC doses of 0.4 U/kg in a crossover design.

Study TDR11626 investigated the safety and tolerability of 8-day repeated dose regimens at 2 dose levels of U300 (0.4 and 0.6 U/kg/day) and compared their PD and PK properties to those of U100 (0.4

<div style=\"page-break-after: always\"></div>

U/kg/day) in a crossover euglycaemic clamp setting in steady state conditions, at the end of each treatment period, in 30 patients with T1DM.

Study PKD11627 investigated the glucodynamic activity and exposure of 3 different single SC doses of U300 (0.4 [T1], 0.6 [T2], and 0.9 [T3] U/kg) versus a standard dose of 0.4 U/kg U100 as comparator (R) in a crossover euglycaemic clamp setting in 24 male and female patients with T1DM.

Study  PKD13560  was  a  double-blind,  randomized,  2-treatment  crossover  bioequivalence  study comparing 2 different formulations of U300, using the euglycaemic clamp technique, in 50 patients with T1DM.

Study PKD12270 investigated the metabolic effects, the exposure to insulin glargine and the safety and tolerability of single SC doses of U300 in 18 Japanese T1DM patients. Two different SC doses of U300 (0.4 [T1] and 0.6 [T2] U/kg) versus a standard dose of 0.4 U/kg U100 as comparator were assessed in a euglycaemic clamp setting.

Study  PDY12335  was  a  randomized,  open-label,  2-sequence,  2-period,  2-treatment  crossover multiple  dosing  study  in  20  Japanese  male  and  female  patients  with  T1DM  comparing  24-hour glycaemic profile in CGM between U300 and U100 at steady state.

Table 2 Overview of the HOE901-U300 Phase 1 clinical development program

| Protocol No.              | Patients randomized       | Reference Therapy                                      | Dose Duration                       | Main Objectives                                 |
|---------------------------|---------------------------|--------------------------------------------------------|-------------------------------------|-------------------------------------------------|
| Phase 1: Healthy subjects | Phase 1: Healthy subjects | Phase 1: Healthy subjects                              | Phase 1: Healthy subjects           | Phase 1: Healthy subjects                       |
| PKD10086                  | 24                        | Lantus                                                 | 0.4 U/kg Single dose                | Bioequivalence                                  |
| Phase 1: T1DM             | Phase 1: T1DM             | Phase 1: T1DM                                          | Phase 1: T1DM                       | Phase 1: T1DM                                   |
| PKD11627                  | 24                        | Lantus                                                 | 0.4, 0.6, 0.9 U/kg Single dose      | PK/PD                                           |
| TDR11626                  | 30                        | Lantus                                                 | 0.4, 0.6 U/kg once daily 8 days     | PK/PD at steady state                           |
| PKD13560                  | 50                        | HOE901-U300 standard formulation versus polysorbate 20 | 0.4 U/kg once daily 6 days          | Bioequivalence of 2 formulations of HOE901-U300 |
| PKD12270                  | 18                        | Lantus                                                 | 0.4, 0.6 U/kg Single dose           | PK/PD in Japanese patients                      |
| PDY12335                  | 20                        | Lantus                                                 | Once daily, self-titration; 28 days | PK/PD, CGM in Japanese patients                 |

## 2.4.2. Pharmacokinetics

The pharmacokinetics of insulin glargine is well known. The assessment of the pharmacokinetics was mainly based on comparative bioavailability between the already marketed product with 100 U/ml and the new formulation with 300 U/ml.

<div style=\"page-break-after: always\"></div>

## Absorption

After administration of the new formulation in equal doses at steady state as insulin glargine 100 U/ml, the rate of absorption is considerably lower but the extent is more a less similar (study 11626). The new formulation shows a flatter concentration-time curve reflecting in a low PTF and fluctuation compared with 100U/ml (see figure below)

<!-- image -->

Source =PKS Study:TDR11626;Scenario:S-D-A-EV-OD,Version 2

.

Figure 1 - Mean (± S.D.) insulin glargine concentration time profiles starting with dosing on Day 8 (at steady state) with the old formulation (R) and new formulation (T).

The old formulation of 100 U/ml is not bioequivalent with the new formulation of 300 U/ml after subcutaneous administration of single equal doses to healthy subjects (study 10086). The extent of exposure  (AUC)  after  administration  of  the  new  formulation  with  300  U/ml  is  only  65%  of  the exposure after administration of the old formulation of 100 U/ml.

After administration of 0.4 U/kg and 0.6 U/kg of the new formulation (300 U/ml) as single doses (study 11627) to patients with type 1 diabetes, the exposure was nearly similar for the rate as well as for the extent and was half of the value after administration of 0.4 U/kg as insulin glargine 100U/ml. After administration of 0.9 U/kg as the new formulation a comparable exposure was achieved.

The addition of polysorbate to the new formulation (study 13560) did not influence the bioavailability of insulin glargine after subcutaneous administration of 0.4 U/kg. The 90% CI is well within the acceptance range of bioequivalence.

## Interactions

No new studies were conducted to evaluate effects of extrinsic factors to support the registration and approval of HOE901-U300. Further information on such studies previously performed and submitted had been assessed in the original marketing application for insulin glargine (HOE901-U100; Lantus [EMEA/H/C/000284] and Optisulin [EMEA/H/C/000309]).

## Dose proportionality and time dependencies

With respect to dose proportionality after administration of different doses with the new formulation, no conclusion can be drawn as the absorption from the injection site behaves rather erratic.

After administration of different amount of insulin glargine the following concentration-time curves were determined.

<div style=\"page-break-after: always\"></div>

Figure  2  -  Mean  and  S.D  plasma  concentration-  time  curves  of  insulin  glargine  after subcutaneous administration of three different doses of the new formulation and one dose of the old formulation

<!-- image -->

## Special populations

The lack of studies in special populations is acceptable for this variation.

The studies in Japanese patients did only reveal that the bioavailability between the two different formulations are considerably different and comparable with Caucasian patients. The exposure in Japanese volunteers however is lower. As there is no direct pharmacokinetic comparison, a conclusion on the influence of race is not possible.

## 2.4.3. Pharmacodynamics

## Mechanism of action

Insulin glargine, like human insulin acts via the human insulin receptor system. The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogues lower BG levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.

## Primary pharmacology

Study PKD10086 (single dose in healthy volunteers) did not demonstrate equivalence in terms of bioavailability or activity between the 300 U/mL and the 100 U/mL solutions for injection, although the 300 U/mL (U300) formulation produced less fluctuation in insulin glargine concentration and activity around the averages compared with the 100 U/mL formulation.

In  Study PKD11627 (T1DM) single dose pharmacokinetic and pharmacodynamic profiles for U300 treatments (T1 to T3) were flatter and prolonged over the 36 hours observation period as compared to 0.4 U/kg U100 treatment , and the exposure (INS-AUC0-36) and glucose disposal (GIR-AUC0-36h) were lower for matching doses.

Study TDR11626 investigated the safety and tolerability of 8-day repeated dose regimens at 2 dose levels of U300 (0.4 and 0.6 U/kg/day) and compared their PD and PK properties to those of U100 (0.4 U/kg/day) in a crossover euglycaemic clamp setting in steady state conditions, at the end of each treatment period, in 30 patients with T1DM.

U300 displayed  a  flatter  and  more  constant  serum  insulin  glargine  and  glucodynamic  profile  as compared to Lantus, particularly over the first 24 hours after last dosing.

<div style=\"page-break-after: always\"></div>

Insulin  glargine  exposure  was  quantifiable  in  more than  50%  of  subjects  until  32  and  36  hours sampling times post U300 dose, for 0.4 and 0.6 U/kg/day, respectively and U100 was quantifiable until 28 hours post dose. Exposure to insulin glargine and activity was slightly lower within 24 hours with U300 than with U100 with matching doses (INS-AUC0-24; point-estimated treatment ratio 0.83 [90% CI: 0.69 to 1.00)]), with little or no difference within 36 hours (INS-AUC0-36; point-estimated treatment ratio 0.93 [90% CI: 0.77 to 1.12]). The higher dose of U300 produced a correspondingly greater exposure and activity with otherwise similar concentration and activity time profiles.

During the 36-hour clamp period, BG was more tightly controlled and for longer with both doses of U300 than with 0.4 U/kg U100 at or below 110, 130 and 150 mg/dL, as well as at or below the level of euglycaemia (≤105 mg/dL). The end of activity was later for both doses of U300 than for 0.4 U/kg U100.

In addition, the differentiation between parent compound, insulin glargine, and 2 metabolites (M1 and M2)  in  plasma  was  generated  as  supportive  data,  using  a  specific  LC-MS/MS  assay  with immunoaffinity  enriched  metabolites.  This  analysis  confirmed  comparable  metabolism  of  insulin glargine regardless of the formulation, with the main metabolite being M1 (21 A -Gly-human insulin). Also, steady state (for M1) was reached after 3 to 4 days of treatment with U300 compared with 1 to 2 days with U100.

<!-- image -->

*Glucoseinfusionrate

Local regression smoothing (LOESS), smoothing factor 0.20.

## Figure 3 - TDR11626 - 36-hour mean smoothed glucose infusion rate profiles at steady state for 0.4 U/kg U100 and 0.4 U/kg U300

The flatter and prolonged concentration and glucodynamic time profiles observed in study PKD11627 were confirmed in study PKD12270 in Japanese patients with T1DM.

Study  PDY12335  was  a  randomized,  open-label,  2-sequence,  2-period,  2-treatment  crossover multiple  dosing  study  in  20  Japanese  male  and  female  patients  with  T1DM  comparing  24-hour glycaemic profile in CGM between U300 and Lantus at steady state. The mean CGM profiles from Day 2 18:00 to Day 3 24:00 of CGM periods suggest similar BG concentration profiles over time with U300 and U100.

## Secondary pharmacology

Of the 100 patients with T1DM participating in the cross-over multiple dose studies of the Phase 1 program and for whom AIA assessments were available, 68 were AIA-negative and 32 AIA-positive prior to treatment. All 32 AIA-positive patients showed cross-reactivity to human insulin. Five patients with a negative AIA status at baseline converted to positive status at the end of the studies. All patients positive prior to treatment remained positive at the end of the studies.

<div style=\"page-break-after: always\"></div>

The mean exposure to free insulin glargine for AIA-positive patients receiving U300 or U100 was reduced, and this was more pronounced at a lower dose.

The impact of AIA status on pharmacodynamic responses was less pronounced as on exposure, with no difference between U300 and U100, and became negligible with higher dose.

## 2.4.4. Discussion on clinical pharmacology

The PD of insulin glargine 300 U/mL (U300) was compared to U100 (Lantus) in 6 phase 1 trials involving  24  healthy  subjects  and  142  subjects  with  T1DM  using  PK  assessments  and  mostly euglycaemic clamps for PD.

The U300  and U100  formulations are not bio-equivalent. The single and multiple dose pharmacokinetic and pharmacodynamic profiles for U300 are flatter and prolonged over the 36 hours observation period as compared to U100.

At  steady  state  with  equal  doses  of  the  new  formulation  300  U/ml  and  100  U/ml,  the  rate  of absorption was considerably lower with the new formulation but extent was more or less similar: INS-AUC0-24 point-estimated treatment ratio 0.83 (90% CI: 0.69 to 1.00), with little or no difference within 36 hours.

After single dose administration the extent of exposure of the new formulation was only 50-65% of that of 100 U/ml.

Overall it can be concluded that direct switching from the old formulation of 100 U/ml to the new formulation of 300 U/ml with equal doses is not warranted by the pharmacokinetic data after single doses.  However,  after  repeated  dosing  a  lower  Cmax  is  achieved  resulting  in  a  less  variable plasma-concentration-time curve and a more or less similar extent of exposure.

In all pharmacokinetic studies insulin glargine U300 was administered subcutaneously by injection in the periumbilical area of the abdomen. The SmPC recommends injection in the abdomen wall, the deltoid or the thigh. In the clinical phase 3 studies, no significant differences between HOE901-U300 and U100 was observed in HbA1c or hypoglycaemia when different injections sites (abdomen or thigh) were used. The data for the injection site 'upper arm' is scarce but evoke no concern. The same administration recommendations as for Lantus are thus supported.

Further analysis confirmed comparable metabolism of insulin glargine regardless of the formulation, with the main metabolite being M1 (21 A -Gly-human insulin). Also, steady state (for M1) was reached after 3 to 4 days of treatment with U300 compared with 1 to 2 days with U100.

In these short-term studies, formation of anti-insulin antibodies was similar between the U100 and U300 formulations. The impact of AIA status on pharmacodynamic responses was less pronounced as on exposure, with no difference between U300 and U100, and became negligible with higher dose.

## 2.4.5. Conclusions on clinical pharmacology

The new formulation of insulin glargine 300 U/ml is not bioequivalent to the old formulation 100 U/ml. The single and multiple dose pharmacokinetic and pharmacodynamic profiles for U300 are flatter and prolonged over the 36 hours observation period as compared to U100. Direct switching from the old formulation of 100 U/ml to the new formulation of 300 U/ml with equal doses is not warranted by the pharmacokinetic data after single doses. However, after repeated dosing a lower Cmax is achieved resulting is a less variable plasma-concentration-time curve and a similar extent of exposure.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical efficacy

Data supporting the efficacy of U300 are based on results from the main 6-month on-treatment period of 4 multinational, open-label, randomized, controlled, Phase 3 studies in patients with T1DM (EFC12456)  and  T2DM  (EFC11628,  EFC11629  and  EFC12347).  In  these  Phase  3  studies,  the objectives were to demonstrate that U300 is as effective as Lantus in terms of HbA1c reduction, and based on the PK/PD profile shown in the euglycaemic clamp studies is associated with a lower risk of hypoglycaemia.

The  exploratory  Phase  2  study  PDY12777  employing  CGM  provides  supportive  efficacy  data  in patients with T1DM. Results from two 3-month administration substudies embedded in the extension periods of studies EFC11628 and EFC11629 in patients with T2DM support the efficacy and safety of U300 when administered at intervals up to 3 hours earlier or later than the patient's usual 24-hour injection interval.

## 2.5.1. Main studies

An overview of the main studies is presented in Table 3, Table 4 and Table 5.

Table 3 - Overview of Phase 2/3 studies in T1DM

| Studies in T1DM       | EFC12456                                                                                                | PDY12777                                                                                                                                                                                                   |
|-----------------------|---------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Phase                 | 3                                                                                                       | 2 (Exploratory CGM study)                                                                                                                                                                                  |
| Population            | T1DM on basal insulin in combination with mealtime insulin analog                                       | T1DM on basal insulin in combination with mealtime insulin analog                                                                                                                                          |
| Region                | North America, Europe, Japan                                                                            | USA                                                                                                                                                                                                        |
| Comparator            | Lantus                                                                                                  | Lantus                                                                                                                                                                                                     |
| Randomization         | 1:1:1:1 U300 morning injection U300 evening injection Lantus morning injection Lantus evening injection | 1:1:1:1 U300 injection sequence: Period A morning  Period B evening Period A evening  Period B morning Lantus injection sequence Period A morning  Period B evening Period A evening  Period B morning |
| Main Objectives       | Efficacy and safety                                                                                     | Efficacy and safety                                                                                                                                                                                        |
| Route                 | Once daily SC injection                                                                                 | Once daily SC injection                                                                                                                                                                                    |
| Injection device:     | U300: modified Tactipen Lantus: SoloStar                                                                | U300 and Lantus: Half-unit U100-syringe; whole-unit U100-syringe for Lantus doses >30 units                                                                                                                |
| Duration of treatment | 6 months (main study period) 6 months comparative extension period a                                    | 16 weeks (2 x 8 weeks)                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Number of patients randomized   | U300: 274 Lantus: 275   | U300: 30 Lantus: 29   |
|---------------------------------|-------------------------|-----------------------|

Table 4 - Overview of Phase 3 studies in T2DM

| Studies in T2DM               | EFC11628                                                               | EFC11629                                                               | EFC12347                                                               |
|-------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
| Phase                         | 3                                                                      | 3                                                                      | 3                                                                      |
| Population                    | T2DM on basal insulin in combination with mealtime insulin analog      | T2DM on basal insulin in combination with OAD                          | Insulin-naïve T2DM not adequately controlled on non-insulin AHA        |
| Region                        | North America, South America, Europe, South Africa                     | North America, South America, Europe, South Africa                     | North America, Europe, Japan                                           |
| Comparator                    | Lantus                                                                 | Lantus                                                                 | Lantus                                                                 |
| Randomization                 | 1:1                                                                    | 1:1                                                                    | 1:1                                                                    |
| Main Objectives               | Efficacy and safety                                                    | Efficacy and safety                                                    | Efficacy and safety                                                    |
| Route                         | Once daily SC injection                                                | Once daily SC injection                                                | Once daily SC injection                                                |
| Injection device              | U300:modified Solostar Lantus: Solostar                                | U300: modified Solostar Lantus: Solostar                               | U300: modified Tactipen Lantus: Solostar                               |
| Duration of treatment         | 6 months (main study period) 6 months comparative extension period (a) | 6 months (main study period) 6 months comparative extension period (a) | 6 months (main study period) 6 months comparative extension period (a) |
| Number of patients randomized | U300: 404 Lantus: 403                                                  | U300: 404 Lantus: 407                                                  | U300: 439 Lantus: 439                                                  |

a Extension period ongoing at the time of the dossier cut-off date; results of safety extension periods not included in the dossier; OAD = oral antihyperglycaemic drugs

Table 5 - Overview of Phase 3 sub-studies in T2DM

| 3-month substudies            | EFC11628                                                                       | EFC11629                                                                       |
|-------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Patient population:           | Patients randomized and treated with U300 during the main study period         | Patients randomized and treated with U300 during the main study period         |
| Comparison                    | U300 injection intervals at fixed 24-hour intervals at intervals of 24±3 hours | U300 injection intervals at fixed 24-hour intervals at intervals of 24±3 hours |
| Randomization                 | 1:1                                                                            | 1:1                                                                            |
| Objective:                    | Efficacy and safety                                                            | Efficacy and safety                                                            |
| Duration:                     | 3 months (Month 6 - Month 9 extension period)                                  | 3 months (Month 6 - Month 9 extension period)                                  |
| Number of patients randomized | Fixed intervals: 53 Adaptable intervals:56                                     | Fixed intervals: 44 Adaptable intervals: 45                                    |

## Methods

The 4 Phase 3 studies were  multinational, multicenter, open-label, centrally randomized, comparative, parallel group studies, each comprising a 6-month main study period followed by a 6-month comparative safety extension period. The studies EFC11628 and EFC11629 also included a 4-week post-treatment follow-up period after completion of the 52-week study duration. The active control was Lantus in all studies. The studies utilized a common core protocol that standardized most

<div style=\"page-break-after: always\"></div>

aspects  of  the  study  design,  including  the  comparator  Lantus  (insulin  glargine  100  U/mL),  1:1 randomization, stratification by screening HbA1c (&lt;8.0% versus ≥8.0%), inclusion/exclusion criteria, targets for fasting pre-breakfast self-monitored plasma glucose (SMPG), recommendations for dosing of U300 and Lantus, primary and secondary efficacy variables and safety variables, including the definitions used for the hypoglycaemia categories and analyses. All 4 Phase 3 studies were designed to show noninferiority of U300 versus Lantus based on the change in HbA1c from baseline to endpoint at Month 6 with a noninferiority margin of 0.4% HbA1c.

In both studies in T1DM (EFC12456, PDY12777) patients were randomized to morning or evening injections of U300 and Lantus to evaluate the efficacy and safety of different injection times of U300. Study  PDY12777  was  an  exploratory,  open-label,  randomized,  parallel-group  Phase  2  study  to compare the efficacy and safety of U300 and Lantus in patients with T1DM using CGM parameter. Within each treatment group of U300 or Lantus the sequence of the injection time of the basal insulin during the 8-week study period A followed by 8-week study period B was assigned by randomization (morning-evening or evening-morning; 1:1). The study consisted of an up to 4-week screening and training period, a treatment period of 2 x 8 weeks, and a 4-week post-treatment follow-up period. The primary endpoint was the percentage of time in glucose range 4.4 to 7.8 mmol/L (80 to 140 mg/dL) as measured by CGM during the last 2 weeks of both 8-week treatment periods.

The efficacy and safety of U300 when injected at intervals of up to 3 hours earlier or later than the patient's usual once daily injection time was evaluated in 2 substudies embedded in the extension periods of studies EFC11628 and EFC11629 in T2DM. Both substudies were open-label, randomized (1:1), 3-month studies in patients who were randomized and treated with U300 during the main study periods and had completed the 6-month study visit.

All studies comprised an up to 2-week screening period, during which the patients' eligibility criteria were checked and patients were trained on study procedures such as regular SMPG measurements and diary entries. The duration of the pivotal efficacy studies was 6 months (main study periods). The 6-month  main  study  period  duration  with  a  'treat-to-target'  dosing  schedule  of  the  insulin  is considered to be sufficient for achieving glycaemic control with U300 or Lantus after changing over from the pre-study basal insulin or initiating basal insulin in previously insulin-naïve patients. The 6-month period enabled an adequate assessment of the changes in HbA1c and the concomitant risk of hypoglycaemia during both the initial period after changing to a new insulin regimen, when most of the  adjustment  to  the  insulin  dose  occurred,  and  the  maintenance  period,  when  only  minor refinements of the insulin dose were made.

## Study participants

Separate studies were done in T1DM and T2DM due to the different underlying pathophysiologies. Three studies were done in T2DM to cover the broad spectrum of this patient population, including insulin-naïve patients not adequately controlled on non-insulin AHA and requiring insulin, patients already treated with basal insulin in combination with OAD, and patients requiring basal and mealtime insulin for glycaemic control. Adult patients at least 18 years of age with a screening HbA1c in the range of ≥ 7.0 to ≤ 10.0% for insulin-pretreated patients (EFC11628, EFC11629, EFC12456) and ≤ 9.0% (PDY12777) or ≥ 7.0 to ≤ 11.0% in insulin-naïve patients (EFC12347) were eligible for the studies. Patients with T1DM had to be on basal insulin in combination with a mealtime insulin for at least one year, insulin-naïve T2DM patients had to have a known history of T2DM for at least one year and  pretreatment  with  non-insulin  AHA  for  6 months  and  sulfonylurea  and  glinides  were  to  be discontinued at baseline

(EFC12347).  T2DM  patients  pretreated  with  basal  insulin  in  combination  with  OAD  had  to  be receiving this insulin regimen for at least 6 months (EFC11629) and patients with T2DM on basal insulin  in  combination  with  a  mealtime  insulin  had  to  be  on  this  regimen  for  at  least  1  year (EFC11628). In studies EFC11628 and EFC11629 in T2DM patients pretreated with basal insulin the daily basal insulin dose had to be at least 42 U.

<div style=\"page-break-after: always\"></div>

Study inclusion and exclusion criteria for selecting the patient population were as unrestrictive as possible across the studies to reflect the general population of patients with diabetes mellitus. Only patients with concomitant illnesses or medications that could limit the ability of patients to safely complete the study periods, confound the evaluation of study findings, or that conformed to potential contraindications of insulin therapy, were excluded.

## Objectives

The primary efficacy objective of the Phase 3 studies was to demonstrate noninferiority of U300 versus Lantus on glycaemic control in adults as measured by:

- EFC12456 (T1DM) and EFC11628, EFC11629, and EFC12347 (all T2DM): change in glycated HbA1c from baseline to endpoint (Month 6) measured in a central laboratory. The studies were designed to show noninferiority of U300 versus Lantus with a noninferiority margin of 0.4% HbA1c.
- Substudies EFC11628 and EFC11629 (T2DM): change in HbA1c from Month 6 (baseline of substudy) to Month 9 (endpoint of substudy).

The secondary efficacy objectives for the Phase 3 studies were to compare U300 and Lantus on Nocturnal hypoglycaemia, Pre-injection plasma glucose, Variability of pre-injection plasma glucose Fasting plasma glucose (FPG), % patients overall and without hypoglycaemia reaching HbA1c &lt;7%, % patients reaching FPG target overall and without hypoglycaemia FPG targets (&lt;5.6 mmol/L (100 mg/dL) in studies in T2DM and &lt;7.2 mmol/L, (130 mg/dL) in T1DM), 8-point SMPG profiles (taken at 03:00 hours, before and 2 hours after each main meal, and at bedtime), 24-hour average plasma glucose and variability of 24-hour average plasma glucose.

## Outcomes/endpoints

## Primary endpoint

In the 4 pivotal Phase 3 studies, the primary efficacy endpoint was change from baseline to endpoint (Month 6) in HbA1c. Noninferiority was tested with a noninferiority margin of 0.4% HbA1c, which was in agreement with the guidance documents of the key regulatory agencies at the time of planning the Phase 3 program. The change in HbA1c from baseline to endpoint (Month 6) was analyzed using a Mixed Model for Repeated Measurements (MMRM) approach under the missing at random framework in  the  4  pivotal  studies,  but  was  also  analyzed  using  Last  Observation  Carried  Forward  (LOCF) imputation in the CSRs for EFC11628 and EFC11629. The primary efficacy analysis was based on the modified  intent-to-treat  (mITT)  population.  The  mITT  population  was  defined  as  all  randomized patients who received at least one dose of open-label U300 or Lantus study medication, and who had both a baseline assessment and at least one post-baseline assessment of any primary or secondary efficacy endpoint.

## Secondary endpoints

Secondary  endpoints included percentage of patients experiencing at least one nocturnal hypoglycaemia  from  start  of  Week 9  to  Month  6,  severe  hypoglycaemia  and  hypoglycaemia documented  by  SMPG  ≤3.9  mmol/L  (70 mg/dL),  pre-injection  plasma  glucose,  fasting  plasma glucose (FPG), 8-point SMPG profiles, fasting pre-breakfast SMPG and insulin doses.

## Statistical methods

In order to investigate the clinical correlates of the flatter profile and longer duration of action of U300 compared with Lantus in the Phase 1 PK/PD studies, 3 main secondary efficacy endpoints were pre-specified in the protocols of the 3 Phase 3 studies in T2DM (EFC11628, EFC11629, EFC12347). Superiority of U300 over Lantus was tested in a pre-specified order of priority only if noninferiority of U300 versus Lantus was demonstrated for the primary endpoint (hierarchical testing strategy). This stepwise closed testing procedure stopped as soon as a test for an endpoint was found not statistically significant.  The  hypotheses  of  'less  nocturnal  hypoglycaemia'  and  'more  sustained  duration  of action' were sequentially tested in terms of a lower incidence of nocturnal hypoglycaemia, a larger

<div style=\"page-break-after: always\"></div>

decrease and lower variability of pre-basal insulin injection plasma glucose. These main secondary efficacy endpoints were not part of a hierarchical testing procedure in study EFC12456 in T1DM, but assessed as other secondary efficacy endpoints.

For the 2 Phase 3 studies (EFC11629 and EFC12347) with non-insulin AHA as background therapy, a meta-analysis based on pooled efficacy data from the main 6-month on-treatment period was also performed.

## Results

## Participant flow

The distribution of missing data patterns of HbA1c and number of patients excluded from primary efficacy analysis in each treatment group are presented per study with associated reasons (Figure 4, Figure 5, Figure 6, Figure 7).

No differences between U300 and Lantus were found for demographics and baseline characteristics across missing data patterns of HbA1c. Nor was there any difference between treatment groups within each missing data pattern.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 4 - Disposition of patients in trial EFC12456

<!-- image -->

Figure 5 - Disposition of patients in trial EFC11628

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 6 - Disposition of patients in trial EFC11629

Figure 7 - Disposition of patients in trial EFC12347

<!-- image -->

## Baseline data

All Phase 2/3 studies were well balanced regarding the baseline characteristics. The studies included 608 randomized patients with T1DM and 2496 randomized patients with T2DM; 719 (23.2%) patients were aged 65 years or older, 1872 (75.0%) patients with T2DM had a body mass index (BMI) of at least 30 kg/m² and 495 (15.9%) patients had some degree of renal impairment (GFR [MDRD] ≤60 mL/min). The majority of the patients were Caucasian/white (n=2717; 87.5%), other ethnicities were represented by n=210 (6.8%) Black, n=144 (4.6%) Asian/Oriental, and n=463 (14.9%) Hispanic (Table 6). Geographical areas included North America, South America, Europe, South Africa, and Japan. Overall, patients treated in the 4 pivotal Phase 3 studies adequately represent the patient population who might be expected to receive U300 when marketed after approval.

<div style=\"page-break-after: always\"></div>

Table 6 - Summary of study populations

|                                                                                          | T1DM          | T1DM          | T2DM          | T2DM          | T2DM        |
|------------------------------------------------------------------------------------------|---------------|---------------|---------------|---------------|-------------|
|                                                                                          | EFC12456      | PDY12777      | EFC11628      | EFC11629      | EFC12347    |
| Number of patients randomized                                                            | N=549         | N=59          | N=807         | N=811         | N=878       |
| Age (years; mean SD)                                                                     | 47.3 (13.7)   | 44.2 (14.3)   | 60.0 (8.6)    | 58.2 (9.2)    | 57.7 (10.1) |
| ≥ 65 years (%)                                                                           | 55 (10.0%)    | 2 (3.4%)      | 246 (30.4%)   | 190 (23.4%)   | 226 (25.7)  |
| Male, N (%)                                                                              | 313 (57.0%)   | 32 (54.2%)    | 427 (52.9%)   | 372 (45.9%)   | 507 (57.7%) |
| Weight (kg; mean,SD)                                                                     | 81.8 (18.7)   | 82.1 (17.3)   | 106.3 (20.8)  | 98.3 (21.6)   | 95.3 (22.9) |
| BMI (kg/m² mean; SD)                                                                     | 27.6 (5.1)    | 27.3 (5.3)    | 36.6 (6.4)    | 34.8 (6.4)    | 33.0 (6.7)  |
| ≥ 30 kg/m²                                                                               | 153 (27.9%)   | 16 (27.1%)    | 699 (86.6%)   | 614 (75.7%)   | 559 (63.6%) |
| GFR (MDRD) < 60 mL/min/1.73m²                                                            | 67 (12.2%)    | 7 (11.9%)     | 188 (23.3%)   | 114 (14.1%)   | 119 (13.6%) |
| Duration of diabetes (years; mean SD)                                                    | 21.0 (12.9)   | 22.1 (13.8)   | 15.8 (7.5)    | 12.6 (7.0)    | 9.8 (6.4)   |
| ≥ 10 years                                                                               | 431 (78.9%)   | 45 (76.3%)    | 633 (78.4%)   | 501 (61.9%)   | 372 (42.7%) |
| Total insulin dose prior to study (U/kg; mean) in the last 7 days prior to randomization | 0.719 (0.262) | 0.603 (0.193) | 1.197 (0.466) | 0.671 (0.238) | NA          |
| Caucasian/white                                                                          | 467 (85.1%)   | 59 (100%)     | 745 (92.3%)   | 761 (93.8%)   | 685 (78.0%) |
| Asian/Oriental                                                                           | 47 (8.6%)     | -             | 11 (1.4%)     | 10 (1.2%)     | 76 (8.7%)   |
| Black                                                                                    | 26 (4.7%)     | -             | 47 (5.8%)     | 36 (4.4%)     | 101 (11.5%) |
| Hispanic                                                                                 | 26 (4.7%)     | -             | 51 (6.3%)     | 193 (23.8%)   | 193 (22.0%) |

SD=Standard deviation; N=number; GFR= Glomerular filtration rate; MDRD= Modification of diet in renal disease (MDRD) formula; NA = not applicable.

## Summary of main studies

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

Table 7 - Summary of efficacy for trial EFC12456

| Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Design                                                                                                                                                                                                                                                                                   | EFC12456 (EudraCT: 2012-001524-35) This was a Phase 3, 6-month, multicenter, multinational, open-label, randomized, 4-arm parallel-group study followed by a 6-month safety extension period to compare the efficacy and safety of HOE901-U300 and Lantus morning and evening injection in patients with T1DM, and HbA 1c in the range of 7% to 10%, who had been on a basal plus mealtime insulin regimen for at least 1 year. Patients were randomized to receive either HOE901-U300 or Lantus as a morning or evening injection (randomization ratio 1:1:1:1). Randomization was stratified by HbA 1c obtained at the screening visit (<8.0%, ≥8.0%) and geographical region (Non-Japan; Japan). 'Morning' was defined as any time immediately prior to breakfast until lunch and 'evening' as any time immediately prior to the evening meal | EFC12456 (EudraCT: 2012-001524-35) This was a Phase 3, 6-month, multicenter, multinational, open-label, randomized, 4-arm parallel-group study followed by a 6-month safety extension period to compare the efficacy and safety of HOE901-U300 and Lantus morning and evening injection in patients with T1DM, and HbA 1c in the range of 7% to 10%, who had been on a basal plus mealtime insulin regimen for at least 1 year. Patients were randomized to receive either HOE901-U300 or Lantus as a morning or evening injection (randomization ratio 1:1:1:1). Randomization was stratified by HbA 1c obtained at the screening visit (<8.0%, ≥8.0%) and geographical region (Non-Japan; Japan). 'Morning' was defined as any time immediately prior to breakfast until lunch and 'evening' as any time immediately prior to the evening meal |
| Design                                                                                                                                                                                                                                                                                   | Screening period Main treatment phase Safety extension period Post-treatment follow-up                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Up to 2 weeks 6 months 6 months 2 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Statistical methods                                                                                                                                                                                                                                                                      | A stepwise closed testing approach was used for the primary efficacy variable to assess noninferiority and superiority sequentially. To assess noninferiority, the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 overall and Lantus overall was compared with the predefined noninferiority margin of 0.4% HbA 1c , a value <0.4% demonstrated noninferiority. If noninferiority was demonstrated, superiority of HOE901-U300 overall over Lantus overall was tested. The superiority of HOE901-U300 overall over Lantus overall was demonstrated if the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 overall and                                                       | A stepwise closed testing approach was used for the primary efficacy variable to assess noninferiority and superiority sequentially. To assess noninferiority, the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 overall and Lantus overall was compared with the predefined noninferiority margin of 0.4% HbA 1c , a value <0.4% demonstrated noninferiority. If noninferiority was demonstrated, superiority of HOE901-U300 overall over Lantus overall was tested. The superiority of HOE901-U300 overall over Lantus overall was demonstrated if the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 overall and                                                       |
| Treatment groups                                                                                                                                                                                                                                                                         | HOE901-U300 (insulin glargine, 300 U/mL), modified Tactipen, SC injection every 24 hours in the morning or evening; patients were to continue using their mealtime insulin 274 patients randomized 136 to morning injection 138 to evening injection)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | HOE901-U300 starting dose was based on dose of prior total basal insulin and fasting (prebreakfast) SMPG at baseline. Titration to achieve fasting (prebreakfast) SMPG in the range of 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycaemia. The titration of mealtime insulin aimed to achieve a 2-hour postprandial SMPG of <8.9 mmol/L (160 mg/dL) while avoiding hypoglycaemia.                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Treatment groups                                                                                                                                                                                                                                                                         | Lantus (insulin glargine 100 U/mL), Solostar, SC injection every 24 hours in the morning or evening; patients were to continue using their mealtime insulin 275 patients randomized: 137 to morning injection 138 to evening injection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Same as HOE901-U300                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Type 1 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Type 1 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Type 1 Diabetes Mellitus with a 6-month Safety Extension Period                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                           | EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                                                                                         | EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                                                                                                      |
| Patients with Endpoints and definitions                                                                                                                                                                                                                                    | Primary efficacy endpoint                                                                                                                                                                                                                                                  | Primary efficacy endpoint                                                                                                                                                                                                                                                               |
| Patients with Endpoints and definitions                                                                                                                                                                                                                                    | Change in HbA 1c (%)                                                                                                                                                                                                                                                       | Change from baseline to (Month 6) in patients with T1DM                                                                                                                                                                                                                                 |
| Patients with Endpoints and definitions                                                                                                                                                                                                                                    | Secondary efficacy endpoints                                                                                                                                                                                                                                               | Secondary efficacy endpoints                                                                                                                                                                                                                                                            |
| Patients with Endpoints and definitions                                                                                                                                                                                                                                    | Nocturnal hypoglycaemia                                                                                                                                                                                                                                                    | Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                           |
| Patients with Endpoints and definitions                                                                                                                                                                                                                                    | Pre-injection SMPG (mmol/L)                                                                                                                                                                                                                                                | Change in pre-injection SMPG (mmol/L) (obtained within 30 minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                   |
| Patients with Endpoints and definitions                                                                                                                                                                                                                                    | Variability of pre-injection SMPG (%)                                                                                                                                                                                                                                      | Change in variability of pre-injection SMPG (obtained within 30 minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                         |
| Patients with Endpoints and definitions                                                                                                                                                                                                                                    | Number (%) of patients with target HbA 1c <7%                                                                                                                                                                                                                              | at Month 6 at Month 6 and having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last 3 months of the main 6-month on-treatment period - any time of the day - between 00:00 and 05:59 hours |
| Patients with Endpoints and definitions                                                                                                                                                                                                                                    | Number (%) of patients with target HbA 1c ≤6.5%                                                                                                                                                                                                                            | at Month 6                                                                                                                                                                                                                                                                              |
| Patients with Endpoints and definitions                                                                                                                                                                                                                                    | Number (%) of patients with FPG <5.6 mmol/L (100 mg/dL) / FPG <7.2 mmol/L (130 mg/dL)                                                                                                                                                                                      | at Month 6 at Month 6 and having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last 3 months of the main 6-month on-treatment period - any time of the day - between 00:00 and 05:59 hours |
| Patients with Endpoints and definitions                                                                                                                                                                                                                                    | 24-hour plasma glucose (mmol/L)                                                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                        |
| Patients with Endpoints and definitions                                                                                                                                                                                                                                    | Variability of 24-hour plasma glucose (mmol/L)                                                                                                                                                                                                                             | Change in variability of 24-hour plasma glucose based on 8-point SMPG                                                                                                                                                                                                                   |
| Patients with Endpoints and definitions                                                                                                                                                                                                                                    | Daily average total (basal + mealtime) insulin dose (U/kg)                                                                                                                                                                                                                 | Change in daily average total (basal + mealtime) insulin dose from baseline to Month 6                                                                                                                                                                                                  |
| Results and Analysis                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                    |
| Analysis description                                                                                                                                                                                                                                                       | Primary Analysis                                                                                                                                                                                                                                                           | Primary Analysis                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                         | EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                                                                                                       | EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                                                                                                       | EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                                                                                                       | EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                                                                                                       |
| Analysis population and time point description                                                                                                                                                                                                                                           | Modified intention-to-treat (mITT) population - change from baseline to endpoint (Month 6, MMRM0)                                                                                                                                                                                        | Modified intention-to-treat (mITT) population - change from baseline to endpoint (Month 6, MMRM0)                                                                                                                                                                                        | Modified intention-to-treat (mITT) population - change from baseline to endpoint (Month 6, MMRM0)                                                                                                                                                                                        | Modified intention-to-treat (mITT) population - change from baseline to endpoint (Month 6, MMRM0)                                                                                                                                                                                        |
| Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                               | Primary endpoint                                                                                                                                                                                                                                                                         | Comparison groups                                                                                                                                                                                                                                                                        | HOE901-U300 (N=273)                                                                                                                                                                                                                                                                      | Lantus (N=273)                                                                                                                                                                                                                                                                           |
| Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                               | HbA 1c (%)                                                                                                                                                                                                                                                                               | N                                                                                                                                                                                                                                                                                        | 225                                                                                                                                                                                                                                                                                      | 229                                                                                                                                                                                                                                                                                      |
| Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                               | HbA 1c (%)                                                                                                                                                                                                                                                                               | Endpoint (Month 6): Mean (SD)                                                                                                                                                                                                                                                            | 7.70 (0.99)                                                                                                                                                                                                                                                                              | 7.68 (0.80)                                                                                                                                                                                                                                                                              |
| Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                               | HbA 1c (%)                                                                                                                                                                                                                                                                               | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]                                                                                                                                                                                                                        | -0.40 (0.051) [-0.501 to -0.299]                                                                                                                                                                                                                                                         | -0.44 (0.051) [-0.543 to -0.344]                                                                                                                                                                                                                                                         |
| Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                               | HbA 1c (%)                                                                                                                                                                                                                                                                               | Change from baseline to endpoint (Month 6): LS mean difference (SE) HOE901-U300 overall versus Lantus overall [95% CI]                                                                                                                                                                   | 0.04 (0.072) [-0.098 to 0.185]                                                                                                                                                                                                                                                           | 0.04 (0.072) [-0.098 to 0.185]                                                                                                                                                                                                                                                           |
| Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                               | Secondary analysis of primary endpoint HbA 1c (%)                                                                                                                                                                                                                                        | Change from baseline to endpoint (Month 6): LS mean difference (SE) for morning injection: HOE901-U300 versus Lantus [95% CI]                                                                                                                                                            | -0.07 (0.102) [-0.265 to 0.135]                                                                                                                                                                                                                                                          | -0.07 (0.102) [-0.265 to 0.135]                                                                                                                                                                                                                                                          |
| Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                               | Secondary analysis of primary endpoint HbA 1c (%)                                                                                                                                                                                                                                        | Change from baseline to endpoint (Month 6): LS mean difference (SE) for evening injection: HOE901-U300 versus Lantus [95% CI]                                                                                                                                                            | 0.15 (0.102) [-0.049 to 0.352]                                                                                                                                                                                                                                                           | 0.15 (0.102) [-0.049 to 0.352]                                                                                                                                                                                                                                                           |
| Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                               | Secondary analysis of primary endpoint HbA 1c (%)                                                                                                                                                                                                                                        | Change from baseline to endpoint (Month 6): LS mean (SE) for HOE901-U300: morning versus evening injection [95% CI]                                                                                                                                                                      | -0.15 (0.102) -0.353 to 0.049]                                                                                                                                                                                                                                                           | -0.15 (0.102) -0.353 to 0.049]                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                          | Study identifier EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                                                                                      | Study identifier EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                                                                                      | Study identifier EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                                                                                      | Study identifier EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                                                                                      | Study identifier EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          | Comparison groups                                                                                                                                                                                                                                                                        | HOE901-U300 (N=273)                                                                                                                                                                                                                                                                      | Lantus (N=273)                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          | n (%)                                                                                                                                                                                                                                                                                    | 162 (59.3)                                                                                                                                                                                                                                                                               | 153 (56.0)                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          | RR [95% CI] versus Lantus0                                                                                                                                                                                                                                                               | 1.06 [0.92 to 1.23]                                                                                                                                                                                                                                                                      | 1.06 [0.92 to 1.23]                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          | Month 6 Average pre-injection SMPG (mmol/L)                                                                                                                                                                                                                                              | N                                                                                                                                                                                                                                                                                        | 117                                                                                                                                                                                                                                                                                      | 105                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          | Month 6 Average pre-injection SMPG (mmol/L)                                                                                                                                                                                                                                              | Month 6: Mean (SD)                                                                                                                                                                                                                                                                       | 9.07 (2.63)                                                                                                                                                                                                                                                                              | 9.29 (2.37)                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          | Month 6 Average pre-injection SMPG (mmol/L)                                                                                                                                                                                                                                              | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]                                                                                                                                                                                                                        | -1.16 (0.223) [-1.604 to -0.725]                                                                                                                                                                                                                                                         | -0.82 (0.233) [-1.277 to -0.357]                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          | Month 6 Average pre-injection SMPG (mmol/L)                                                                                                                                                                                                                                              | Change from baseline to endpoint (Month 6): LS mean difference (SE) HOE901-U300 overall versus Lantus overall [95% CI]                                                                                                                                                                   | -0.35 (0.322) [-0.982 to 0.287]                                                                                                                                                                                                                                                          | -0.35 (0.322) [-0.982 to 0.287]                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          | Average pre-injection SMPG (mg/dL)                                                                                                                                                                                                                                                       | N                                                                                                                                                                                                                                                                                        | 117                                                                                                                                                                                                                                                                                      | 105                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          | Average pre-injection SMPG (mg/dL)                                                                                                                                                                                                                                                       | Month 6: Mean (SD)                                                                                                                                                                                                                                                                       | 163.40 (47.38)                                                                                                                                                                                                                                                                           | 167.37 (42.75)                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          | Average pre-injection SMPG (mg/dL)                                                                                                                                                                                                                                                       | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]                                                                                                                                                                                                                        | -20.97 (4.017) [-28.889 to -13.060]                                                                                                                                                                                                                                                      | -14.72 (4.206) [-23.003 to -6.428]                                                                                                                                                                                                                                                       |
|                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          | Average pre-injection SMPG (mg/dL)                                                                                                                                                                                                                                                       | Change from baseline to endpoint (Month 6): LS mean difference (SE) HOE901-U300 overall versus Lantus overall [95% CI]                                                                                                                                                                   | -6.26 (5.799) [-17.686 to 5.168]                                                                                                                                                                                                                                                         | -6.26 (5.799) [-17.686 to 5.168]                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                          | Variability of pre-injection SMPG (%)                                                                                                                                                                                                                                                    | Variability of pre-injection SMPG (%)                                                                                                                                                                                                                                                    | N                                                                                                                                                                                                                                                                                        | 117                                                                                                                                                                                                                                                                                      | 105                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          | Month 6: Mean (SD)                                                                                                                                                                                                                                                                       | 30.66 (13.26)                                                                                                                                                                                                                                                                            | 30.60 (13.97)                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]                                                                                                                                                                                                                        | -3.03 (1.573) [-6.131 to 0.066]                                                                                                                                                                                                                                                          | -1.76 (1.651) [-5.014 to 1.491]                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in   | Title : A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Patients with Type Study identifier                                                                                                                                                                        | EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                         | EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                         | EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                         | EFC12456 (EudraCT: 2012-001524-35)                                                                                                                                                                         |
| Patients with Type Study identifier                                                                                                                                                                        |                                                                                                                                                                                                            | Change from baseline to endpoint (Month 6): LS mean difference (SE) HOE901-U300 overall versus Lantus overall [95% CI]                                                                                     | 1.27 (2.266) [-5.735 to 3.193]                                                                                                                                                                             | 1.27 (2.266) [-5.735 to 3.193]                                                                                                                                                                             |
| Patients with Type Study identifier                                                                                                                                                                        | Number (%) of patients at Month 6                                                                                                                                                                          | HbA 1c <7%                                                                                                                                                                                                 | 46 (16.8)                                                                                                                                                                                                  | 41 (15.0)                                                                                                                                                                                                  |
| Patients with Type Study identifier                                                                                                                                                                        |                                                                                                                                                                                                            | HbA 1c <7% and no emergent severe or confirmed hypoglycaemia                                                                                                                                               | 17 (6.2)                                                                                                                                                                                                   | 16 (5.9)                                                                                                                                                                                                   |
| Patients with Type Study identifier                                                                                                                                                                        |                                                                                                                                                                                                            | HbA 1c <7% and no nocturnal emergent severe or confirmed hypoglycaemia                                                                                                                                     | 30 (11.0)                                                                                                                                                                                                  | 29 (10.6)                                                                                                                                                                                                  |
| Patients with Type Study identifier                                                                                                                                                                        |                                                                                                                                                                                                            | HbA 1c ≤6.5%                                                                                                                                                                                               | 22 (8.1)                                                                                                                                                                                                   | 15 (5.5)                                                                                                                                                                                                   |
| Patients with Type Study identifier                                                                                                                                                                        | Number (%) of patients at Month 6                                                                                                                                                                          | FPG <5.6 mmol/L (100 mg/dL)                                                                                                                                                                                | 27 (9.9)                                                                                                                                                                                                   | 35 (12.8)                                                                                                                                                                                                  |
| Patients with Type Study identifier                                                                                                                                                                        |                                                                                                                                                                                                            | FPG <5.6 mmol/L (100 mg/dL) and no emergent severe or confirmed hypoglycaemia                                                                                                                              | 9 (3.3)                                                                                                                                                                                                    | 12 (4.4)                                                                                                                                                                                                   |
| Patients with Type Study identifier                                                                                                                                                                        |                                                                                                                                                                                                            | FPG <5.6 mmol/L (100 mg/dL) and no nocturnal emergent severe or confirmed hypoglycaemia                                                                                                                    | 22 (8.1)                                                                                                                                                                                                   | 29 (10.6)                                                                                                                                                                                                  |
| Patients with Type Study identifier                                                                                                                                                                        |                                                                                                                                                                                                            | FPG <7.2 mmol/L (130 mg/dL)                                                                                                                                                                                | 69 (25.3)                                                                                                                                                                                                  | 70 (25.6)                                                                                                                                                                                                  |
| Patients with Type Study identifier                                                                                                                                                                        | Variability of 24-hour plasma glucose based on 8-point SMPG (%)                                                                                                                                            | Change from baseline to endpoint (Month 6): LS mean [95% CI]                                                                                                                                               | -3.92 (1.132) [-6.148 to -1.699]                                                                                                                                                                           | -2.87 (1.116) [-5.062 to -0.673]                                                                                                                                                                           |
| Patients with Type Study identifier                                                                                                                                                                        |                                                                                                                                                                                                            | At endpoint (Month 6): LS mean difference between HOE901-U300 overall and Lantus overall [95% CI]                                                                                                          | -1.06 [-4.180 to 2.068]                                                                                                                                                                                    | -1.06 [-4.180 to 2.068]                                                                                                                                                                                    |
| Patients with Type Study identifier                                                                                                                                                                        | Mean daily total (basal + mealtime) insulin                                                                                                                                                                | Month 6 OC                                                                                                                                                                                                 | 0.81                                                                                                                                                                                                       | 0.73                                                                                                                                                                                                       |
| Patients with Type Study identifier                                                                                                                                                                        | dose (U/kg)                                                                                                                                                                                                | Mean change from baseline                                                                                                                                                                                  | 0.19                                                                                                                                                                                                       | 0.10                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

Title :  A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period

Study identifier EFC12456 (EudraCT: 2012-001524-35)

CI: confidence interval, CMH: Cochran-Mantel-Haenszel, FPG: fasting plasma glucose, HbA1c: glycated hemoglobin A1c, LS: least squares, mITT: modified intention-to-treat, MMRM: mixed-model for repeated measurements, N: number of randomized patients, n: number of patients with measurements, OC: Observed Case, SC: subcutaneous, SD: standard deviation, SE: standard error, SMPG: self-monitored plasma glucose, T1DM: type 1 diabetes mellitus, RR: relative risk MMRM analysis with randomized groups (HOE901-U300 morning injection, HOE901-U300 evening injection, Lantus morning injection and Lantus evening injection), randomization strata of screening HbA1c (&lt;8.0, ≥8.0%),randomization strata of geographical region (Non-Japan; Japan), visit (Week 12, Month 6) and visit-by-randomized groups interaction as fixed categorical effects as well as baseline HbA1c value and baseline HbA1c-by-visit interaction as continuous fixed covariates Based on relative risk stratified by randomization strata of screening HbA1c (&lt;8.0, ≥8.0%),randomization strata of geographical region (Non-Japan; Japan), and time of injection (morning, evening) using a CMH methodology

Table 8 - Summary of efficacy for trial EFC11628

| Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                               | EFC11628 (EudraCT: 2010-023769-23)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | EFC11628 (EudraCT: 2010-023769-23)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Design                                                                                                                                                                                                                                                                         | This was a Phase 3, 6-month, multicenter, randomized, open-label, parallel-group study followed by a 6-month safety extension period to compare the efficacy and safety of HOE901-U300 and Lantus in patients with T2DM, and HbA 1c in the range 7% to 10%, injecting at least 42 U Lantus or equivalent NPH insulin. As there were no generally accepted recommendations for the switch from insulin detemir to insulin glargine, insulin detemir was considered a prohibited prior medication in the last 3 months before screening visit for T2DM patients on previous insulin treatment. Patients were randomized in a 1:1 ratio to receive either HOE901-U300 or Lantus. The randomization was stratified by screening HbA 1c value (<8%, ≥8%).                | This was a Phase 3, 6-month, multicenter, randomized, open-label, parallel-group study followed by a 6-month safety extension period to compare the efficacy and safety of HOE901-U300 and Lantus in patients with T2DM, and HbA 1c in the range 7% to 10%, injecting at least 42 U Lantus or equivalent NPH insulin. As there were no generally accepted recommendations for the switch from insulin detemir to insulin glargine, insulin detemir was considered a prohibited prior medication in the last 3 months before screening visit for T2DM patients on previous insulin treatment. Patients were randomized in a 1:1 ratio to receive either HOE901-U300 or Lantus. The randomization was stratified by screening HbA 1c value (<8%, ≥8%).                |
|                                                                                                                                                                                                                                                                                | Screening period Main treatment phase Safety extension period Post-treatment follow-up                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 2 weeks 6 months 6 months 4 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Statistical methods                                                                                                                                                                                                                                                            | A stepwise closed testing approach was used for the primary efficacy variable to assess noninferiority and superiority sequentially. To assess noninferiority, the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 and Lantus was compared with the predefined noninferiority margin of 0.4% HbA 1c , a value <0.4% demonstrates noninferiority. If noninferiority was demonstrated, superiority of HOE901-U300 over Lantus was tested. The superiority of HOE901-U300 over Lantus was demonstrated if the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 and Lantus on mITT population was <0 | A stepwise closed testing approach was used for the primary efficacy variable to assess noninferiority and superiority sequentially. To assess noninferiority, the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 and Lantus was compared with the predefined noninferiority margin of 0.4% HbA 1c , a value <0.4% demonstrates noninferiority. If noninferiority was demonstrated, superiority of HOE901-U300 over Lantus was tested. The superiority of HOE901-U300 over Lantus was demonstrated if the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 and Lantus on mITT population was <0 |

<div style=\"page-break-after: always\"></div>

| Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with   |                                                                                                                                                                                         |                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                               | EFC11628 (EudraCT: 2010-023769-23)                                                                                                                                                      |                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                          |
| Treatment groups                                                                                                                                                                                               | HOE901-U300 (insulin glargine, 300 U/mL), modified Solostar, SC injection every 24 hours in the evening; patients were to continue using their mealtime insulin 404 patients randomized |                                                                                                                                                                              | HOE901-U300 starting dose was based on dose of prior total basal insulin and fasting (prebreakfast) SMPG at baseline. Titration to achieve fasting (prebreakfast) SMPG in the range of 4.4 to 5.6 mmol/L (80 to 100 mg/dL) without hypoglycaemia. The titration of mealtime insulin aimed to achieve a 2-hour postprandial SMPG of <8.9 mmol/L (160 mg/dL) while avoiding hypoglycaemia. |
|                                                                                                                                                                                                                | Lantus (insulin glargine 100 U/mL), Solostar, SC injection every 24 hours in the evening; patients were to continue using their mealtime insulin                                        |                                                                                                                                                                              | Same as HOE901-U300                                                                                                                                                                                                                                                                                                                                                                      |
| 403 patients randomized Endpoints and definitions and 05:59 hours, drug mean value                                                                                                                             | Primary efficacy endpoint from start over last                                                                                                                                          | of Week 7 days                                                                                                                                                               | 9 to endpoint (Month 6)                                                                                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                | Change in HbA 1c (%)                                                                                                                                                                    | Change from baseline to endpoint (Month 6) in patients with T2DM                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                | Secondary efficacy endpoints                                                                                                                                                            |                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                | Nocturnal hypoglycaemia                                                                                                                                                                 | Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 |                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                | Pre-injection SMPG (mmol/L)                                                                                                                                                             | Change in pre-injection SMPG from baseline to endpoint (Month 6) obtained within 30 minutes prior to injection of study                                                      |                                                                                                                                                                                                                                                                                                                                                                                          |
| of study drug                                                                                                                                                                                                  | Variability of pre-injection SMPG (%) (coefficient of                                                                                                                                   | Change in variability from baseline to endpoint (Month 6) of pre-injection SMPG obtained within 30 minutes prior to injection variation                                      | of values over last 7 days)                                                                                                                                                                                                                                                                                                                                                              |
| Other secondary efficacy endpoints                                                                                                                                                                             |                                                                                                                                                                                         |                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                | Number (%) of patients with target HbA 1c <7%                                                                                                                                           |                                                                                                                                                                              | at endpoint (Month 6) at endpoint (Month 6) and having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last 3 months of the main 6-month on-treatment period any time of the day - between 00:00 and 05:59 hours                                                                              |
|                                                                                                                                                                                                                | Number (%) of patients with target HbA ≤6.5%                                                                                                                                            |                                                                                                                                                                              | at endpoint (Month 6)                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                               | EFC11628 (EudraCT: 2010-023769-23)                                                                                                                                                                                                                                             | EFC11628 (EudraCT: 2010-023769-23)                                                                                                                                                                                                                                             | EFC11628 (EudraCT: 2010-023769-23)                                                                                                                                                                                                                                             | EFC11628 (EudraCT: 2010-023769-23)                                                                                                                                                                                                                                             | EFC11628 (EudraCT: 2010-023769-23)                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                | Number (%) of patients with FPG <5.6 mmol/L (100 mg/dL) / FPG ≤6.7 mmol/L (120 mg/dL)                                                                                                                                                                                          | Number (%) of patients with FPG <5.6 mmol/L (100 mg/dL) / FPG ≤6.7 mmol/L (120 mg/dL)                                                                                                                                                                                          | at endpoint (Month 6) at endpoint (Month 6) and having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last 3 months of the main 6-month on-treatment period any time of the day    | at endpoint (Month 6) at endpoint (Month 6) and having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last 3 months of the main 6-month on-treatment period any time of the day    | at endpoint (Month 6) at endpoint (Month 6) and having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last 3 months of the main 6-month on-treatment period any time of the day    |
|                                                                                                                                                                                                                                                                                | 24-hour plasma glucose (mmol/L)                                                                                                                                                                                                                                                | 24-hour plasma glucose (mmol/L)                                                                                                                                                                                                                                                | - between 00:00 and 05:59 hours Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                               | - between 00:00 and 05:59 hours Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                               | - between 00:00 and 05:59 hours Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                               |
|                                                                                                                                                                                                                                                                                | Variability of 24-hour plasma glucose (mmol/L) (%)                                                                                                                                                                                                                             | Variability of 24-hour plasma glucose (mmol/L) (%)                                                                                                                                                                                                                             | Change in variability of 24-hour plasma glucose based on 8-point SMPG                                                                                                                                                                                                          | Change in variability of 24-hour plasma glucose based on 8-point SMPG                                                                                                                                                                                                          | Change in variability of 24-hour plasma glucose based on 8-point SMPG                                                                                                                                                                                                          |
|                                                                                                                                                                                                                                                                                | Daily average total (basal + mealtime) insulin dose (U/kg)                                                                                                                                                                                                                     | Daily average total (basal + mealtime) insulin dose (U/kg)                                                                                                                                                                                                                     | Change in daily average total insulin dose from baseline to endpoint (Month 6)                                                                                                                                                                                                 | Change in daily average total insulin dose from baseline to endpoint (Month 6)                                                                                                                                                                                                 | Change in daily average total insulin dose from baseline to endpoint (Month 6)                                                                                                                                                                                                 |
| Results and Analysis                                                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                           |
| Analysis description                                                                                                                                                                                                                                                           | Primary Analysis                                                                                                                                                                                                                                                               | Primary Analysis                                                                                                                                                                                                                                                               | Primary Analysis                                                                                                                                                                                                                                                               | Primary Analysis                                                                                                                                                                                                                                                               | Primary Analysis                                                                                                                                                                                                                                                               |
| Analysis population and time point description                                                                                                                                                                                                                                 | Modified intention-to-treat (mITT) population - change from baseline to endpoint (Month 6, LOCF)                                                                                                                                                                               | Modified intention-to-treat (mITT) population - change from baseline to endpoint (Month 6, LOCF)                                                                                                                                                                               | Modified intention-to-treat (mITT) population - change from baseline to endpoint (Month 6, LOCF)                                                                                                                                                                               | Modified intention-to-treat (mITT) population - change from baseline to endpoint (Month 6, LOCF)                                                                                                                                                                               | Modified intention-to-treat (mITT) population - change from baseline to endpoint (Month 6, LOCF)                                                                                                                                                                               |
| Descriptive statistics, point estimate, and effect estimate                                                                                                                                                                                                                    | Primary endpoint                                                                                                                                                                                                                                                               | Comparison groups                                                                                                                                                                                                                                                              | Comparison groups                                                                                                                                                                                                                                                              | HOE901-U300 (N=404)                                                                                                                                                                                                                                                            | Lantus (N=400)                                                                                                                                                                                                                                                                 |
| Descriptive statistics, point estimate, and effect estimate                                                                                                                                                                                                                    | HbA 1c (%)                                                                                                                                                                                                                                                                     | N                                                                                                                                                                                                                                                                              | N                                                                                                                                                                                                                                                                              | 391                                                                                                                                                                                                                                                                            | 394                                                                                                                                                                                                                                                                            |
| Descriptive statistics, point estimate, and effect estimate                                                                                                                                                                                                                    | HbA 1c (%)                                                                                                                                                                                                                                                                     | Endpoint (Month 6): Mean                                                                                                                                                                                                                                                       | Endpoint (Month 6): Mean                                                                                                                                                                                                                                                       | 7.25 (0.85)                                                                                                                                                                                                                                                                    | 7.28 (0.92)                                                                                                                                                                                                                                                                    |
| Descriptive statistics, point estimate, and effect estimate                                                                                                                                                                                                                    | HbA 1c (%)                                                                                                                                                                                                                                                                     | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]                                                                                                                                                                                                              | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]                                                                                                                                                                                                              | -0.83 (0.060) [-0.946 to -0.709]                                                                                                                                                                                                                                               | -0.83 (0.061) [-0.944 to -0.706]                                                                                                                                                                                                                                               |
| Descriptive statistics, point estimate, and effect estimate                                                                                                                                                                                                                    | HbA 1c (%)                                                                                                                                                                                                                                                                     | Change from baseline to endpoint (Month 6):LS mean difference (SE) HOE901-U300 versus Lantus                                                                                                                                                                                   | Change from baseline to endpoint (Month 6):LS mean difference (SE) HOE901-U300 versus Lantus                                                                                                                                                                                   | -0.00 (0.056) [-0.112 to 0.107]                                                                                                                                                                                                                                                | -0.00 (0.056) [-0.112 to 0.107]                                                                                                                                                                                                                                                |
| Descriptive statistics, point estimate, and effect estimate                                                                                                                                                                                                                    | Severe and/or confirmed nocturnal hypoglycaemia between start of Week 9 and endpoint                                                                                                                                                                                           | N                                                                                                                                                                                                                                                                              | N                                                                                                                                                                                                                                                                              | 404                                                                                                                                                                                                                                                                            | 400                                                                                                                                                                                                                                                                            |
| Descriptive statistics, point estimate, and effect estimate                                                                                                                                                                                                                    | Severe and/or confirmed nocturnal hypoglycaemia between start of Week 9 and endpoint                                                                                                                                                                                           | n (%) with at least 1 nocturnal hypoglycaemia                                                                                                                                                                                                                                  | n (%) with at least 1 nocturnal hypoglycaemia                                                                                                                                                                                                                                  | 146 (36.1)                                                                                                                                                                                                                                                                     | 184 (46.0)                                                                                                                                                                                                                                                                     |
| Descriptive statistics, point estimate, and effect estimate                                                                                                                                                                                                                    | Severe and/or confirmed nocturnal hypoglycaemia between start of Week 9 and endpoint                                                                                                                                                                                           | RR [95% CI] versus Lantus                                                                                                                                                                                                                                                      | RR [95% CI] versus Lantus                                                                                                                                                                                                                                                      | 0.79 [0.67 to 0.93]                                                                                                                                                                                                                                                            | 0.79 [0.67 to 0.93]                                                                                                                                                                                                                                                            |
| Descriptive statistics, point estimate, and effect estimate                                                                                                                                                                                                                    | Severe and/or confirmed nocturnal hypoglycaemia between start of Week 9 and endpoint                                                                                                                                                                                           | p-value (CMH)                                                                                                                                                                                                                                                                  | p-value (CMH)                                                                                                                                                                                                                                                                  | 0.0045                                                                                                                                                                                                                                                                         | 0.0045                                                                                                                                                                                                                                                                         |
| Descriptive statistics, point estimate, and effect estimate                                                                                                                                                                                                                    | Average                                                                                                                                                                                                                                                                        | N                                                                                                                                                                                                                                                                              | N                                                                                                                                                                                                                                                                              | 365                                                                                                                                                                                                                                                                            | 360                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period   |                                              |                                                                                                        |                                    |                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|--------------------------------------------------------------------------------------------------------|------------------------------------|------------------------------------|
|                                                                                                                                                                                                                                                                                | EFC11628 (EudraCT: 2010-023769-23)           |                                                                                                        |                                    |                                    |
| Study identifier                                                                                                                                                                                                                                                               | pre-injection SMPG (mmol/L)                  | Endpoint (Month 6) Mean (SD)                                                                           | 9.10 (2.42)                        | 9.27 (2.44)                        |
|                                                                                                                                                                                                                                                                                |                                              | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]                                      | -0.90 (0.182) [-1.260 to -0.544]   | -0.84 (0.182) [-1.196 to -0.480]   |
|                                                                                                                                                                                                                                                                                |                                              | Change from baseline to endpoint (Month 6): LS mean difference (SE) HOE901-U300 versus Lantus [95% CI] | -0.06 (0.162) [-0.383 to 0.254]    |                                    |
|                                                                                                                                                                                                                                                                                |                                              | p-value (ANCOVA)                                                                                       | 0.6909                             |                                    |
|                                                                                                                                                                                                                                                                                | Average pre-injection SMPG (mg/dL)           | N                                                                                                      | 365                                | 360                                |
|                                                                                                                                                                                                                                                                                |                                              | Endpoint (Month 6): Mean (SD)                                                                          | 163.98 (43.56)                     | 167.02 (44.05)                     |
|                                                                                                                                                                                                                                                                                |                                              | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]                                      | -16.25 (3.284) [-22.701 to -9.807] | -15.09 (3.284) [-21.541 to -8.645] |
|                                                                                                                                                                                                                                                                                |                                              | Change from baseline to endpoint (Month 6): LS mean difference (SE) HOE901-U300 versus Lantus [95% CI] | -1.16 (2.920) [-6.895 to 4.571]    |                                    |
|                                                                                                                                                                                                                                                                                |                                              | p-value (ANCOVA)                                                                                       | 0.6909                             |                                    |
|                                                                                                                                                                                                                                                                                | Variability of pre-injection SMPG (%)        | N                                                                                                      | 365                                | 360                                |
|                                                                                                                                                                                                                                                                                |                                              | Endpoint (Month 6): Mean (SD)                                                                          | 22.21 (11.75)                      | 21.60 (11.52)                      |
|                                                                                                                                                                                                                                                                                |                                              | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]                                      | -1.10 (1.222) [-3.502 to 1.295]    | -1.08 (1.222) [-3.476 to 1.324]    |
|                                                                                                                                                                                                                                                                                |                                              | Change from baseline to endpoint (Month 6): LS mean difference (SE) HOE901-U300 versus Lantus [95% CI] | -0.03 (1.087) [-2.161 to 2.107]    |                                    |
| Other secondary endpoints                                                                                                                                                                                                                                                      |                                              |                                                                                                        |                                    |                                    |
|                                                                                                                                                                                                                                                                                | Number (%) of patients at endpoint (Month 6) | N                                                                                                      | 365                                | 360                                |
|                                                                                                                                                                                                                                                                                |                                              | HbA 1c <7%                                                                                             | 155 (39.6)                         | 161 (40.9)                         |
|                                                                                                                                                                                                                                                                                |                                              | HbA 1c <7% and no emergent severe or confirmed hypoglycaemia                                           | 100 (25.4)                         | 97 (24.6)                          |

<div style=\"page-break-after: always\"></div>

| Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study                                                                                                                                                                                                                                                                          | EFC11628 (EudraCT: 2010-023769-23)                                                                                                                                                                                                                                             | EFC11628 (EudraCT: 2010-023769-23)                                                                                                                                                                                                                                             | EFC11628 (EudraCT: 2010-023769-23)                                                                                                                                                                                                                                             | EFC11628 (EudraCT: 2010-023769-23)                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                | HbA 1c <7% and no nocturnal emergent severe or confirmed hypoglycaemia                                                                                                                                                                                                         | 139 (35.5)                                                                                                                                                                                                                                                                     | 144 (36.5)                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                | HbA 1c ≤6.5%                                                                                                                                                                                                                                                                   | 82 (21.0)                                                                                                                                                                                                                                                                      | 85 (21.6)                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                   | FPG <5.6 mmol/L (100 mg/dL)                                                                                                                                                                                                                                                    | 103 (26.5)                                                                                                                                                                                                                                                                     | 91 (23.2)                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                   | FPG <5.6 mmol/L (100 mg/dL) and no emergent severe or confirmed hypoglycaemia                                                                                                                                                                                                  | 64 (16.3)                                                                                                                                                                                                                                                                      | 57 (14.5)                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                   | FPG <5.6 mmol/L (100 mg/dL) and no nocturnal emergent severe or confirmed (<3.0 mmol/L;<54mg/dL) hypoglycaemia                                                                                                                                                                 | 86 (22.1)                                                                                                                                                                                                                                                                      | 79 (20.2)                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                   | FPG ≤6.7 mmol/L (120 mg/dL)                                                                                                                                                                                                                                                    | 180 (46.3)                                                                                                                                                                                                                                                                     | 176 (44.9)                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                | 24-hour plasma glucose based on 8-point SMPG (mmol/L)                                                                                                                                                                                                                          | Change from baseline to endpoint (Month 6)                                                                                                                                                                                                                                     | -0.987 (-17.789)                                                                                                                                                                                                                                                               | -1.073 (-19.338)                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                | Variability of 24-hour plasma glucose based on 8-point SMPG (%)                                                                                                                                                                                                                | Change from baseline to endpoint (Month 6): LS mean [95% CI]                                                                                                                                                                                                                   | -2.26 [-4.474 to -0.052]                                                                                                                                                                                                                                                       | -0.33 [-2.559 to 1.893]                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                                | Variability of 24-hour plasma glucose based on 8-point SMPG (%)                                                                                                                                                                                                                | At endpoint (Month 6): LS mean difference HOE901-U300 versus Lantus [95% CI]                                                                                                                                                                                                   | -1.93 [-3.913 to 0.053]                                                                                                                                                                                                                                                        | -1.93 [-3.913 to 0.053]                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                                | Mean daily total (basal + mealtime) insulin dose (U/kg)                                                                                                                                                                                                                        | Month 6 OC                                                                                                                                                                                                                                                                     | 1.54                                                                                                                                                                                                                                                                           | 1.43                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                | Mean daily total (basal + mealtime) insulin dose (U/kg)                                                                                                                                                                                                                        | Mean change from baseline                                                                                                                                                                                                                                                      | 0.35                                                                                                                                                                                                                                                                           | 0.27                                                                                                                                                                                                                                                                           |

ANCOVA: analysis of covariance, CI: confidence interval, CMH: Cochran-Mantel-Haenszel, FPG=fasting plasma glucose, HbA1c: glycated hemoglobin A1c, LOCF: last observation carried forward, mITT:

modified intention-to-treat, LS: least squares, N: number of randomized patients, NPH: neutral protamine Hagedorn, n: number of patients with measurements, OC: Observed Case,

SC: subcutaneous, SD: standard deviation, SE: standard error, SMPG: self-monitored plasma glucose, T2DM: type 2 diabetes mellitus

<div style=\"page-break-after: always\"></div>

## Table 9 - Summary of efficacy for trial EFC11629

| Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Design                                                                                                                                                                                                                                                                                                | EFC11629 (EudraCT: 2010-023770-39) This was a Phase 3, 6-month, multicenter, randomized, open-label, parallel-group followed by a 6-month safety extension period to compare the efficacy and safety of HOE901-U300 and Lantus in patients with T2DM, and HbA 1c in the range 7% to 10%, injecting at least 42 U Lantus or equivalent NPH insulin with OADs. As there were no generally accepted recommendations for the switch from insulin detemir to insulin glargine, insulin detemir was considered a prohibited prior medication in the last 3 months before screening visit for T2DM patients on previous insulin treatment. Patients were randomized in a 1:1 ratio to receive either HOE901-U300 or Lantus. The randomization was stratified by screening HbA value (<8%, ≥8%). | EFC11629 (EudraCT: 2010-023770-39) This was a Phase 3, 6-month, multicenter, randomized, open-label, parallel-group followed by a 6-month safety extension period to compare the efficacy and safety of HOE901-U300 and Lantus in patients with T2DM, and HbA 1c in the range 7% to 10%, injecting at least 42 U Lantus or equivalent NPH insulin with OADs. As there were no generally accepted recommendations for the switch from insulin detemir to insulin glargine, insulin detemir was considered a prohibited prior medication in the last 3 months before screening visit for T2DM patients on previous insulin treatment. Patients were randomized in a 1:1 ratio to receive either HOE901-U300 or Lantus. The randomization was stratified by screening HbA value (<8%, ≥8%). | EFC11629 (EudraCT: 2010-023770-39) This was a Phase 3, 6-month, multicenter, randomized, open-label, parallel-group followed by a 6-month safety extension period to compare the efficacy and safety of HOE901-U300 and Lantus in patients with T2DM, and HbA 1c in the range 7% to 10%, injecting at least 42 U Lantus or equivalent NPH insulin with OADs. As there were no generally accepted recommendations for the switch from insulin detemir to insulin glargine, insulin detemir was considered a prohibited prior medication in the last 3 months before screening visit for T2DM patients on previous insulin treatment. Patients were randomized in a 1:1 ratio to receive either HOE901-U300 or Lantus. The randomization was stratified by screening HbA value (<8%, ≥8%). |
| Design                                                                                                                                                                                                                                                                                                | Screening period Main treatment phase Safety extension period Post-treatment follow-up                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Screening period Main treatment phase Safety extension period Post-treatment follow-up                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 1c 2 weeks 6 months 6 months 4 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Statistical methods                                                                                                                                                                                                                                                                                   | A stepwise closed testing approach was used for the primary efficacy variable to assess noninferiority and superiority sequentially. To assess noninferiority, the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 and Lantus was compared with the predefined noninferiority margin of 0.4% HbA 1c , a value <0.4% demonstrates noninferiority. If noninferiority was demonstrated, superiority of HOE901-U300 over Lantus was tested. The superiority of HOE901-U300 over Lantus was demonstrated if the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 and Lantus on mITT population was <0 (zero).              | A stepwise closed testing approach was used for the primary efficacy variable to assess noninferiority and superiority sequentially. To assess noninferiority, the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 and Lantus was compared with the predefined noninferiority margin of 0.4% HbA 1c , a value <0.4% demonstrates noninferiority. If noninferiority was demonstrated, superiority of HOE901-U300 over Lantus was tested. The superiority of HOE901-U300 over Lantus was demonstrated if the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 and Lantus on mITT population was <0 (zero).              | A stepwise closed testing approach was used for the primary efficacy variable to assess noninferiority and superiority sequentially. To assess noninferiority, the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 and Lantus was compared with the predefined noninferiority margin of 0.4% HbA 1c , a value <0.4% demonstrates noninferiority. If noninferiority was demonstrated, superiority of HOE901-U300 over Lantus was tested. The superiority of HOE901-U300 over Lantus was demonstrated if the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 and Lantus on mITT population was <0 (zero).              |
| Treatment groups                                                                                                                                                                                                                                                                                      | HOE901-U300 (insulin glargine, 300 U/mL), modified Solostar, SC injection every 24 hours in the evening 403 patients randomized                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | HOE901-U300 (insulin glargine, 300 U/mL), modified Solostar, SC injection every 24 hours in the evening 403 patients randomized                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | HOE901-U300 starting dose was based on dose of prior total basal insulin and fasting (prebreakfast) SMPG at baseline. Titration to achieve fasting (prebreakfast) SMPG in the range of 4.4 to 5.6 mmol/L (80 to 100 mg/dL) without hypoglycaemia. The titration of mealtime insulin aimed to achieve a 2-hour postprandial SMPG of <8.9 mmol (160 mg/dL) while avoiding hypoglycaemia.                                                                                                                                                                                                                                                                                                                                                                                                   |
| Treatment groups                                                                                                                                                                                                                                                                                      | Lantus (insulin glargine, 100 U/mL), Solostar, SC injection every 24 hours in the evening 405 patients randomized                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Lantus (insulin glargine, 100 U/mL), Solostar, SC injection every 24 hours in the evening 405 patients randomized                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Same as HOE901-U300                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                                                                                                             | Primary efficacy endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Primary efficacy endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Primary efficacy endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                                                                                                                                             | Change in HbA 1c (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Change from baseline to endpoint (Month 6) in patients with T2DM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Change from baseline to endpoint (Month 6) in patients with T2DM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Endpoints and definitions                                                                                                                                                                                                                                                                             | Secondary efficacy endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Secondary efficacy endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Secondary efficacy endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Period Study identifier                                                                                                                                                                                                                                                                               | EFC11629 (EudraCT: 2010-023770-39)                                                                                                                                                                                                                                                                    | EFC11629 (EudraCT: 2010-023770-39)                                                                                                                                                                                                                                                                        |
| Period Study identifier                                                                                                                                                                                                                                                                               | Nocturnal hypoglycaemia                                                                                                                                                                                                                                                                               | Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to endpoint (Month 6)                                                                  |
| Period Study identifier                                                                                                                                                                                                                                                                               | Pre-injection SMPG (mmol/L)                                                                                                                                                                                                                                                                           | Change in pre-injection SMPG (mmol/L) (obtained within 30 minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                     |
| Period Study identifier                                                                                                                                                                                                                                                                               | Variability of pre-injection SMPG                                                                                                                                                                                                                                                                     | Change in variability of pre-injection SMPG (obtained within 30 minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                           |
| Period Study identifier                                                                                                                                                                                                                                                                               | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                    | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                        |
| Period Study identifier                                                                                                                                                                                                                                                                               | Number (%) of patients with target HbA 1c <7%                                                                                                                                                                                                                                                         | at endpoint (Month 6) at endpoint (Month 6) having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last 3 months of the main 6-month on-treatment period - any time of the day -between 00:00 and 05:59 hours. |
| Period Study identifier                                                                                                                                                                                                                                                                               | Number (%) of patients with target HbA 1c ≤6.5%                                                                                                                                                                                                                                                       | at endpoint (Month 6)                                                                                                                                                                                                                                                                                     |
| Period Study identifier                                                                                                                                                                                                                                                                               | Number (%) of patients with FPG <5.6 mmol/L (100 mg/dL) / FPG ≤6.7 mmol/L (120 mg/dL)                                                                                                                                                                                                                 | at endpoint (Month 6) at endpoint (Month 6) having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last 3 months of the main 6-month on-treatment period at any time of the day.                               |
| Period Study identifier                                                                                                                                                                                                                                                                               | 24-hour plasma glucose (mmol/L)                                                                                                                                                                                                                                                                       | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                          |
| Period Study identifier                                                                                                                                                                                                                                                                               | Variability of 24-hour plasma glucose (mmol/L)                                                                                                                                                                                                                                                        | Change in variability of 24-hour plasma glucose based on 8-point SMPG.                                                                                                                                                                                                                                    |
| Period Study identifier                                                                                                                                                                                                                                                                               | Daily average basal insulin dose (U/kg)                                                                                                                                                                                                                                                               | Change in daily average basal insulin dose from baseline to endpoint (Month 6)                                                                                                                                                                                                                            |
| Results and Analysis                                                                                                                                                                                                                                                                                  | Results and Analysis                                                                                                                                                                                                                                                                                  | Results and Analysis                                                                                                                                                                                                                                                                                      |
| Analysis description                                                                                                                                                                                                                                                                                  | Primary Analysis                                                                                                                                                                                                                                                                                      | Primary Analysis                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Period Study identifier                                                                                                                                                                                                                                                                               | EFC11629 (EudraCT: 2010-023770-39)                                                                                                                                                                                                                                                                    | EFC11629 (EudraCT: 2010-023770-39)                                                                                                                                                                                                                                                                    | EFC11629 (EudraCT: 2010-023770-39)                                                                                                                                                                                                                                                                    | EFC11629 (EudraCT: 2010-023770-39)                                                                                                                                                                                                                                                                    | EFC11629 (EudraCT: 2010-023770-39)                                                                                                                                                                                                                                                                    |
| Analysis population and time point                                                                                                                                                                                                                                                                    | Modified intention-to-treat (mITT) population - change from baseline to endpoint (Month 6, LOCF)                                                                                                                                                                                                      | Modified intention-to-treat (mITT) population - change from baseline to endpoint (Month 6, LOCF)                                                                                                                                                                                                      | Modified intention-to-treat (mITT) population - change from baseline to endpoint (Month 6, LOCF)                                                                                                                                                                                                      | Modified intention-to-treat (mITT) population - change from baseline to endpoint (Month 6, LOCF)                                                                                                                                                                                                      | Modified intention-to-treat (mITT) population - change from baseline to endpoint (Month 6, LOCF)                                                                                                                                                                                                      |
| description Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                                | Primary endpoint                                                                                                                                                                                                                                                                                      | Primary endpoint                                                                                                                                                                                                                                                                                      | Comparison groups                                                                                                                                                                                                                                                                                     | HOE901-U300 (N=403)                                                                                                                                                                                                                                                                                   | Lantus (N=405)                                                                                                                                                                                                                                                                                        |
| description Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                                | HbA 1c (%)                                                                                                                                                                                                                                                                                            | HbA 1c (%)                                                                                                                                                                                                                                                                                            | n                                                                                                                                                                                                                                                                                                     | 386                                                                                                                                                                                                                                                                                                   | 392                                                                                                                                                                                                                                                                                                   |
| description Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                       | Endpoint (Month 6): Mean (SD)                                                                                                                                                                                                                                                                         | 7.57 (1.02)                                                                                                                                                                                                                                                                                           | 7.56 (1.04)                                                                                                                                                                                                                                                                                           |
| description Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                       | Change from baseline to endpoint (Month 6): LS Mean (SE) [95% CI]                                                                                                                                                                                                                                     | -0.57 (0.094) [-0.756 to 0.387]                                                                                                                                                                                                                                                                       | -0.56 (0.093) [-0.744 to -0.379]                                                                                                                                                                                                                                                                      |
| description Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                       | Change from baseline to endpoint (Month 6): LS Mean difference (SE) HOE901-U300 versus Lantus [95% CI]                                                                                                                                                                                                | -0.01 (0.066) [-0.139 to 0.119]                                                                                                                                                                                                                                                                       | -0.01 (0.066) [-0.139 to 0.119]                                                                                                                                                                                                                                                                       |
| description Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                                | Secondary endpoints                                                                                                                                                                                                                                                                                   | Secondary endpoints                                                                                                                                                                                                                                                                                   | Comparison groups                                                                                                                                                                                                                                                                                     | HOE901-U300 (N=403)                                                                                                                                                                                                                                                                                   | Lantus (N=405)                                                                                                                                                                                                                                                                                        |
| description Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                                | Severe and/or                                                                                                                                                                                                                                                                                         | Severe and/or                                                                                                                                                                                                                                                                                         | n                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                       |
| description Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                                | confirmed nocturnal hypoglycaemia between start of Week 9 and                                                                                                                                                                                                                                         | confirmed nocturnal hypoglycaemia between start of Week 9 and                                                                                                                                                                                                                                         | n (%) with at least 1 nocturnal hypoglycaemia                                                                                                                                                                                                                                                         | 87 (21.6)                                                                                                                                                                                                                                                                                             | 113 (27.9)                                                                                                                                                                                                                                                                                            |
| description Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                       | RR [95% CI] versus Lantus                                                                                                                                                                                                                                                                             | 0.77 [0.61 to 0.99]                                                                                                                                                                                                                                                                                   | 0.77 [0.61 to 0.99]                                                                                                                                                                                                                                                                                   |
| description Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                       | p-value (CMH)                                                                                                                                                                                                                                                                                         | 0.0380                                                                                                                                                                                                                                                                                                | 0.0380                                                                                                                                                                                                                                                                                                |
| description Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                       | Average pre-injection SMPG (mmol/L)                                                                                                                                                                                                                                                                   | n                                                                                                                                                                                                                                                                                                     | 353                                                                                                                                                                                                                                                                                                   | 350                                                                                                                                                                                                                                                                                                   |
| description Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                       | Average pre-injection SMPG (mmol/L)                                                                                                                                                                                                                                                                   | Endpoint (Month 6): Mean (SD)                                                                                                                                                                                                                                                                         | 10.23 (3.03)                                                                                                                                                                                                                                                                                          | 10.28 (3.05)                                                                                                                                                                                                                                                                                          |
| description Descriptive statistics, point estimate and effect estimate                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                       | Average pre-injection SMPG (mmol/L)                                                                                                                                                                                                                                                                   | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]                                                                                                                                                                                                                                     | -0.56 (0.278) [-1.101 to -0.010]                                                                                                                                                                                                                                                                      | -0.51 (0.275) [-1.052 to 0.028]                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   |                                       |                                                                   |                                                                     |                                        |                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|----------------------------------------|----------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                      | EFC11629 (EudraCT: 2010-023770-39)    |                                                                   |                                                                     |                                        |                                  |
|                                                                                                                                                                                                                                                                                                       |                                       | baseline endpoint (Month LS mean (SE) versus [95% CI] p-value     | Change from to 6): difference HOE901-U300 Lantus (ANCOVA)           | -0.04 (0.201) [-0.438 to 0.350] 0.8279 |                                  |
|                                                                                                                                                                                                                                                                                                       |                                       | Average pre-injection SMPG (mg/dL)                                | n                                                                   | 353                                    | 350                              |
|                                                                                                                                                                                                                                                                                                       |                                       |                                                                   | Endpoint (Month 6): Mean (SD)                                       | 184.31 (54.51)                         | 185.10 (54.90)                   |
|                                                                                                                                                                                                                                                                                                       |                                       |                                                                   | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]   | -10.01 (5.004) [-19.833 to -0.184]     | -9.22 (4.951) [-18.944 to 0.499] |
|                                                                                                                                                                                                                                                                                                       |                                       |                                                                   | Change from baseline to endpoint (Month 6): LS mean                 | -0.79 (3.615) [-7.883 to 6.311]        |                                  |
|                                                                                                                                                                                                                                                                                                       |                                       |                                                                   | difference (SE) HOE901-U300 versus Lantus [95% CI] p-value (ANCOVA) | 0.8279                                 |                                  |
|                                                                                                                                                                                                                                                                                                       | Variability of pre-injection SMPG (%) |                                                                   | n                                                                   | 353                                    | 350                              |
|                                                                                                                                                                                                                                                                                                       |                                       |                                                                   | Endpoint (Month 6): Mean (SD)                                       | 19.84 (10.40)                          | 20.37 (11.65)                    |
|                                                                                                                                                                                                                                                                                                       |                                       | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI] | -2.34 (1.425) [-5.142 to 0.452]                                     |                                        | -0.53 (1.408) [-3.297 to 2.231]  |

<div style=\"page-break-after: always\"></div>

| Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycaemic drug(s) in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Period Study identifier                                                                                                                                                                                                                                                                               | EFC11629 (EudraCT: 2010-023770-39)                                                                                                                                                                                                                                                                    | EFC11629 (EudraCT: 2010-023770-39)                                                                                                                                                                                                                                                                    | EFC11629 (EudraCT: 2010-023770-39)                                                                                                                                                                                                                                                                    | EFC11629 (EudraCT: 2010-023770-39)                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                       | Change from baseline to endpoint (Month 6): LS mean difference (SE) HOE901-U300 versus Lantus [95% CI]                                                                                                                                                                                                | -1.81 (1.029) [-3.833 to 0.210]                                                                                                                                                                                                                                                                       | -1.81 (1.029) [-3.833 to 0.210]                                                                                                                                                                                                                                                                       |
|                                                                                                                                                                                                                                                                                                       | Other secondary endpoints                                                                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                                                                     | HOE901-U300 (N=404)                                                                                                                                                                                                                                                                                   | Lantus (N=400)                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | HbA 1c <7%                                                                                                                                                                                                                                                                                            | n=386                                                                                                                                                                                                                                                                                                 | n=392                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | HbA 1c <7%                                                                                                                                                                                                                                                                                            | 118 (30.6)                                                                                                                                                                                                                                                                                            | 119 (30.4)                                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | HbA 1c <7% and no emergent severe or confirmed hypoglycaemia                                                                                                                                                                                                                                          | n=388                                                                                                                                                                                                                                                                                                 | n=396                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | HbA 1c <7% and no emergent severe or confirmed hypoglycaemia                                                                                                                                                                                                                                          | 93 (24.0)                                                                                                                                                                                                                                                                                             | 94 (23.7)                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | HbA 1c <7% and no                                                                                                                                                                                                                                                                                     | n=387                                                                                                                                                                                                                                                                                                 | n=394                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | nocturnal emergent severe or confirmed hypoglycaemia                                                                                                                                                                                                                                                  | 107 (27.6)                                                                                                                                                                                                                                                                                            | 113 (28.7)                                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | HbA 1c ≤6.5%                                                                                                                                                                                                                                                                                          | n=386                                                                                                                                                                                                                                                                                                 | n=392                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | HbA 1c ≤6.5%                                                                                                                                                                                                                                                                                          | 56 (14.5)                                                                                                                                                                                                                                                                                             | 58 (14.8)                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | FPG <5.6 mmol/L (100 mg/dL)                                                                                                                                                                                                                                                                           | n=384                                                                                                                                                                                                                                                                                                 | n=390                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | FPG <5.6 mmol/L (100 mg/dL)                                                                                                                                                                                                                                                                           | 113 (29.4)                                                                                                                                                                                                                                                                                            | 131 (33.6)                                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | FPG <5.6 mmol/L (100 mg/dL) and                                                                                                                                                                                                                                                                       | n=386                                                                                                                                                                                                                                                                                                 | n=395                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | no emergent severe or confirmed hypoglycaemia                                                                                                                                                                                                                                                         | 81 (21.0)                                                                                                                                                                                                                                                                                             | 97 (24.6)                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | FPG <5.6 mmol/L (100 mg/dL) and no nocturnal emergent severe                                                                                                                                                                                                                                          | n=385                                                                                                                                                                                                                                                                                                 | n=393                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | FPG <5.6 mmol/L (100 mg/dL) and no nocturnal emergent severe                                                                                                                                                                                                                                          | 100 (26.0)                                                                                                                                                                                                                                                                                            | 121 (30.8)                                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | hypoglycaemia FPG ≤6.7 mmol/L (120 mg/dL)                                                                                                                                                                                                                                                             | n=384                                                                                                                                                                                                                                                                                                 | n=390                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                       | Number (%) of patients at endpoint (Month 6)                                                                                                                                                                                                                                                          | hypoglycaemia FPG ≤6.7 mmol/L (120 mg/dL)                                                                                                                                                                                                                                                             | 187 (48.7)                                                                                                                                                                                                                                                                                            | 211 (54.1)                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Study identifier EFC11629                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Study identifier EFC11629                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Study identifier EFC11629                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Study identifier EFC11629                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 2010-023770-39) Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]                                                                                                                                                                                                                                                                                                                                                                                                                    | -0.905 (0.2203) [-1.3373 to -0.4723]                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | -1.115 (0.2187) [-1.5447 to -0.6859]                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Variability of 24-hour plasma glucose based on 8-point SMPG (%)                                                                                                                                                                                                                                                                                                                                                                                                                                      | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI] Change from                                                                                                                                                                                                                                                                                                                                                                                                                        | -1.63 (1.302) [-4.191 to 0.921]                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -0.90 (1.292) [-3.437 to 1.635]                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Variability of 24-hour plasma glucose based on 8-point SMPG (%)                                                                                                                                                                                                                                                                                                                                                                                                                                      | baseline to endpoint (Month 6): LS mean difference (SE) HOE901-U300 versus Lantus [95% CI]                                                                                                                                                                                                                                                                                                                                                                                                           | -0.73 (0.960) [-2.618 to 1.150]                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -0.73 (0.960) [-2.618 to 1.150]                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Mean daily average basal insulin dose (U/kg)                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Month 6 OC:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Mean daily average basal insulin dose (U/kg)                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Month 6 OC:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.93                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.84                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Mean daily average basal insulin dose (U/kg)                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Mean change from baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0.30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ANCOVA: analysis of covariance, CI: confidence interval, CMH: Cochran-Mantel-Haenszel, FPG: fasting plasma glucose, HbA 1c : glycated hemoglobin A 1c , LOCF: last observation carried forward, LS: least squares, mITT: modified intention-to-treat, N: number of randomized patients, n: number of patients with measurements, NPH: neutral protamine Hagedorn, OC: Observed Case, SC: subcutaneous, SD: standard deviation, SE: standard error, SMPG: self-monitored plasma glucose, T2DM: type 2 | ANCOVA: analysis of covariance, CI: confidence interval, CMH: Cochran-Mantel-Haenszel, FPG: fasting plasma glucose, HbA 1c : glycated hemoglobin A 1c , LOCF: last observation carried forward, LS: least squares, mITT: modified intention-to-treat, N: number of randomized patients, n: number of patients with measurements, NPH: neutral protamine Hagedorn, OC: Observed Case, SC: subcutaneous, SD: standard deviation, SE: standard error, SMPG: self-monitored plasma glucose, T2DM: type 2 | ANCOVA: analysis of covariance, CI: confidence interval, CMH: Cochran-Mantel-Haenszel, FPG: fasting plasma glucose, HbA 1c : glycated hemoglobin A 1c , LOCF: last observation carried forward, LS: least squares, mITT: modified intention-to-treat, N: number of randomized patients, n: number of patients with measurements, NPH: neutral protamine Hagedorn, OC: Observed Case, SC: subcutaneous, SD: standard deviation, SE: standard error, SMPG: self-monitored plasma glucose, T2DM: type 2 | ANCOVA: analysis of covariance, CI: confidence interval, CMH: Cochran-Mantel-Haenszel, FPG: fasting plasma glucose, HbA 1c : glycated hemoglobin A 1c , LOCF: last observation carried forward, LS: least squares, mITT: modified intention-to-treat, N: number of randomized patients, n: number of patients with measurements, NPH: neutral protamine Hagedorn, OC: Observed Case, SC: subcutaneous, SD: standard deviation, SE: standard error, SMPG: self-monitored plasma glucose, T2DM: type 2 | ANCOVA: analysis of covariance, CI: confidence interval, CMH: Cochran-Mantel-Haenszel, FPG: fasting plasma glucose, HbA 1c : glycated hemoglobin A 1c , LOCF: last observation carried forward, LS: least squares, mITT: modified intention-to-treat, N: number of randomized patients, n: number of patients with measurements, NPH: neutral protamine Hagedorn, OC: Observed Case, SC: subcutaneous, SD: standard deviation, SE: standard error, SMPG: self-monitored plasma glucose, T2DM: type 2 |

<div style=\"page-break-after: always\"></div>

## Table 10 - Summary of efficacy for trial EFC12347

| Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                              | Period EFC12347 (EudraCT: 2012-000146-35)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Period EFC12347 (EudraCT: 2012-000146-35)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Design                                                                                                                                                                                                                                                                                                        | This was a Phase 3, 6-month, multicenter, randomized, open-label, parallel-group study followed by a 6-month safety extension period to compare the efficacy and safety of HOE901-U300 and Lantus in insulin-naïve patients with T2DM, and HbA 1c in the range 7% to 11%, not adequately controlled with non-insulin AHA. Patients were randomized in a 1:1 ratio to receive either HOE901-U300 or Lantus. The randomization was stratified by screening HbA 1c at screening (<8%, ≥8%) and geographical region (Non-Japan or Japan).                                                                                                                                                                                                                               | This was a Phase 3, 6-month, multicenter, randomized, open-label, parallel-group study followed by a 6-month safety extension period to compare the efficacy and safety of HOE901-U300 and Lantus in insulin-naïve patients with T2DM, and HbA 1c in the range 7% to 11%, not adequately controlled with non-insulin AHA. Patients were randomized in a 1:1 ratio to receive either HOE901-U300 or Lantus. The randomization was stratified by screening HbA 1c at screening (<8%, ≥8%) and geographical region (Non-Japan or Japan).                                                                                                                                                                                                                               |
| Design                                                                                                                                                                                                                                                                                                        | Screening period 2 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Screening period 2 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Design                                                                                                                                                                                                                                                                                                        | Main treatment phase Safety extension period Post-treatment follow-up 6 months 6 months 2 to 4 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Main treatment phase Safety extension period Post-treatment follow-up 6 months 6 months 2 to 4 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Statistical methods                                                                                                                                                                                                                                                                                           | A stepwise closed testing approach was used for the primary efficacy variable to assess noninferiority and superiority sequentially. To assess noninferiority, the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 and Lantus was compared with the predefined noninferiority margin of 0.4% HbA 1c , a value <0.4% demonstrates noninferiority. If noninferiority was demonstrated, superiority of HOE901-U300 over Lantus was tested. The superiority of HOE901-U300 over Lantus was demonstrated if the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 and Lantus on mITT population was <0 | A stepwise closed testing approach was used for the primary efficacy variable to assess noninferiority and superiority sequentially. To assess noninferiority, the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 and Lantus was compared with the predefined noninferiority margin of 0.4% HbA 1c , a value <0.4% demonstrates noninferiority. If noninferiority was demonstrated, superiority of HOE901-U300 over Lantus was tested. The superiority of HOE901-U300 over Lantus was demonstrated if the upper bound of the two-sided 95% CI for the difference in the mean change in HbA 1c from baseline to endpoint between HOE901-U300 and Lantus on mITT population was <0 |
| Treatment groups                                                                                                                                                                                                                                                                                              | (zero). HOE901-U300 (insulin glargine, 300 U/mL), modified Tactipen, SC injection every 24 hours in the evening patients were to continue using their non-insulin AHA The initial daily dose of basal insulin was 0.2 U/kg, rounded to the closest number divisible by 3. Doses were titrated to achieve the target FPG in the range of 4.4 to 5.6 mmol/L (80 to 100 mg/dL). After reaching the target range,                                                                                                                                                                                                                                                                                                                                                       | (zero). HOE901-U300 (insulin glargine, 300 U/mL), modified Tactipen, SC injection every 24 hours in the evening patients were to continue using their non-insulin AHA The initial daily dose of basal insulin was 0.2 U/kg, rounded to the closest number divisible by 3. Doses were titrated to achieve the target FPG in the range of 4.4 to 5.6 mmol/L (80 to 100 mg/dL). After reaching the target range,                                                                                                                                                                                                                                                                                                                                                       |
| Treatment groups                                                                                                                                                                                                                                                                                              | Lantus (insulin glargine 100 U/mL), Solostar, SC injection every 24 hours in the evening; patients were to continue using their non-insulin AHA Same as HOE901-U300.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Lantus (insulin glargine 100 U/mL), Solostar, SC injection every 24 hours in the evening; patients were to continue using their non-insulin AHA Same as HOE901-U300.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                                                                                                                                                     | Primary efficacy endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Primary efficacy endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Endpoints and definitions                                                                                                                                                                                                                                                                                     | Change in HbA 1c (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Change from baseline to endpoint (Month 6) in patients with T2DM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Endpoints and definitions                                                                                                                                                                                                                                                                                     | Secondary efficacy endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Secondary efficacy endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Period   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Diabetes Safety Extension Study identifier                                                                                                                                                                                                                                                                  | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   | (EudraCT:                                                                                                                                                                                                                                                                                                   |
| Diabetes Safety Extension Study identifier                                                                                                                                                                                                                                                                  | EFC12347 Nocturnal hypoglycaemia                                                                                                                                                                                                                                                                            | 2012-000146-35) Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                               | 2012-000146-35) Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                               | 2012-000146-35) Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                               | 2012-000146-35) Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                               | 2012-000146-35) Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                               | 2012-000146-35) Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                               | 2012-000146-35) Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                               | 2012-000146-35) Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                               | 2012-000146-35) Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                               | 2012-000146-35) Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                               | 2012-000146-35) Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                               | 2012-000146-35) Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                               | 2012-000146-35) Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                               | 2012-000146-35) Incidence (%) of patients with at least 1 nocturnal hypoglycaemia, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL) that occurred between 00:00 and 05:59 hours, from start of Week 9 to Month 6                                                               |                                                                                                                                                                                                                                                                                                             |
| Diabetes Safety Extension Study identifier                                                                                                                                                                                                                                                                  | Pre-injection SMPG (mmol/L) 30                                                                                                                                                                                                                                                                              | Change in pre-injection SMPG (mmol/L) (obtained within minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                          | Change in pre-injection SMPG (mmol/L) (obtained within minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                          | Change in pre-injection SMPG (mmol/L) (obtained within minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                          | Change in pre-injection SMPG (mmol/L) (obtained within minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                          | Change in pre-injection SMPG (mmol/L) (obtained within minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                          | Change in pre-injection SMPG (mmol/L) (obtained within minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                          | Change in pre-injection SMPG (mmol/L) (obtained within minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                          | Change in pre-injection SMPG (mmol/L) (obtained within minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                          | Change in pre-injection SMPG (mmol/L) (obtained within minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                          | Change in pre-injection SMPG (mmol/L) (obtained within minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                          | Change in pre-injection SMPG (mmol/L) (obtained within minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                          | Change in pre-injection SMPG (mmol/L) (obtained within minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                          | Change in pre-injection SMPG (mmol/L) (obtained within minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                          | Change in pre-injection SMPG (mmol/L) (obtained within minutes prior to injection of study drug; mean over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                                          |                                                                                                                                                                                                                                                                                                             |
| Diabetes Safety Extension Study identifier                                                                                                                                                                                                                                                                  | Variability of pre-injection SMPG (%) 30                                                                                                                                                                                                                                                                    | Variability of pre-injection SMPG (obtained within minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                          | Variability of pre-injection SMPG (obtained within minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                          | Variability of pre-injection SMPG (obtained within minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                          | Variability of pre-injection SMPG (obtained within minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                          | Variability of pre-injection SMPG (obtained within minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                          | Variability of pre-injection SMPG (obtained within minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                          | Variability of pre-injection SMPG (obtained within minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                          | Variability of pre-injection SMPG (obtained within minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                          | Variability of pre-injection SMPG (obtained within minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                          | Variability of pre-injection SMPG (obtained within minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                          | Variability of pre-injection SMPG (obtained within minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                          | Variability of pre-injection SMPG (obtained within minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                          | Variability of pre-injection SMPG (obtained within minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                          | Variability of pre-injection SMPG (obtained within minutes prior to injection of study drug; coefficient of variation over last 7 days values) from baseline to endpoint (Month 6)                                                                                                                          |                                                                                                                                                                                                                                                                                                             |
| Diabetes Safety Extension Study identifier                                                                                                                                                                                                                                                                  | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          | Other secondary efficacy endpoints                                                                                                                                                                                                                                                                          |
| Diabetes Safety Extension Study identifier                                                                                                                                                                                                                                                                  | Number (%) of patients with target HbA 1c <7% 3 - -                                                                                                                                                                                                                                                         | At Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period any time of the day between 00:00 and 05:59 hours                               | At Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period any time of the day between 00:00 and 05:59 hours                               | At Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period any time of the day between 00:00 and 05:59 hours                               | At Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period any time of the day between 00:00 and 05:59 hours                               | At Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period any time of the day between 00:00 and 05:59 hours                               | At Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period any time of the day between 00:00 and 05:59 hours                               | At Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period any time of the day between 00:00 and 05:59 hours                               | At Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period any time of the day between 00:00 and 05:59 hours                               | At Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period any time of the day between 00:00 and 05:59 hours                               | At Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period any time of the day between 00:00 and 05:59 hours                               | At Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period any time of the day between 00:00 and 05:59 hours                               | At Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period any time of the day between 00:00 and 05:59 hours                               | At Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period any time of the day between 00:00 and 05:59 hours                               | At Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period any time of the day between 00:00 and 05:59 hours                               |                                                                                                                                                                                                                                                                                                             |
| Diabetes Safety Extension Study identifier                                                                                                                                                                                                                                                                  | Number (%) of patients with target HbA ≤6.5% at                                                                                                                                                                                                                                                             | Month 6                                                                                                                                                                                                                                                                                                     | Month 6                                                                                                                                                                                                                                                                                                     | Month 6                                                                                                                                                                                                                                                                                                     | Month 6                                                                                                                                                                                                                                                                                                     | Month 6                                                                                                                                                                                                                                                                                                     | Month 6                                                                                                                                                                                                                                                                                                     | Month 6                                                                                                                                                                                                                                                                                                     | Month 6                                                                                                                                                                                                                                                                                                     | Month 6                                                                                                                                                                                                                                                                                                     | Month 6                                                                                                                                                                                                                                                                                                     | Month 6                                                                                                                                                                                                                                                                                                     | Month 6                                                                                                                                                                                                                                                                                                     | Month 6                                                                                                                                                                                                                                                                                                     | Month 6                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                             |
| Diabetes Safety Extension Study identifier                                                                                                                                                                                                                                                                  | 1c Number (%) of patients with FPG <5.6 mmol/L (100 mg/dL) / FPG ≤6.7 mmol/L (120 mg/dL) 3 24-hour plasma                                                                                                                                                                                                   | at Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period at any time of the day                                                          | at Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period at any time of the day                                                          | at Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period at any time of the day                                                          | at Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period at any time of the day                                                          | at Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period at any time of the day                                                          | at Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period at any time of the day                                                          | at Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period at any time of the day                                                          | at Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period at any time of the day                                                          | at Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period at any time of the day                                                          | at Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period at any time of the day                                                          | at Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period at any time of the day                                                          | at Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period at any time of the day                                                          | at Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period at any time of the day                                                          | at Month 6 at Month 6 having experienced no hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose <3.0 mmol/L (54 mg/dL) that occurred during the last months of the main 6-month on-treatment period at any time of the day                                                          |                                                                                                                                                                                                                                                                                                             |
| Diabetes Safety Extension Study identifier                                                                                                                                                                                                                                                                  | glucose (mmol/L)                                                                                                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                            | Change of mean 24-hour plasma glucose based on 8-point SMPG, from baseline to endpoint (Month 6)                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                             |
| Diabetes Safety Extension Study identifier                                                                                                                                                                                                                                                                  | Variability of 24-hour plasma glucose (%) 8-point                                                                                                                                                                                                                                                           | Change in variability of 24-hour plasma glucose based on SMPG                                                                                                                                                                                                                                               | Change in variability of 24-hour plasma glucose based on SMPG                                                                                                                                                                                                                                               | Change in variability of 24-hour plasma glucose based on SMPG                                                                                                                                                                                                                                               | Change in variability of 24-hour plasma glucose based on SMPG                                                                                                                                                                                                                                               | Change in variability of 24-hour plasma glucose based on SMPG                                                                                                                                                                                                                                               | Change in variability of 24-hour plasma glucose based on SMPG                                                                                                                                                                                                                                               | Change in variability of 24-hour plasma glucose based on SMPG                                                                                                                                                                                                                                               | Change in variability of 24-hour plasma glucose based on SMPG                                                                                                                                                                                                                                               | Change in variability of 24-hour plasma glucose based on SMPG                                                                                                                                                                                                                                               | Change in variability of 24-hour plasma glucose based on SMPG                                                                                                                                                                                                                                               | Change in variability of 24-hour plasma glucose based on SMPG                                                                                                                                                                                                                                               | Change in variability of 24-hour plasma glucose based on SMPG                                                                                                                                                                                                                                               | Change in variability of 24-hour plasma glucose based on SMPG                                                                                                                                                                                                                                               | Change in variability of 24-hour plasma glucose based on SMPG                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                             |
| Diabetes Safety Extension Study identifier                                                                                                                                                                                                                                                                  | Daily average basal insulin dose (U/kg)                                                                                                                                                                                                                                                                     | Change in daily average basal insulin dose from baseline to Month 6                                                                                                                                                                                                                                         | Change in daily average basal insulin dose from baseline to Month 6                                                                                                                                                                                                                                         | Change in daily average basal insulin dose from baseline to Month 6                                                                                                                                                                                                                                         | Change in daily average basal insulin dose from baseline to Month 6                                                                                                                                                                                                                                         | Change in daily average basal insulin dose from baseline to Month 6                                                                                                                                                                                                                                         | Change in daily average basal insulin dose from baseline to Month 6                                                                                                                                                                                                                                         | Change in daily average basal insulin dose from baseline to Month 6                                                                                                                                                                                                                                         | Change in daily average basal insulin dose from baseline to Month 6                                                                                                                                                                                                                                         | Change in daily average basal insulin dose from baseline to Month 6                                                                                                                                                                                                                                         | Change in daily average basal insulin dose from baseline to Month 6                                                                                                                                                                                                                                         | Change in daily average basal insulin dose from baseline to Month 6                                                                                                                                                                                                                                         | Change in daily average basal insulin dose from baseline to Month 6                                                                                                                                                                                                                                         | Change in daily average basal insulin dose from baseline to Month 6                                                                                                                                                                                                                                         | Change in daily average basal insulin dose from baseline to Month 6                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                             |
| Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                        |
| Analysis description                                                                                                                                                                                                                                                                                        | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    | Analysis                                                                                                                                                                                                                                                                                                    |
| Analysis population and time point description                                                                                                                                                                                                                                                              | intention-to-treat (mITT) MMRM) Comparison groups                                                                                                                                                                                                                                                           | population                                                                                                                                                                                                                                                                                                  | change Lantus                                                                                                                                                                                                                                                                                               | change Lantus                                                                                                                                                                                                                                                                                               | from                                                                                                                                                                                                                                                                                                        | baseline to endpoint                                                                                                                                                                                                                                                                                        | change Lantus                                                                                                                                                                                                                                                                                               | change Lantus                                                                                                                                                                                                                                                                                               | change Lantus                                                                                                                                                                                                                                                                                               | change Lantus                                                                                                                                                                                                                                                                                               | change Lantus                                                                                                                                                                                                                                                                                               | change Lantus                                                                                                                                                                                                                                                                                               | change Lantus                                                                                                                                                                                                                                                                                               | change Lantus                                                                                                                                                                                                                                                                                               | change Lantus                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             | HOE901-U300                                                                                                                                                                                                                                                                                                 | HOE901-U300                                                                                                                                                                                                                                                                                                 | HOE901-U300                                                                                                                                                                                                                                                                                                 | HOE901-U300                                                                                                                                                                                                                                                                                                 | HOE901-U300                                                                                                                                                                                                                                                                                                 | HOE901-U300                                                                                                                                                                                                                                                                                                 | HOE901-U300                                                                                                                                                                                                                                                                                                 | HOE901-U300                                                                                                                                                                                                                                                                                                 | HOE901-U300                                                                                                                                                                                                                                                                                                 | HOE901-U300                                                                                                                                                                                                                                                                                                 | HOE901-U300                                                                                                                                                                                                                                                                                                 | HOE901-U300                                                                                                                                                                                                                                                                                                 | HOE901-U300                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             | (N=430)                                                                                                                                                                                                                                                                                                     | (N=430)                                                                                                                                                                                                                                                                                                     | (N=430)                                                                                                                                                                                                                                                                                                     | (N=430)                                                                                                                                                                                                                                                                                                     | (N=430)                                                                                                                                                                                                                                                                                                     | (N=430)                                                                                                                                                                                                                                                                                                     | (N=430)                                                                                                                                                                                                                                                                                                     | (N=430)                                                                                                                                                                                                                                                                                                     | (N=430)                                                                                                                                                                                                                                                                                                     | (N=430)                                                                                                                                                                                                                                                                                                     | (N=430)                                                                                                                                                                                                                                                                                                     | (N=430)                                                                                                                                                                                                                                                                                                     | (N=430)                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             | (N=432)                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs Safety Extension Period   | and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs Safety Extension Period   | and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs Safety Extension Period   | and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs Safety Extension Period   | and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs Safety Extension Period   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                          | Study identifier EFC12347 (EudraCT:                                                                                                                                                                      | Study identifier EFC12347 (EudraCT:                                                                                                                                                                      | Study identifier EFC12347 (EudraCT:                                                                                                                                                                      | Study identifier EFC12347 (EudraCT:                                                                                                                                                                      |
|                                                                                                                                                                                                          | HbA 1c (%)                                                                                                                                                                                               | 2012-000146-35) N                                                                                                                                                                                        | 365                                                                                                                                                                                                      | 350                                                                                                                                                                                                      |
|                                                                                                                                                                                                          | HbA 1c (%)                                                                                                                                                                                               | Endpoint (Month 6): Mean (SD)                                                                                                                                                                            | 7.08 (0.96)                                                                                                                                                                                              | 7.05 (0.95)                                                                                                                                                                                              |
|                                                                                                                                                                                                          | HbA 1c (%)                                                                                                                                                                                               | Change from baseline to endpoint (Month 6): LS Mean (SE) [95% CI]                                                                                                                                        | -1.42 (0.047) [-1.511 to -1.326]                                                                                                                                                                         | -1.46 (0.048) [-1.555 to -1.367]                                                                                                                                                                         |
|                                                                                                                                                                                                          | HbA 1c (%)                                                                                                                                                                                               | Change from baseline to endpoint (Month 6): LS Mean difference (SE) HOE901-U300 versus Lantus [95% CI]                                                                                                   | 0.04 (0.067) [-0.090 to 0.174]                                                                                                                                                                           | 0.04 (0.067) [-0.090 to 0.174]                                                                                                                                                                           |
|                                                                                                                                                                                                          | Secondary endpoints                                                                                                                                                                                      | Comparison groups                                                                                                                                                                                        | HOE901-U300 (N=432)                                                                                                                                                                                      | Lantus (N=430)                                                                                                                                                                                           |
|                                                                                                                                                                                                          | Severe and/or confirmed nocturnal hypoglycaemia between start of Week 9 and Month 6                                                                                                                      | n (%) with at least 1 nocturnal hypoglycaemia                                                                                                                                                            | 67 (15.5)                                                                                                                                                                                                | 75 (17.4)                                                                                                                                                                                                |
|                                                                                                                                                                                                          | Severe and/or confirmed nocturnal hypoglycaemia between start of Week 9 and Month 6                                                                                                                      | RR [95% CI] versus Lantus                                                                                                                                                                                | 0.89 [0.66 to 1.20]                                                                                                                                                                                      | 0.89 [0.66 to 1.20]                                                                                                                                                                                      |
|                                                                                                                                                                                                          | Severe and/or confirmed nocturnal hypoglycaemia between start of Week 9 and Month 6                                                                                                                      | p-value (CMH)                                                                                                                                                                                            | 0.4536                                                                                                                                                                                                   | 0.4536                                                                                                                                                                                                   |
|                                                                                                                                                                                                          | Average pre-injection SMPG (mmol/L) Average                                                                                                                                                              | N                                                                                                                                                                                                        | 173                                                                                                                                                                                                      | 179                                                                                                                                                                                                      |
|                                                                                                                                                                                                          | Average pre-injection SMPG (mmol/L) Average                                                                                                                                                              | Endpoint (Month 6): Mean (SD)                                                                                                                                                                            | 8.90 (2.24)                                                                                                                                                                                              | 8.68 (2.31)                                                                                                                                                                                              |
|                                                                                                                                                                                                          | Average pre-injection SMPG (mmol/L) Average                                                                                                                                                              | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]                                                                                                                                        | -2.16 (0.162) [-2.478 to -1.842]                                                                                                                                                                         | -2.33 (0.156) [-2.632 to -2.019]                                                                                                                                                                         |
|                                                                                                                                                                                                          | Average pre-injection SMPG (mmol/L) Average                                                                                                                                                              | At endpoint (Month 6): LS mean difference (SE) HOE901-U300 versus Lantus [95% CI]                                                                                                                        | 0.17 (0.224) [-0.275 to 0.605]                                                                                                                                                                           | 0.17 (0.224) [-0.275 to 0.605]                                                                                                                                                                           |
|                                                                                                                                                                                                          | pre-injection SMPG (mg/dL)                                                                                                                                                                               | N                                                                                                                                                                                                        | 173                                                                                                                                                                                                      | 179                                                                                                                                                                                                      |
|                                                                                                                                                                                                          | pre-injection SMPG (mg/dL)                                                                                                                                                                               | Endpoint (Month 6): Mean (SD)                                                                                                                                                                            | 160.37 (40.34)                                                                                                                                                                                           | 156.33 (41.65)                                                                                                                                                                                           |
|                                                                                                                                                                                                          | pre-injection SMPG (mg/dL)                                                                                                                                                                               | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]                                                                                                                                        | -38.92 (2.912) [-44.646 to -33.192]                                                                                                                                                                      | -41.89 (2.812) [-47.423 to -36.364]                                                                                                                                                                      |
|                                                                                                                                                                                                          | pre-injection SMPG (mg/dL)                                                                                                                                                                               | At endpoint (Month 6): LS mean difference (SE) HOE901-U300 versus Lantus [95% CI]                                                                                                                        | 2.97 (4.028) [-4.946 to 10.895]                                                                                                                                                                          | 2.97 (4.028) [-4.946 to 10.895]                                                                                                                                                                          |
|                                                                                                                                                                                                          | Variability of pre-injection SMPG (%)                                                                                                                                                                    | N                                                                                                                                                                                                        | 358                                                                                                                                                                                                      | 327                                                                                                                                                                                                      |
|                                                                                                                                                                                                          | Variability of pre-injection SMPG (%)                                                                                                                                                                    | Endpoint (Month 6): Mean (SD)                                                                                                                                                                            | 18.80 (9.81)                                                                                                                                                                                             | 18.38 (9.35)                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month   | Title : 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | Period EFC12347 (EudraCT: 2012-000146-35)                                                                                                                                                                                                                                                                     | Period EFC12347 (EudraCT: 2012-000146-35)                                                                                                                                                                                                                                                                     | Period EFC12347 (EudraCT: 2012-000146-35)                                                                                                                                                                                                                                                                     | Period EFC12347 (EudraCT: 2012-000146-35)                                                                                                                                                                                                                                                                     |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | (MMRM)                                                                                                                                                                                                                                                                                                        | Change from baseline to endpoint (Month 6): LS mean (SE) [95% CI]                                                                                                                                                                                                                                             | 18.70 (0.502) [17.719 to 19.690]                                                                                                                                                                                                                                                                              | 18.33 (0.521) [17.306 to 19.350]                                                                                                                                                                                                                                                                              |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | (MMRM)                                                                                                                                                                                                                                                                                                        | Change from baseline to endpoint (Month 6): LS mean difference (SE) versus Lantus [95% CI]                                                                                                                                                                                                                    | 0.38 (0.723) [-1.043 to 1.796]                                                                                                                                                                                                                                                                                | 0.38 (0.723) [-1.043 to 1.796]                                                                                                                                                                                                                                                                                |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | Other secondary endpoints                                                                                                                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                                                                                                             | HOE901-U300 (N=432)                                                                                                                                                                                                                                                                                           | Lantus (N=430)                                                                                                                                                                                                                                                                                                |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | Number (%) of patients at Month 6                                                                                                                                                                                                                                                                             | N                                                                                                                                                                                                                                                                                                             | 432                                                                                                                                                                                                                                                                                                           | 430                                                                                                                                                                                                                                                                                                           |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | Number (%) of patients at Month 6                                                                                                                                                                                                                                                                             | HbA 1c <7%                                                                                                                                                                                                                                                                                                    | 186 (43.1)                                                                                                                                                                                                                                                                                                    | 181 (42.1)                                                                                                                                                                                                                                                                                                    |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | Number (%) of patients at Month 6                                                                                                                                                                                                                                                                             | HbA 1c <7% without severe/confirmed hypoglycaemia at any time of the day                                                                                                                                                                                                                                      | 175 (40.5)                                                                                                                                                                                                                                                                                                    | 163 (37.9)                                                                                                                                                                                                                                                                                                    |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | Number (%) of patients at Month 6                                                                                                                                                                                                                                                                             | HbA 1c <7% without severe/confirmed nocturnal hypoglycaemia                                                                                                                                                                                                                                                   | 184 (42.6)                                                                                                                                                                                                                                                                                                    | 175 (40.7)                                                                                                                                                                                                                                                                                                    |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | Number (%) of patients at Month 6                                                                                                                                                                                                                                                                             | HbA 1c ≤6.5%                                                                                                                                                                                                                                                                                                  | 108 (25.0)                                                                                                                                                                                                                                                                                                    | 118 (27.4)                                                                                                                                                                                                                                                                                                    |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | Number (%) of patients at Month 6                                                                                                                                                                                                                                                                             | N                                                                                                                                                                                                                                                                                                             | 432                                                                                                                                                                                                                                                                                                           | 430                                                                                                                                                                                                                                                                                                           |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | Number (%) of patients at Month 6                                                                                                                                                                                                                                                                             | FPG <5.6 mmol/L (100 mg/dL)                                                                                                                                                                                                                                                                                   | 113 (26.2)                                                                                                                                                                                                                                                                                                    | 127 (29.5)                                                                                                                                                                                                                                                                                                    |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | Number (%) of patients at Month 6                                                                                                                                                                                                                                                                             | FPG <5.6 mmol/L (100 mg/dL) and no emergent severe or confirmed hypoglycaemia                                                                                                                                                                                                                                 | 104 (24.1)                                                                                                                                                                                                                                                                                                    | 110 (25.6)                                                                                                                                                                                                                                                                                                    |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | Number (%) of patients at Month 6                                                                                                                                                                                                                                                                             | FPG <5.6 mmol/L (100 mg/dL) and no nocturnal emergent severe or confirmed hypoglycaemia                                                                                                                                                                                                                       | 112 (25.9)                                                                                                                                                                                                                                                                                                    | 121 (28.1)                                                                                                                                                                                                                                                                                                    |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | Number (%) of patients at Month 6                                                                                                                                                                                                                                                                             | FPG ≤6.7 mmol/L (120 mg/dL)                                                                                                                                                                                                                                                                                   | 217 (50.2)                                                                                                                                                                                                                                                                                                    | 231 (53.7)                                                                                                                                                                                                                                                                                                    |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | 24-hour plasma glucose based on 8-point SMPG (mmol/l [mg/dL])                                                                                                                                                                                                                                                 | Change from baseline to endpoint (Month 6): LS mean (SE)                                                                                                                                                                                                                                                      | -2.72 (-49.06)                                                                                                                                                                                                                                                                                                | -2.90 (-52.24)                                                                                                                                                                                                                                                                                                |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | 24-hour plasma glucose based on 8-point SMPG (mmol/l [mg/dL])                                                                                                                                                                                                                                                 | Change from baseline to endpoint (Month 6): LS mean difference HOE901-U300 versus Lantus (95% CI)                                                                                                                                                                                                             | 0.18 (-0.068 to 0.421)                                                                                                                                                                                                                                                                                        | 0.18 (-0.068 to 0.421)                                                                                                                                                                                                                                                                                        |
| Safety Extension Study identifier                                                                                                                                                                                                                                                                             | Variability of 24-hour plasma glucose                                                                                                                                                                                                                                                                         | Change from baseline to endpoint (Month 6): LS mean (95% CI)                                                                                                                                                                                                                                                  | 1.53 (0.264 to 2.790)                                                                                                                                                                                                                                                                                         | 1.41 (0.143 to 2.682)                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

Title :  6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycaemic Drugs with a 6-month Safety Extension Period

| Study identifier   | EFC12347 (EudraCT: 2012-000146-35)   | EFC12347 (EudraCT: 2012-000146-35)                                                                | EFC12347 (EudraCT: 2012-000146-35)   | EFC12347 (EudraCT: 2012-000146-35)   |
|--------------------|--------------------------------------|---------------------------------------------------------------------------------------------------|--------------------------------------|--------------------------------------|
|                    | based on 8-point SMPG (%)            | Change from baseline to endpoint (Month 6): LS mean difference HOE901-U300 versus Lantus (95% CI) | 0.11 (-1.676 to 1.905)               | 0.11 (-1.676 to 1.905)               |
|                    | Mean daily basal insulin dose (U/kg) | Month 6 OC                                                                                        | 0.62                                 | 0.53                                 |
|                    |                                      | Mean change from baseline                                                                         | 0.43                                 | 0.34                                 |

CI: confidence interval, CMH: Cochran-Mantel-Haenszel, FPG: fasting plasma glucose, HbA1c: glycated hemoglobin A1c, LS: least squares, mITT: modified intention-to-treat, MMRM: mixed model for repeated measurements, N: number of randomized patients, n: number of patients with measurements, OC: Observed case, RR: relative risk, SC: subcutaneous, SD: standard deviation, SE: standard error, SMPG: self-monitored plasma glucose, T2DM: type 2 diabetes mellitus;

## Clinical studies in special populations

No studies were conducted specifically to address the efficacy of U300 in the elderly, in children, or in subjects with impaired renal or hepatic function. Due to the structural similarity between insulin glargine and human insulin, the same changes in pharmacokinetic (PK) and pharmacodynamic (PD) profiles,  and  therefore  efficacy,  are  expected  with  both  drugs  in  subjects  with  impaired  renal  or hepatic function. Careful dose titration is required in subjects with severe renal disease or hepatic failure because insulin metabolism is known to be impaired, and these subjects are often insulin resistant.  Insulin  requirements  may  be  altered  during  intercurrent  conditions  such  as  illness, emotional disturbances or stress.

Overall  in  all  4  studies  EFC12456,  EFC11628,  EFC11629  and  EFC12347  and  the  pooled  analysis EFC11629 and EFC12347, the treatment effect (mean change in HbA1c from baseline to endpoint [Month 6]) of U300 versus Lantus was consistent across tested subgroups defined by baseline/screening factors such as age, gender, race, ethnicities, baseline BMI, duration of diabetes, HbA1c  at  screening  (&lt;8%  or  ≥8%)  and  geographical  area,  as  indicated  by  p-values  for treatment-by-subgroup interaction &gt;0.10. In a few cases, interactions with treatment were observed (eg, geographical area in study EFC12456, duration of diabetes in study EFC11628); however, since similar findings were not observed in the other studies and as no adjustment for multiplicity was performed, no conclusion can be drawn on whether U300 or Lantus performs differently in some specific subgroups.

## Analysis performed across trials (pooled analyses and meta-analysis)

## Primary endpoint

## Primary efficacy endpoint: change in HbA1c from baseline to endpoint (Month 6)

The primary objective of these studies, to demonstrate non-inferiority of U300 to Lantus in the change in HbA1c from baseline to endpoint (Month 6), was achieved in study EFC12456 in T1DM and in all 3 studies in T2DM covering the broad range of the population of patients with T2DM (Table 11). Based on the predefined non-inferiority margin of 0.4%, the non-inferiority of U300 compared with Lantus was shown as the upper bound of the 95% CI was below 0.4%, and meeting even more stringent

<div style=\"page-break-after: always\"></div>

criteria with the observed upper bound in all studies below 0.3%.

In the study in T1DM and the 2 studies in insulin-pretreated patients with T2DM, the largest decrease of HbA1c occurred during the first 3 months of treatment, with only minor further decreases between Month 3 and Month 6. In the study in insulin-naïve T2DM patients, HbA1c continued to decrease in both treatment groups between Month 3 and Month 6.

Table 11 - Primary efficacy analysis - Summary of mean change in HbA1c (%) from baseline to endpoint (Month 6) in the Phase 3 studies and in meta-analysis of EFC11629 and EFC12347 (MMRM analysis) - mITT population

|                                                       | Treatment group                     | Treatment group                     |                                     |                                     |
|-------------------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| Study                                                 | U300                                | Lantus                              | LS Mean Difference (SE) vs. Lantus  | 95% CI                              |
| T1DM                                                  |                                     |                                     |                                     |                                     |
| EFC12456 n (mITT)                                     | 273                                 | 273                                 |                                     |                                     |
| Baseline (Mean)                                       | 8.13                                | 8.12                                |                                     |                                     |
| Month 6 endpoint (MMRM) LS Mean (SE) change from      | 7.70                                | 7.68                                |                                     |                                     |
| baseline to Month 6 endpoint (MMRM)                   | -0.40                               | -0.44                               |                                     |                                     |
|                                                       | (0.051)                             | (0.051)                             | 0.04 (0.072)                        | (-0.098 to 0.185)                   |
| T2DM                                                  |                                     |                                     |                                     |                                     |
| EFC11628 n (mITT)                                     | 404                                 | 400                                 |                                     |                                     |
| Baseline (Mean)                                       | 8.13                                | 8.14                                |                                     |                                     |
| Month 6 endpoint (MMRM) LS Mean (SE) change from      | 7.23                                | 7.27                                |                                     |                                     |
| baseline to Month 6 endpoint                          | -0.90                               | -0.87                               |                                     |                                     |
| (MMRM)                                                | (0.041)                             | (0.041)                             | -0.03 (0.058)                       | (-0.144 to 0.083)                   |
| EFC11629 n (mITT)                                     | 403                                 | 405                                 |                                     |                                     |
| Baseline (Mean)                                       | 8.27                                | 8.22                                |                                     |                                     |
| Month 6 endpoint (MMRM)                               | 7.47                                | 7.49                                |                                     |                                     |
| LS Mean (SE) change from baseline to Month 6 endpoint | -0.73                               | -0.70                               |                                     |                                     |
| (MMRM)                                                | (0.048)                             | (0.048)                             | -0.03 (0.068)                       | (-0.168 to 0.099)                   |
| EFC12347 n (mITT)                                     | 432                                 | 430                                 |                                     |                                     |
| Baseline (Mean)                                       | 8.49                                | 8.58                                |                                     |                                     |
| Month 6 endpoint (MMRM)                               | 7.08                                | 7.05                                |                                     |                                     |
| LS Mean (SE) change from baseline to Month 6 endpoint | -1.42                               | -1.46                               |                                     |                                     |
| (MMRM)                                                | (0.047)                             | (0.048)                             | 0.04 (0.067)                        | (-0.090 to 0.174)                   |
| Meta-analysis EFC11629 and EFC12347                   | Meta-analysis EFC11629 and EFC12347 | Meta-analysis EFC11629 and EFC12347 | Meta-analysis EFC11629 and EFC12347 | Meta-analysis EFC11629 and EFC12347 |
| n (mITT)                                              | 835                                 | 835                                 |                                     |                                     |
| Baseline (Mean)                                       | 8.38                                | 8.40                                |                                     |                                     |
| Month 6 endpoint (MMRM)                               | 7.27                                | 7.27                                |                                     |                                     |
| LS Mean (SE) change from baseline to Month 6          | -1.08                               | -1.09                               |                                     |                                     |
| endpoint (MMRM)                                       | (0.034)                             | (0.034)                             | 0.01 (0.048)                        | (-0.083 to 0.106)                   |

MMRM = Mixed model for repeated measurements; Month 6 endpoint (MMRM) value is either the observed value at month 6 or the value retrieved (time windows in the SAP)

MMRM with  treatment  (or  randomized  group  for  EFC12456),  randomization  strata  of  screening HbA1c, world region (or randomization strata of geographical region for EFC12347 and EFC12456), visit and visit-by-treatment interaction as fixed categorical effects, baseline value and

<div style=\"page-break-after: always\"></div>

baseline-by-visit interaction as fixed continuous covariates

For meta-analysis, same MMRM as above with addition of fixed effect study, study-by-visit interaction and deletion of world region or randomization strata of geographical region

## Secondary efficacy endpoints

## First main secondary efficacy endpoint: Occurrence of nocturnal hypoglycaemia

The percentage of patients with nocturnal hypoglycaemia including the categories of severe and/or confirmed  hypoglycaemia  by  SMPG  ≤3.9  mmol/L  (70  mg/dL)  reported  between  00:00  and 05:59 hours between Week 9 and Month 6 was similar in the U300 and Lantus groups in study EFC12456 in T1DM.

In the 3 studies in T2DM (EFC11628, EFC11629, EFC12347), the percentages were consistently lower in the U300 groups compared with the Lantus groups reaching statistical significance in the studies in insulin pretreated patients with risk reductions of 21% (EFC11628) and 23% (EFC11629). In study EFC12347 in insulin-naïve T2DM patients the risk reduction was 11%. In patients treated with basal insulin in combination with non-insulin AHA risk reduction was 18% (pooled analysis EFC11629 and EFC12347)  (Table 12).  The  percentage  of  patients  reporting  severe  and/or  confirmed  nocturnal hypoglycaemia in the EFC12347 study was overall the lowest among the 3 studies in T2DM, indicating the overall lower risk of hypoglycaemia in this patient population with relative shorter duration of T2DM and only recent start of insulin treatment.

Table 12 - Secondary efficacy analysis - Number (%) of patients with at least one severe and/or confirmed (SMPG ≤3.9 mmol/L [70 mg/dL]) nocturnal hypoglycaemia (00:00 to 05:59) occurring between start of Week 9 to Month 6, in pivotal Phase 3 studies and in meta-analysis of EFC11629 and EFC12347

|                                     | Severe and/or confirmed nocturnal hypoglycaemia (00:00 to 05:59)   | Severe and/or confirmed nocturnal hypoglycaemia (00:00 to 05:59)   | Severe and/or confirmed nocturnal hypoglycaemia (00:00 to 05:59)   | Severe and/or confirmed nocturnal hypoglycaemia (00:00 to 05:59)   |
|-------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
| Phase 3 study Treatment group       | n/N(%)                                                             | RR vs. Lantus (ab)                                                 | 95% CI (ab)                                                        | p-value (abc)                                                      |
| T1DM - EFC12456                     |                                                                    |                                                                    |                                                                    |                                                                    |
| U300                                | 162/273 (59.3%)                                                    | 1.06                                                               | (0.92 to 1.23)                                                     | NA                                                                 |
| Lantus                              | 153/273 (56.0%)                                                    |                                                                    |                                                                    |                                                                    |
| T2DM - EFC11628                     |                                                                    |                                                                    |                                                                    |                                                                    |
| U300                                | 146/404 (36.1%)                                                    | 0.79                                                               | (0.67 to 0.93)                                                     | 0.0045                                                             |
| Lantus                              | 184/400 (46.0%)                                                    |                                                                    |                                                                    |                                                                    |
| T2DM - EFC11629                     |                                                                    |                                                                    |                                                                    |                                                                    |
| U300                                | 87/403 (21.6%)                                                     | 0.77                                                               | (0.61 to 0.99)                                                     | 0.0380                                                             |
| Lantus                              | 113/405 (27.9%)                                                    |                                                                    |                                                                    |                                                                    |
| T2DM - EFC12347                     |                                                                    |                                                                    |                                                                    |                                                                    |
| U300                                | 67/432 (15.5%)                                                     | 0.89                                                               | (0.66 to 1.20)                                                     | 0.4536                                                             |
| Lantus                              | 75/430 (17.4%)                                                     |                                                                    |                                                                    |                                                                    |
| Meta-analysis EFC11629 and EFC12347 | Meta-analysis EFC11629 and EFC12347                                |                                                                    |                                                                    |                                                                    |
| U300                                | 154/835 (18.4%)                                                    | 0.82                                                               | (0.68 to 0.99)                                                     | NA                                                                 |
| Lantus                              | 188/835 (22.5%)                                                    |                                                                    |                                                                    |                                                                    |

N = mITT population, n/N (%) = number and percentage of patients with at least one nocturnal hypoglycaemia event, indicated as severe and/or confirmed by plasma glucose ≤3.9 mmol/L (70 mg/dL)

a. Relative risks (RR) between U300 and Lantus using an analysis of Cochran-Mantel-Haenszel (CMH) with treatment as factor and stratified on randomization strata of screening HbA1c (&lt;8.0, ≥8.0%). For  EFC12347  model  also  stratified  on  randomization  strata  of  geographical  region  (non-Japan,

<div style=\"page-break-after: always\"></div>

Japan)  .  For  EFC12456,  model  also  stratified  on  randomization  strata  of  geographical  region (non-Japan, Japan) and daytime of injection (morning/evening)

b. For the meta-analysis of EFC11629 and EFC12347, a fixed effect meta-analysis using CMH method was used with treatment as factor and stratified on randomization strata of screening HbA1c (&lt;8.0, ≥8.0%) and study c. NA = not applicable for EFC12456 and for the meta-analysis of EFC11629 and EFC12347 because no hierarchical procedure was planned

## Change in pre-injection SMPG from baseline to endpoint (Month 6)

In all 4 pivotal studies, the least square (LS) mean change from baseline to endpoint (Month 6) in average pre injection SMPG was similar in the U300 and Lantus groups. Similar results were also seen in  the  meta-analysis  on  the  pooled  data  from  the  2  studies  (EFC11629  and  EFC12347)  with non-insulin AHA as background therapy. Superiority of U300 with respect to Lantus was not shown in EFC11628 and EFC11629.

## Change in variability of pre-injection SMPG from baseline to endpoint (Month 6)

The variability of pre-injection SMPG, calculated as mean of coefficient of variation over at least 3 SMPG measurements during the 7 days preceding the visit, decreased from baseline to endpoint (Month 6) similarly in the U300 and Lantus treatment groups in EFC12456 and EFC11628. In study EFC11629  variability  decreased  more  in  the  U300  group  than  Lantus  group.  As  no  statistically significant  difference  was  shown for the 2nd main  secondary efficacy endpoint in EFC11628 and EFC11629, no testing was done in these studies for the 3rd main secondary efficacy endpoint.

## Other secondary efficacy endpoints

In all 4 studies, similar percentages of U300 and Lantus treated patients reached HbA1c levels below 7.0% at Month 6 overall and without reporting severe and/or confirmed hypoglycaemia with the low threshold of &lt;3.0 mmol/L (54 mg/dL) during the last 3 months of study treatment.

Fasting plasma glucose (measured in the central laboratory) showed overall substantial decreases in both treatment groups in the 4 studies with most of the decrease seen in the first 3 months of study treatment. Although the difference in the LS mean change of FPG in study EFC12347 was in favor of Lantus, it was not associated with a greater HbA1c reduction in this study.

In all 4 studies, the results of 8-point SMPG profiles, mean change in 24-hour average plasma glucose and variability of 24-hour plasma glucose in insulin-pretreated patients showed consistently similar improvements in the U300 and Lantus groups at the end of the 6-month treatment.

## Supportive studies

In extension studies of two of the pivotal trials, participants were asked to deviate from the usual time of injection at least 2 times per week by at 3 hours. This lead to small differences in HbA1c between flexible  and  fixed  dosing  intervals  (HbA1c,  LS  mean  difference,  substudy  EFC11628:  0.05%, 95% CI: -0.189 to 0.298]; EFC11629: 0.13%, 95% CI: -0.152 to 0.415).

More than 50% of the patients with T1DM and approximately 40% of the patients with T2DM were AIA-positive at baseline. Anti-insulin antibody positive-patients in both the U300 and Lantus groups already  had  higher  basal  insulin  doses  at  baseline  compared  with  AIA-negative  patients.  Mean changes in U300 and Lantus doses from baseline to endpoint (Month 6) were similar regardless of the AIA status (positive or negative).

## 2.5.2. Discussion on clinical efficacy

## Design and conduct of clinical studies

<div style=\"page-break-after: always\"></div>

The 4 Phase 3 studies were multinational, multicenter, open-label, centrally randomized, comparative, parallel  group  studies,  each  comprising  a  6-month  main  study  period  followed  by  a  6-month comparative safety extension period. The studies EFC11628 and EFC11629 also included a 4-week post-treatment follow-up period after completion of the 52-week study duration. The active control was Lantus in all studies. The studies utilized a common core protocol that standardized most aspects of the study design, including the comparator Lantus (insulin glargine 100 U/mL), 1:1 randomization, stratification  by  screening  HbA1c  (&lt;8.0%  versus  ≥8.0%),  inclusion/exclusion  criteria,  targets  for fasting pre-breakfast self-monitored plasma glucose (SMPG), recommendations for dosing of U300 and Lantus, primary and secondary efficacy variables and safety variables, including the definitions used for the hypoglycaemia categories and analyses. All 4 Phase 3 studies were designed to show non-inferiority of U300 versus Lantus based on the change in HbA1c from baseline to endpoint at Month 6 with a non-inferiority margin of 0.4% HbA1c. All studies had finalised their extension periods by September 2014. These data were submitted for the T2DM studies during the procedure by the Applicant. Data for EFC12456 study (T1DM) were not yet available at the time of the initial MAA, but will be provided post-approval.

Separate studies were done in T1DM and T2DM due to the different underlying pathophysiologies. Three studies were done in T2DM to cover the broad spectrum of this patient population, including insulin-naïve patients not adequately controlled on non-insulin AHA and requiring insulin, patients already treated with basal insulin in combination with OAD, and patients requiring basal and mealtime insulin for glycaemic control. Adult patients at least 18 years of age with a screening HbA1c in the range of ≥7.0 to ≤10.0% for insulin-pretreated patients (EFC11628, EFC11629, EFC12456) and ≤9.0% (PDY12777) or ≥7.0 to ≤11.0% in insulin-naïve patients (EFC12347) were eligible for the studies.

The design and conduct of the studies were appropriate to establish efficacy and safety of U300 in comparison to Lantus, keeping in mind the large similarities between the two products. As such, Lantus was the appropriate comparator.

The approach to assess efficacy of the U300 insulin by a non-inferiority trial is in line with regulatory guidance (CPMP/EWP/1080/00 Rev. 1) and accepted. However, the non-inferiority margin is not specified in this guideline and is not further justified in the dossier. In general, a non-inferiority margin of 0.3% is used in the assessment of glucose lowering drugs.

The Applicant has added substudies and a large number of exploratory secondary endpoints to the pivotal trials. These were all exploratory in nature, resulting in descriptive analyses.

## Efficacy data and additional analyses

The participants in the trials (taken together) were well-representative of the target population for U300. As the trials employed a non-inferiority design, and participation in any trial is associated with HbA1c improvement, baseline HbA1c is of particular importance. The baseline values were between 8.12 and 8.58%, which is reasonable.

Across the main studies, the discontinuation rates were generally low (7-17%) and balanced between groups. In studies EFC12456 and EFC12347 about 15 % of patients in both study arms discontinued. The reasons for discontinuation were balanced between groups. Notably, the highest discontinuation rate was observed for 'Other reasons'. The majority of discontinuations were not safety related. Single cases were due to perceived lack of efficacy or hypoglycaemia; however, these cases were balanced between groups.

## Primary endpoint

In all studies, U300 was convincingly non-inferior to Lantus, with point estimates for the difference in HbA1c ranging from -0.03% to 0.04% and the highest upper limit of the 95% confidence interval at 0.185%; well below the pre-specified non-inferiority margin of 0.4%. Although a margin of 0.4% is

<div style=\"page-break-after: always\"></div>

considered too wide for glucose lowering drugs and 0.3 is considered more appropriate, the highest upper limit is also well below that margin.

## Secondary endpoints

## Summary of secondary endpoint results

## Nocturnal hypoglycaemia

Severe and/or confirmed hypoglycaemia (SMPG ≤3.9 mmol/L (70 mg/dL)) during the night was similar between groups in T1DM; in the 3 studies in T2DM the percentages were lower in the U300 groups compared with the Lantus groups reaching statistical significance in the studies in insulin pretreated patients with risk reductions of 21% (EFC11628: 36.1 vs 46.1%) and 23% (EFC11629: 21.6 vs 27.9%).

## Change in pre-injection SMPG

In all 4 pivotal studies, the least square (LS) mean change from baseline to endpoint (Month 6) in average pre-injection SMPG was similar in the U300 and Lantus groups. The prolonged duration of action of U300 had been expected to result in better pre-injection SMPG; the Applicant explains the lack of a difference by the effects of mealtime insulin injections and/or meal intake (dinner). It is usual in clinical practice to cover relative shortage of long-acting insulin by mealtime short acting insulin.

## Variability of pre-injection SMPG

The variability of pre-injection SMPG, calculated as mean of coefficient of variation over at least 3 SMPG measurements during the 7 days preceding the visit, decreased from baseline to endpoint (Month 6) similarly in the U300 and Lantus treatment groups in EFC12456 and EFC11628. In study EFC11629 variability decreased more in the U300 group than Lantus group, but no testing was done in accordance with the hierarchical statistical analysis.

## FPG

In all 4 pivotal studies, FPG had decreased in the U300 and Lantus groups at endpoint (Month 6), with a difference in the LS mean change of FPG from baseline in favour of Lantus between 0.05 and 0.39 mmol/L. This was statistically significant in study EFC12347 and in the pooled analysis of EFC11629 and EFC12347. This is somewhat surprising as the fasting pre-breakfast SMPG was used to titrate the long-acting insulin dose.;

The prolonged action of U300 may have caused relative shift of long-acting insulin action from night to day. Notably, the prebreakfast SMPG (which was followed more closely than FPG) decreased more gradually with HOE901-U300 than with Lantus. The Applicant has clarified that the dose titration was indeed  steeper  in  the  HOE901-U300  group  than  in  the  Lantus  group  and  that  this  was  more pronounced in patients without nocturnal hypoglycaemia. The Applicant further proposed that the lack of difference between treatments could be due to the more pronounced effect of Lantus on FPG (when taken as an evening dose). This appears plausible.

The decrease in FPG was largest in the first 3 months of study treatment in all studies and both treatment groups

## HbA1c and FPG responder analyses

The  percentages  of  patients  reaching  HbA1c  &lt;7.0%  and  the  percentages  of  patients  reaching FPG &lt;6.7 mmol/L (120 mg/dL) at Month 6 were comparable between the U300 and Lantus groups. Also, the percentages of patients reaching these levels of HbA1c or FPG without reporting severe and/or confirmed hypoglycaemia by SMPG &lt;3.0 mmol/L (54 mg/dL) any time of the day or between 00:00 and 05:59 hours during the last 3 months of the main 6-month on-treatment period were overall similar.

<div style=\"page-break-after: always\"></div>

## 8-point SMPG profile

Eight-point profiles were comparable between treatment groups at baseline in all 4 studies and had decreased similarly at all timepoints at endpoint (Month 6) in both treatment groups.

## 24-hour average plasma glucose

In all 4 studies, 24-hour average plasma glucose based on the 8-point SMPG profile was comparable between the treatment groups and had decreased similarly in the U300 and Lantus group at Month 6.

In study PDY12777, the glucose variation over the day was investigated by means of CGM. Although the time spent within the target range (4.4 to 7.8 mmol/L [80 to 140 mg/dL]) was comparable for Lantus  and  HOE901-U300,  the  average  glucose  profile  by  hour  of  day  appeared  flatter  with HOE901-U300. This is in line with the flatter PD profile and longer duration of action seen with HOE901-U300. The findings are not entirely in line with the findings in the CGM study in Japanese patients  (PDY12335).  The  Applicant  has  clarified  the  differences.  These  were  mainly  due  to differences in study design, conduct and evaluation. It is noted that when used in a basal-bolus regimen no clear differences in the CGM profiles are observed between HOE901-U300 and Lantus, which is somewhat unexpected considering the difference in hypoglycaemia pattern.

## Fasting pre-breakfast SMPG

Basal insulin U300 or Lantus was titrated according to the fasting pre-breakfast SMPG. Switching from Lantus to U300 is associated with a temporary (2-4 week) increase in fasting SMPG. Decrease of fasting SMPG is faster with Lantus compared to more gradual with U300.

<div style=\"page-break-after: always\"></div>

## Doses of basal insulin and mealtime insulin preparations

## Patients pretreated with insulin

After trial initiation, basal insulin use increased in both U300 and Lantus groups, but more in the U300 group, resulting in approximately 10% (EFC11628, EFC11629; T2DM) to 18% (EFC12456; T1DM) higher U300 doses than Lantus doses at Month 6. This is representatively illustrated by Figure 8 .

Figure 8 - Mean (+/- SE) in average daily basal and mealtime insulin doses (U/kg) by visit during the main 6-month on-treatment period in EFC11628 mITT population

<!-- image -->

## Insulin-naïve patients with T2DM

In study EFC12347 in insulin-naïve T2DM patients not adequately controlled on non-insulin AHA, the recommended starting dose was 0.2 U/kg for both U300 and Lantus. The U300 and Lantus doses were increased throughout the study. The increase in the insulin dose was similar in both treatment groups during the first 4 weeks of the study, thereafter, the U300 dose continued to increase at the same rate, while the Lantus dose continued to increase by smaller increments, resulting in a higher mean U300 dose (0.62 U/kg) than Lantus dose (0.54 U/kg) at Month 6.

## Basal insulin in combination with a mealtime insulin analogue

Mealtime insulin doses remained almost unchanged in both treatment groups when basal insulin was combined with mealtime insulin. The post-lunch and post-dinner plasma glucose excursions in the 8-point SMPG profiles and the absence of a lower hypoglycaemia risk during daytime suggest that the optimization of the mealtime insulin doses versus the basal insulin doses could have been further improved.

<div style=\"page-break-after: always\"></div>

## Injection of the basal insulin in the morning or evening

In  study  EFC12456 patients with T1DM were assigned per randomization to morning or evening injection of U300 or Lantus. At Month 6 in the morning injection groups the daily U300 (baseline: 0.31 U/kg;  Month  6:  0.49  U/kg)  and  Lantus  doses  (baseline:  0.32  U/kg;  Month  6:  0.45  U/kg)  were comparable. In the evening injection groups the U300 dose was up-titrated (baseline: 0.34 U/kg; Month 6:  0.45 U/kg),  while  the  Lantus  dose  was  kept  almost  unchanged  during  the  study (baseline: 0.33 U/kg; Month 6: 0.36 U/kg), contributing to a relatively large difference between the U300 and Lantus doses in the evening injection  groups.  In  both  U300  and Lantus morning and evening injection groups, the mealtime insulin doses were comparable and were almost unchanged during the study.

At endpoint (Month 6), the total insulin dose (basal + mealtime insulin) was higher in both the U300 morning (0.83 U/kg) and evening (0.80 U/kg) injection groups than in the Lantus morning (0.76 U/kg) and evening (0.69 U/kg) injection groups.

The increase in the ratio of basal insulin over total insulin was similarly higher for U300 evening injections (evening 0.57) than for Lantus (evening 0.52), while increase for morning injections was similar (U300 morning 0.61; Lantus morning 0.60).

## Injection devices in clinical studies

In studies EFC11628 and EFC11629 the modified Solostar pen was used for administration of U300, allowing dose settings in multiples of 3 U. In studies EFC12347 and EFC12456 the modified Tactipen was used allowing dose settings in multiples of 1.5 U. The Solostar pen was used for injection of Lantus in all studies. In all studies the dose recommendations were identical for U300 and Lantus, depending on the fasting  pre-breakfast SMPG.  The  insulin titration  data  in  the  4  pivotal  studies suggest, that the Investigators/patients followed the titration recommendation in the study protocols in both treatment groups regardless of the pens used in the studies. This is shown by the substantial increase in the U300 and Lantus doses during the titration periods and the use of either the modified Solostar or the modified Tactipen did not result in a reluctance to titrate the U300 dose. It should however be kept in mind, that the protocol required upward titration steps of at least 10% of the insulin dose, precluding smaller steps which would have been possible with Lantus but not with U300.

The pen that is proposed to be marketed is a Solostar with 1U accuracy. The pen can deliver 80 U maximally and thus more patients will need to inject twice compared to the pens used in the clinical studies. However, the benefit of the new pen is that it allows for more precise adjustment (one unit) and mix-ups of the pens for U300 and Lantus do not lead to a different injected dose, as the absolute number of units injected is the same for both pens.

## Rescue treatment

Rescue treatment was started in a low number of patients in both treatment groups without notable differences.

## Efficacy in morning and evening injection

In study EFC12456 and in the exploratory CGM study PDY12777, both conducted in patients with T1DM, patients were randomized to receive U300 or Lantus once daily in the morning (any time prior to breakfast until lunch) or evening (anytime immediately prior to the evening meal until bedtime).

At the end of the 6-month treatment period in the study EFC12456, HbA1c had decreased similarly in the morning injection groups of U300 and Lantus, whereas a smaller decrease was seen in the U300 evening injection group compared with the Lantus evening injection group. Comparing morning and evening injection groups within the U300 group, the morning injection resulted in a larger decrease of

<div style=\"page-break-after: always\"></div>

HbA1c than the evening injection,  although  the  LS  mean  difference  between  U300  morning  and evening injection group was not clinically relevant.

## Extension phase

Data from the extension phases in the T2DM trials (12 months) showed that the effect on HbA1c is maintained over the 12 month period with only modest increase in insulin dose. The effect of U300 remains  comparable  to  that  of  Lantus  but  with  a  lower  rate  of  hypoglycaemia  (and  especially nocturnal hypoglycaemia) in insulin-experienced patients.

## Discussion of secondary endpoints

The key secondary endpoint of nocturnal hypoglycaemia was achieved in two trials in T2DM. In T1DM, there  was  a  slight  increase  in  risk.  When  compared  to  the  more  comprehensive  analysis  of hypoglycaemias in the safety section, there are overall small advantages which may be clinically relevant for some patients.

Most other endpoints were exploratory and descriptive only. The results confirm the large similarities between Lantus and U300. As expected, hypoglycaemias and variability with U300 are somewhat reduced.

Basal Insulin use is increased with U300 by 10-18% compared to Lantus. The clinical relevance of this finding is unclear, but may be limited as this is not associated with increased hypoglycaemias or additional  increase  in  weight  (see  Safety  section).  It  may  be  due  to  the  somewhat  reduced bioavailability, as measured in PK/PD studies.

Most patients use Lantus in the evening. When U300 is compared to Lantus, the more prolonged release profile of U300 causes a shift in insulin availability from the night to the day. As the basal insulin dose is adjusted based on fasting glucose and thus on nightly insulin levels, more basal insulin will be required to achieve the same insulin exposure overnight. Apparently, the extra basal insulin that is  available  during  the  day  has  no  clinical  consequences.  No  reduction  of  prandial  insulin  is observed; apparently prandial insulin doses are mainly based on dietary habits.

## 2.5.3. Conclusions on the clinical efficacy

U300 has similar efficacy when compared to Lantus.  The more gradual glucose lowering effect of U300 when compared to Lantus does not translate into important advantages. The higher use of basal insulin may be a disadvantage.

## 2.6. Clinical safety

## Patient exposure

All subjects and patients from Phase 1 and Phase 2/3 studies who were randomized and received at least one dose of investigational medicinal product (IMP) were evaluated for safety. The studies supporting the clinical safety of U300 are EFC11628, EFC11629 and EFC12347 in patients with T2DM and studies EFC12456 and PDY12777 in T1DM (Table 13).

<div style=\"page-break-after: always\"></div>

Table 13 - Duration of Exposure to U300 (all Phase 1 and Phase 2/3 studies)

## Number of subjects/patients treated

| Treatment Duration                      | ≥1day   |        | >12 weeks   | >12 weeks   | >25 weeks   | >25 weeks   | ≥51 weeks   | ≥51 weeks   |
|-----------------------------------------|---------|--------|-------------|-------------|-------------|-------------|-------------|-------------|
|                                         | U300    | Lantus | U300        | Lantus      | U300        | Lantus      | U300        | Lantus      |
| Completed clinical pharmacology studies |         |        | -           | -           | -           | -           |             |             |
| Healthy subjects 23                     | 24      |        |             |             |             |             |             |             |
| T1DM 140                                | 91      |        |             |             |             |             |             |             |
| Phase 2/3 studies 1544                  | 1543    | 1439   |             | 1440        | 1331        | 1317        | 100         | 105         |
| T1DM                                    | 304 303 |        | 275         | 278         | 231         | 236         | 0           | 0           |
| T2DM                                    | 1240    | 1240   | 1164        | 1162        | 1100        | 1081        | 100         | 105         |

## Common adverse events

During the main 6-month period the number of patients with TEAEs and overall pattern of TEAEs were comparable between the treatment groups. TEAEs were reported in 62.8% and 58.9% of U300 and Lantus treated patients respectively in T1DM studies, and in 57.3% and 53.7% of patients, respectively in T2DM studies. In both treatment groups the most commonly reported TEAEs at the system organ class (SOC) level were Infections and Infestations, with nasopharyngitis and upper respiratory tract infection the most common preferred terms (PT) in both T1DM and T2DM (Table 14).

Table 14 ­ Summary of all TEAEs in ≥3% of all pooled U300 or all pooled Lantus patients (EFC11628, EFC11629, EFC12347, EFC12456, and PDY12777)

| Number (%) patients               | T1DM       |             | T2DM        |             | All studies   | Lantus     |
|-----------------------------------|------------|-------------|-------------|-------------|---------------|------------|
|                                   | U300       | Lantus      | U300        | Lantus      | U300          |            |
| Preferred Term n (%)              | (N=304)    | (N=304)     | (N=1242)    | (N=1246)    | (N=1546)      | (N=1550)   |
| Any class                         | 191(62.8%) | 179 (58.9%) | 712 (57.3%) | 669 (53.7%) | 903(58.4%)    | 848(54.7%) |
| Nasopharyngitis                   | 39 (12.8%) | 33 (10.9%)  | 88 (7.1%)   | 72 (5.8%)   | 127 (8.2%)    | 105 (6.8%) |
| Upper respiratory tract infection | 29 (9.5%)  | 23 (7.6%)   | 71 (5.7%)   | 67 (5.4%)   | 100 (6.5%)    | 90 (5.8%)  |
| Headache                          | 14 (4.6%)  | 14 (4.6%)   | 61 (4.9%)   | 47 (3.8%)   | 75 (4.9%)     | 61 (3.9%)  |
| Diarrhoea                         | 7 (2.3%)   | 6 (2.0%)    | 47 (3.8%)   | 38 (3.0%)   | 54 (3.5%)     | 44 (2.8%)  |
| Nausea                            | 8 (2.6%)   | 5 (1.6%)    | 40 (3.2%)   | 27 (2.2%)   | 48 (3.1%)     | 32 (2.1%)  |
| Bronchitis                        | 6 (2.0%)   | 6 (2.0%)    | 41 (3.3%)   | 42 (3.4%)   | 47 (3.0%)     | 48 (3.1%)  |

<div style=\"page-break-after: always\"></div>

TEAEs sorted by frequency in all U300 patients.

Most of the events were mild to moderate in intensity, 5.1% of the U300 treated patients and 4.1% of the Lantus patients had an event of severe intensity; the most frequent in both groups being hypoglycaemia (U300 0.5% and Lantus 0.8%). The percentage of patients with TEAEs considered related to IMP treatment was low and similar in the U300 (5.6%) and Lantus (5.3%) groups; the most common TEAEs related to IMP were hypoglycaemia (U300 0.5% and Lantus 0.7%) and headache (U300 0.5% and Lantus 0.4%).

The results of the subgroup analyses for most common TEAEs were consistent with those for the overall population in the T1DM and the T2DM pools.

## Hypoglycaemia

The definitions used for hypoglycaemia events are in common use and accepted. The Applicant approached hypoglycaemias from a large number of viewpoints (Table 15).

## Table 15 - Aspects of hypoglycaemia

| Category    | severe hypoglycaemia, documented (≤3.9 mmol/L ), documented hypoglycaemia <3.0 mmol/L, documented symptomatic / documented asymptomatic / probable symptomatic hypoglycaemia, relative hypoglycaemia, composite category of severe and/or confirmed hypoglycaemia   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Period      | 0-6 months, 0-2 months, 2-6 months                                                                                                                                                                                                                                  |
| Time of day | any, nocturnal, daytime, nocturnal + waking up, by hour of the day                                                                                                                                                                                                  |
| Count       | patients affected, number of events, event rate                                                                                                                                                                                                                     |
| Analysis    | by trial, pooled T2DM.                                                                                                                                                                                                                                              |

## Severe hypoglycaemia

In T1DM (study EFC12456), rates of severe hypoglycaemia events per patient-year exposure tended to be smaller in the U300 group compared with the Lantus group (Table 16). This difference is driven by daytime events. During the first 8 weeks of study treatment the rate of severe hypoglycaemia was similar between groups. Comparable rates were also found between treatment groups for the morning and evening injection groups, with lower rates after morning injection.

Table 16 - Number of severe hypoglycaemia events per patient-year in T1DM studies

| Severe hypoglycaemia                  | EFC12456   |           | PDY12777   |          |
|---------------------------------------|------------|-----------|------------|----------|
| Number of events (rate/patient-years) | U300       | Lantus    | U300       | Lantus   |
| Total patient-years                   | 124.10     | 126.83    | 9.27       | 8.56     |
| Any time of the day                   | 30 (0.24)  | 43 (0.34) | 1 (0.11)   | 3 (0.35) |
| Nocturnal (00:00 - 05:59)             | 10 (0.08)  | 7 (0.06)  | 0          | 2 (0.23) |
| Daytime (06:00 - 23:59)               | 20 (0.16)  | 36 (0.28) | 1 (0.11)   | 1 (0.12) |

In all 3 studies in T2DM severe hypoglycaemia was reported with similar frequency in the U300 and Lantus  treatment  groups  (Table 17);  with  U300,  28/1242  (2.3%)  patients  experienced  severe hypoglycaemia, with Lantus 33/1246 (2.6%) patients. The highest number of severe hypoglycaemia

<div style=\"page-break-after: always\"></div>

was reported in study EFC11628 in patients with basal insulin in combination with mealtime insulin. The event rates per patient-year for severe hypoglycaemia were low and comparable between the treatment  groups  in  all  3  studies.  During  the  initial  8  weeks  of  study  treatment,  a  comparable percentage of patients reported severe hypoglycaemia, and similarly the rate of severe hypoglycaemia per patient-year in each of the 3 studies in T2DM was comparable.

Table 17 - Number of severe hypoglycaemia events and rate per patient-year in EFC11628, EFC11629 and EFC12347

| Severe hypoglycaemia                  | EFC11628   | EFC11628   | EFC11629   | EFC11629   | EFC12347   | EFC12347   |
|---------------------------------------|------------|------------|------------|------------|------------|------------|
| Number of events (rate/patient-years) | U300       | Lantus     | U300       | Lantus     | U300       | Lantus     |
| Total patient-years                   | 194.86     | 193.40     | 191.33     | 193.80     | 200.98     | 197.73     |
| Any time of the day                   | 53 (0.27)  | 47 (0.24)  | 5 (0.03)   | 12 (0.06)  | 4 (0.02)   | 4 (0.02)   |
| Nocturnal 00:00 - 05:59               | 12 (0.06)  | 15 (0.08)  | 0          | 2 (0.01)   | 0          | 0          |
| by sleep status0                      | -          | -          | -          | -          | 0          | 0          |
| Daytime 06:00 - 23:59                 | 41 (0.21)  | 32 (0.17)  | 5 (0.03)   | 10 (0.05)  | 4 (0.02)   | 4 (0.02)   |

a Sleep status: Hypoglycaemia waking the patient from sleep (not applicable to EFC11628 and EFC11629 where wake status was not collected) Extracted from

## All hypoglycaemia

Some important classes of hypoglycaemia events are summarised in Table 18 .

In both studies in T1DM , comparable percentages of patients reported at least one hypoglycaemia event  for  each  individual  category  of  hypoglycaemia  including  the  category  of  severe  and/or confirmed  hypoglycaemia.  Also,  comparable  percentages  of  patients  in  both  treatment  groups reported nocturnal or daytime hypoglycaemia. The graph of the cumulative mean number of severe and/or confirmed (≤3.9 mmol/L [70 mg/dL]) hypoglycaemia events suggests comparable number of events during the first 3 months of study treatment in the U300 and Lantus group, thereafter, the number of events increases modestly in the U300 group over the Lantus group (Figure 9).

During the first 8 weeks of study treatment hypoglycaemia events of any category were reported by a comparable percentage of patients in both treatment groups. Risk reductions in the U300 group were found for the number (%) patients reporting nocturnal hypoglycaemia during the first 8 weeks of study treatment for nocturnal hypoglycaemia.

During Month 3 to Month 6 (endpoint) of study treatment, all hypoglycaemia reported any time of the day and nocturnal hypoglycaemia were reported by overall comparable percentages of patients in the U300 and Lantus  treatment  groups.  Analyses  of  the  hypoglycaemia  event  rate  per  patient-year exposure  show  numerically  higher  event  rates  in  the  U300  treatment  group  for  symptomatic hypoglycaemia documented by SMPG ≤3.9 mmol/L (70 mg/dL) and, mostly driven by this category, for severe and/or confirmed hypoglycaemia.

Table 18 - Overview of hypoglycaemia

| T1DM    | T2DM    |         |         |
|---------|---------|---------|---------|
| EFC1245 | EFC1162 | EFC1162 | EFC1234 |

<div style=\"page-break-after: always\"></div>

|                           | 6           |              | 8           |              | 9           |              | 7           |              |
|---------------------------|-------------|--------------|-------------|--------------|-------------|--------------|-------------|--------------|
|                           | U300        | Lantus       | U300        | Lantus       | U300        | Lantus       | U300        | Lantus       |
| N                         | 274         | 275          | 404         | 402          | 403         | 406          | 435         | 438          |
| Any time of the day       |             |              |             |              |             |              |             |              |
| Any severity              | 257 (93.8%) | 258 (93.8% ) | 337 (83.4%) | 356 (88.6% ) | 288 (71.5%) | 322 (79.3% ) | 217 (49.9%) | 242 (55.3% ) |
| Severe                    |             |              |             |              |             |              |             |              |
| Any time of the day       | 18 (6.6%)   | 26 (9.5%)    | 20 (5.0%)   | 23 (5.7%)    | 4 (1.0%)    | 6 (1.5%)     | 4 (0.9%)    | 4 (0.9%)     |
| Nocturnal (00:00 - 05:59) | 6 (2.2%)    | 7 (2.5%)     | 8 (2.0%)    | 10 (2.5%)    | 0           | 2 (0.5%)     | 0           | 0            |
| Nocturnal by sleep status | 6 (2.2%)    | 5 (1.8%)     | -           | -            | -           | -            | 0           | 0            |
| Daytime (06:00 -          | 14 (5.1%)   | 19 (6.9%)    | 17 (4.2%)   | 16 (4.0%)    | 4 (1.0%)    | 5 (1.2%)     | 4 (0.9%)    | 4 (0.9%)     |
| Documented symptomatic    |             |              |             |              |             |              |             |              |
| ≤ 3.9 mmol/L (70          | 233 (85.0%) | 230 (83.6% ) | 283 (70.0%) | 313 (77.9% ) | 200 (49.6%) | 233 (57.4% ) | 133 (30.6%) | 157 (35.8% ) |
| < 3.0 mmol/L (54 mg/dL)   | 189 (69.0%) | 192 (69.8% ) | 151 (37.4%) | 167 (41.5% ) | 83 (20.6%)  | 109 (26.8% ) | 33 (7.6%)   | 61 (13.9% )  |
| Asymptomati c             |             |              |             |              |             |              |             |              |
| ≤ 3.9 mmol/L (70          | 192 (70.1%) | 209 (76.0% ) | 255 (63.1%) | 274 (68.2% ) | 200 (49.6%) | 238 (58.6% ) | 137 (31.5%) | 169 (38.6% ) |
| < 3.0 mmol/L (54 mg/dL)   | 93 (33.9%)  | 107 (38.9% ) | 69 (17.1%)  | 66 (16.4% )  | 43 (10.7%)  | 59 (14.5% )  | 7 (1.6%)    | 8 (1.8%)     |
| Severe and/or             |             |              |             |              |             |              |             |              |

<div style=\"page-break-after: always\"></div>

| confirmed               | confirmed   | confirmed    | confirmed   | confirmed    | confirmed   | confirmed    | confirmed   | confirmed    |
|-------------------------|-------------|--------------|-------------|--------------|-------------|--------------|-------------|--------------|
| ≤ 3.9 mmol/L (70        | 255 (93.1%) | 257 (93.5% ) | 331 (81.9%) | 353 (87.8% ) | 282 (70.0%) | 314 (77.3% ) | 201 (46.2%) | 230 (52.5% ) |
| < 3.0 mmol/L (54 mg/dL) | 214 (78.1%) | 221 (80.4% ) | 181 (44.8%) | 201 (50.0% ) | 110 (27.3%) | 143 (35.2% ) | 43 (9.9%)   | 71 (16.2% )  |
| Nocturnal               |             |              |             |              |             |              |             |              |
| Any severity            | 191 (69.7%) | 196 (71.3% ) | 183 (45.3%) | 240 (59.7% ) | 123 (30.5%) | 169 (41.6% ) | 88 (20.2%)  | 105 (24.0% ) |
| Severe                  | 6 (2.2%)    | 7 (2.5%)     | 8 (2.0%)    | 10 (2.5%)    | 0           | 2 (0.5%)     | 0           | 0            |
| Documented symptomatic  |             |              |             |              |             |              |             |              |
| ≤ 3.9 mmol/L (70        | 162 (59.1%) | 159 (57.8% ) | 145 (35.9%) | 194 (48.3% ) | 91 (22.6%)  | 126 (31.0% ) | 54 (12.4%)  | 68 (15.5% )  |
| < 3.0 mmol/L (54 mg/dL) | 112 (40.9%) | 107 (38.9% ) | 49 (12.1%)  | 68 (16.9% )  | 33 (8.2%)   | 47 (11.6% )  | 14 (3.2%)   | 28 (6.4%)    |
| Asymptomati             |             |              |             |              |             |              |             |              |
| ≤ 3.9 mmol/L (70 mg/dL) | 77 (28.1%)  | 96 (34.9% )  | 84 (20.8%)  | 102 (25.4% ) | 43 (10.7%)  | 77 (19.0% )  | 44 (10.1%)  | 56 (12.8% )  |
| < 3.0 mmol/L (54 mg/dL) | 27 (9.9%)   | 27 (9.8%)    | 9 (2.2%)    | 13 (3.2%)    | 10 (2.5%)   | 9 (2.2%)     | 3 (0.7%)    | 1 (0.2%)     |
| Severe and/or confirmed |             |              |             |              |             |              |             |              |
| ≤ 3.9 mmol/L (70        | 188 (68.6%) | 193 (70.2% ) | 180 (44.6%) | 231 (57.5% ) | 114 (28.3%) | 162 (39.9% ) | 78 (17.9%)  | 103 (23.5% ) |
| < 3.0                   | 127         | 126          | 63          | 82           | 40          | 54           | 17          | 29           |

<div style=\"page-break-after: always\"></div>

| mmol/L (54 mg/dL)   | (46.4%)   | (45.8% )   | (15.6%)   | (20.4% )   | (9.9%)   | (13.3% )   | (3.9%)   | (6.6%)   |
|---------------------|-----------|------------|-----------|------------|----------|------------|----------|----------|

favours U300; favours Lantus

Figure 9 - EFC12456 - Cumulative mean number of severe and/or confirmed hypoglycaemia by plasma glucose ≤3.9 mmol/L (70 mg/dL) per patient during the 6-month on-treatment period (Nelson-Aalen estimates)

<!-- image -->

In all studies in T2DM, concomitant use of sulfonylureas was prohibited in order to not jeopardize the hypoglycaemia analyses by hypoglycaemia caused by sulfonylureas. In all 3 studies the percentage of patients  reporting  hypoglycaemia  of  any  category  was  numerically  lower  in  the  U300  groups compared with the Lantus groups; severe hypoglycaemia and asymptomatic hypoglycaemia with SMPG &lt; 3.0 mmol/L (54 mg/dL) were reported by a similar percentage of patients.

In study EFC11628 in patients using basal insulin in combination with mealtime insulin, event rates per patient-year exposure were comparable between the U300 and Lantus group for all categories of

<div style=\"page-break-after: always\"></div>

hypoglycaemia. Relative risk vs Lantus for any hypoglycaemia was 0.94 (95% CI 0.80-1.11).  In the other T2DM studies, in patients using basal insulin in combination with non-insulin AHA, event rates per patient-year exposure were lower in the U300 group than in the Lantus group. Relative risk vs Lantus for any hypoglycaemia was 0.77 (95% CI 0.66-0.90).

In all 3 studies in T2DM all types of nocturnal hypoglycaemia were reported by a lower percentage of patients in the U300 group compared with the Lantus group. Relative risk vs Lantus for any nocturnal hypoglycaemia was 0.76 (95% CI 0.66-0.87); comparable percentages of patients were found for asymptomatic  hypoglycaemia  with  SMPG  &lt;3.0  mmol/L  (54  mg/dL)(RR  vs  Lantus  0.69  [95%  CI 0.30-1.59]).  In  the  studies  in  T2DM,  daytime  hypoglycaemia  was  reported  by  a  similar  (in combination with mealtime insulin) or lower (in combination with non-insulin AHA) percentage of patients in the U300 compared with Lantus group depending on the type of hypoglycaemia.

In all 3 studies the cumulative number of events was lower in the U300 group than in the Lantus group for both hypoglycaemia any time of the day and nocturnal hypoglycaemia events. Differences in favour of U300 are most prominent for nocturnal hypoglycaemia in the studies in insulin-pretreated patients (EFC11628 and EFC11629) and for hypoglycaemia any time of the day in the 2 studies where the basal insulin was given in combination with non-insulin AHA (EFC11629 and EFC12347). Notably, any  separation  between  the  2  treatment  groups  starts  already  during  the  first  weeks  of  study treatment, ie, still in the transition period when changing over from another insulin regimen or in the first weeks of insulin treatment in insulin-naïve patients.

In all 3 studies in T2DM, during the first 8 weeks of study treatment, hypoglycaemia events of all categories were reported by lower percentages of U300 than Lantus treated patients. During the first 8 weeks of study treatment, nocturnal hypoglycaemia was reported by lower percentages of patients in the U300 group compared with the Lantus groups in all 3 studies in T2DM. During Month 3 to Month 6  (endpoint)  of  study  treatment,  in  all  3  studies  in  T2DM,  hypoglycaemia  any  time  of  the  day continued to be reported by a lower percentage of patients and at a lower event rate per patient-year exposure in the U300 group than in the Lantus group. The risk of nocturnal hypoglycaemia, regardless if shown by percentage of patients reporting at least one event or by event rate per patient-year exposure continued to be lower in the U300 group compared with the Lantus group during this study period.

During the 3-month administration substudies of studies EFC11628 and EFC11629 in patients with T2DM, hypoglycaemia events occurring any time of the day and nocturnal hypoglycaemia occurring between 00.00 and 05.59 hours, overall and for each category of hypoglycaemia, were reported by comparable percentages of patients in the U300 adaptable dosing interval group and U300 fixed dosing interval group.

In study EFC12456 in patients with T1DM, hypoglycaemia events occurring any time of the day and nocturnal hypoglycaemia occurring between 00.00 and 05.59 hours, overall and for each category of hypoglycaemia, were reported by comparable percentages of patients and at comparable rates per patient-year in the U300 morning and evening injection groups. In comparison with Lantus, event rates for hypoglycaemia occurring between 06.00 and 24.00 hours tended to be higher with U300 than Lantus for both the morning and evening injection groups (events per patient-year exposure for severe and/or confirmed hypoglycaemia [SMPG ≤3.9 mmol/L; 70 mg/dL], morning injection group: U300 71.48, Lantus 62.90; evening injection U300 69.38, Lantus 64.23).

In T1DM and T2DM, for hypoglycaemia analyses, similar results were observed across subgroups as defined  by  demographic  or  baseline  characteristics.  In  the  T2DM  studies,  the  hypoglycaemia incidence was consistently lower in the U300 group than the Lantus group or at least similar in all subgroups defined by age, race, gender, ethnicity, BMI, HbA1c level and duration of diabetes.

<div style=\"page-break-after: always\"></div>

## Adverse events of special interest

## Injection Site Reactions

No safety signal was detected for injection site reaction TEAEs in the T1DM and T2DM pools for patients receiving U300 or Lantus.

The number of patients reporting any injection site reactions was comparable between the treatment groups, 2.5% of the U300 treated patients and 2.8% of the Lantus treated patients reported injection site reactions (T1DM: U300: 8 patients [2.6%]; Lantus: 5 patients [ 1.6%] and in T2DM: U300: 30 patients [2.4%]; Lantus: 39 patients [3.1%]) during the main 6-month study periods.

## Hypersensitivity Reactions

No safety signal was detected for hypersensitivity reactions, which were reported by comparable percentages of patients in the Phase 2/3 studies overall (U300 5.3% and Lantus 4.5%) and in the T1DM studies (U300 6.6% and Lantus 4.6%) and T2DM studies (U300 5.0% and Lantus 4.4%). The most common hypersensitivity reactions were rash in both the U300 (13 patients, 0.8%) and Lantus (7 patients [0.5%]) groups.

Most events were reported as mild or moderate in intensity. The majority of patients recovered or improved while treatment was ongoing.

Study treatment was discontinued in one Lantus treated patient with T2DM because of injection site rash.

## Malignancy

No  safety  signal  was  detected  for  malignancy  TEAEs  in  the  T1DM  and  T2DM  pools  for  patients receiving U300 or Lantus . The number of cases was comparable between the treatment groups; U300: 6 patients (0.4%) and Lantus: 10 patients (0.6%).

## Cardiovascular safety

No CV safety signal was detected in the T1DM and T2DM pools for patients receiving U300 or Lantus.

Events of the SOC Cardiac disorders were reported by comparable percentages of U300 and Lantus treated patients overall (U300 2.2% and Lantus 2.9%), in the T1DM studies (U300 1.0% and Lantus 1.3%) and in the T2DM studies (U300 2.5% and Lantus 3.3%).

The U300 clinical development program has not been designed to specifically assess the CV risk of U300, as the CV safety profile of the active ingredient insulin glargine has been established for Lantus. Major CV events (MACE) including CV death, non-fatal myocardial infarction and non-fatal stroke were identified by searching the AE and SAE data base using Standardized MedDRA Queries and PTs.

The percentage of patients with any MACE identified by the data base search was low and comparable in the U300 (0.6%) and Lantus (1.0%) groups, and similarly in the T1DM (U300 0.3% and Lantus 0.7%) and T2DM studies (U300 0.7% and Lantus 1.1%).

Table 19 - Major cardiovascular events

| Number (%) patients     | T1DM     |          | T2DM     |           | All studies   | Lantus    |
|-------------------------|----------|----------|----------|-----------|---------------|-----------|
|                         | U300     | Lantus   | U300     | Lantus    | U300          |           |
| Preferred Term n (%)    | (N=304)  | (N=304)  | (N=1242) | (N=1246)  | (N=1546)      | (N=1550)  |
| Any CV death, non-fatal | 1 (0.3%) | 2 (0.7%) | 9 (0.7%) | 14 (1.1%) | 10 (0.6%)     | 16 (1.0%) |
| MI, non-fatal stroke    |          |          |          |           |               |           |

<div style=\"page-break-after: always\"></div>

| Any cardiovascular death   |   1 (0.3%) | 0        | 3 (0.2%)   | 1 (<0.1%)   | 4 (0.3%)   | 1 (<0.1%)   |
|----------------------------|------------|----------|------------|-------------|------------|-------------|
| Any non-fatal MI           |          0 | 0        | 4 (0.3%)   | 4 (0.3%)    | 4 (0.3%)   | 4 (0.3%)    |
| Any non-fatal stroke       |          0 | 2 (0.7%) | 2 (0.2%)   | 10 (0.8%)   | 2 (0.1%)   | 12 (0.8%)   |

CV=cardiovascular; MI=myocardial infarction

As AEs identified in this search may include events that are not MACE, a thorough medical review of all the potential MACE listed in the above table was done. MACE was confirmed in:

- T1DM in one U300 treated patient (sudden death with severe coronary artery disease with chest pain),
- T2DM in 6 U300 treated patients (3 CV deaths, 3 non-fatal MIs) and 9 Lantus treated patients (1 CV death, 3 non-fatal MIs and 5 non-fatal strokes).

All  patients  experiencing  serious  cardiac  TEAEs,  including  MACE,  had  pre-existing,  event  related pathology. None of the events were considered as related to the IMP or NIMP by the Investigator.

## Hepatic safety

No safety signal was detected for hepatic TEAEs on T1DM and T2DM pools for patients receiving U300 or Lantus.

## Serious adverse event and deaths

Overall, serious TEAEs were reported by 5.4% of the patients in both the U300 and Lantus groups, and by comparable percentages of U300 and Lantus patients in the T1DM studies (U300 5.9% and Lantus 7.2%) and T2DM studies (U300 5.2% and Lantus 5.0%), with no single event driving the results.

The most common serious TEAE in the T1DM studies was hypoglycaemia (U300 3.0% and Lantus 3.9%; T2DM: U300 &lt;0.1%, Lantus 0.2%) and the most common in the T2DM studies was coronary artery disease (U300 0.2%, Lantus &lt;0.1%); T1DM: U300 one event, no events on Lantus). The most common SOC with serious TEAEs were Cardiac disorders (U300 1.2% and Lantus 1.0%), mostly due to reports in the T2DM studies (U300 1.3%; Lantus 1.2%). All patients experiencing serious cardiac TEAEs had pre-existing, significant event related pathology, none of the events were considered as related to the IMP or NIMP by the Investigator.

At the cut-off date of 29 October 2013, SAEs were reported during the ongoing extension periods of studies  EFC11628  (n=  68  patients),  EFC11629  (n=30  patients),  EFC12347  (n=11  patients)  and EFC12456 (n=12 patients). In the Japanese studies, SAEs were reported for 14 patients in EFC12449 (Japan, T1DM), and 14 patients in EFC12512 (Japan, T2DM).

No serious TEAEs were reported during the Phase 1 program.

During the main 6-month study periods in the Phase 3 studies, serious TEAEs with fatal outcome were reported by a comparable percentage of patients in the U300 (5/1546, 0.3%) and Lantus (3/1550, 0.2%) groups. In the studies in T1DM, the only TEAE with fatal outcome was reported in 1/304 (0.3%) patient in the U300 group (sudden death, coronary artery disease, chest pain). In the studies in T2DM, TEAEs with fatal outcome were reported in 4/1242 (0.3%) patients in the U300 group and 3/1246 (0.2%) patients in the Lantus group. Causes of death in the U300 group included bronchogenic carcinoma, possible myocardial infarction, sudden death in the course of coronary artery disease, and worsening  of  atherosclerotic  heart  disease.  In  the  Lantus  group  the  reported  fatal  TEAEs  were recurrent  depression  and  drug  overdose  (benzodiazepines),  judged  to  be  a  suicide,  concomitant

<div style=\"page-break-after: always\"></div>

worsening of chronic heart failure (NYHA IV), chronic kidney failure and decompensated diabetes, and exacerbation of chronic pyelonephritis.

Adverse events with fatal outcome were reported after treatment discontinuation in the 6-month study period in 2 patients in the U300 group, both in study EFC11628 (fatal septic thrombosis; fatal pulmonary embolism after total knee replacement).

None of the serious TEAEs with fatal outcome were considered related to the IMP or non-IMP.

At the time of the cut-off for the 6-month study reports, 2 deaths were reported in the extension periods, one in the Lantus group (acute cardiopulmonary arrest) and one in the U300 group (acute myocardial infarction). The event with fatal outcome in the U300 group was considered related to the IMP and non-IMP (metformin).

No TEAEs with fatal outcome were reported in the Phase 1 studies, in the Phase 2 study and during the 3-month administration substudy periods of the EFC11628 and EFC11629 studies.

As of the dossier cut-off date of 29 October 2013, 4 patients had died in the ongoing safety extension periods  of  the  Phase  3  studies.  Causes  of  death  were  bronchopneumonia,  myocardial  infarction, oesophageal adenocarcinoma stage IV and liver cancer. None of these 4 deaths were considered related to IMP by the Investigator.

## Laboratory findings

Laboratory tests and vital signs did not reveal new or unexpected safety issues. Body weight increased more with Lantus than with U300, despite higher insulin use in the U300 group.

Table 20 - Change in body weight during 6 months on-treatment period (Assessor's table)

| kg   |   U300 |   Lantus |
|------|--------|----------|
| T1DM |   0.46 |     1.02 |
| T2DM |   0.52 |     0.79 |

<div style=\"page-break-after: always\"></div>

## Safety in special populations

The results of the subgroup analyses (age group, gender, race, ethnicity, baseline BMI categories, baseline eGFR categories, and hepatic disease ongoing at baseline) for common TEAEs were generally consistent with those for the overall population in the T1DM and T2DM pools.

For the age group ≥65 to &lt;75 years, the incidence of common TEAEs was similar in both treatment groups.  For  the  age  group  ≥75  years,  interpretation  was  limited  because  of  the  low  number  of patients in this subgroup; however, no safety signal was detected.

## Immunological events

At baseline, a similar percentage of U300 and Lantus patients were positive for AIAs in T1DM (61.7% U300 and 53.6% Lantus) as well as T2DM (41.6% U300 and 37.7% Lantus). Throughout the main 6-month  treatment  period,  the  percentage  of  AIA-positive  patients  slightly  increased  in  T1DM patients, in both the U300 and Lantus groups, and remained similar in all T2DM patients. Among the AIA-positive patients, the percentage of those with antibodies cross-reacting with human insulin was similar between treatment groups for T1DM and T2DM. No major differences over time or between treatment groups were observed for antibody titer.

Percentages of patients with any TEAE tended to be higher for AIA-positive than negative patients in both, T1DM and T2DM, although the low denominator in the T1DM AIA-negative groups has to be taken into consideration. In T1DM, 50.9% of U300 and 48.3% of Lantus treated AIA-negative patients had any TEAE, compared with 65% of U300 and 61.3% of Lantus AIA-positive patients. Similarly in T2DM, in both, U300 and Lantus groups, the percentages of patients reporting any TEAEs was higher in the AIA-positive groups (U300 43.1%; Lantus 40.3%) compared with the AIA-negative groups (U300 36.6%; Lantus 35.5%), with no single event contributing to the larger number of patients with events. There was no difference in the percentages of patients reporting any TEAE in the high titer and low titer groups.

Hypoglycaemia  events,  injection  site  reactions  and  hypersensitivity  reactions  were  reported  by similar percentages of AIA-positive and AIA-negative patients in T1DM and T2DM.

These data suggest that there is no difference in the insulin antibody response and in the clinical effects associated with the insulin antibody formation in the U300 and Lantus groups.

## Discontinuation due to adverse events

The percentage of patients with TEAEs leading to treatment discontinuation was low and comparable between treatment groups overall (U300 1.4% and Lantus 1.2%), and in the studies in T1DM (U300 1.3% and Lantus 1.0%) and T2DM (U300 1.4% and Lantus 1.3%). The pattern of TEAEs leading to discontinuation was similar in the U300 and Lantus groups, with no single event driving the results in either treatment group.

## Post marketing experience

U300 has not been marketed in any country.

The efficacy and safety of insulin glargine as 100 U/mL has been shown in more than 200 000 patients with T1DM or T2DM included in clinical trials and observational studies. The benefit/risk profile of insulin glargine as 100 U/mL is well-established.

## 2.6.1. Discussion on clinical safety

Acknowledging the vast experience with Lantus, and the similarities between Lantus and U300, the Applicant's approach to focus the safety evaluation on the differences between U100 and U300 was considered appropriate by CHMP. These would include the effects of the different PK/PD, which could

<div style=\"page-break-after: always\"></div>

lead to hypoglycaemia. On the other hand, local effects, including different immunogenicity, could be important. Accordingly, no new investigations on interactions were performed, which is acceptable. The documented exposure is sufficient, both in comparison to the guideline (ICH-E1) and taking into account the experience with Lantus. In the initial submission, the safety database included 1544 patients exposed to U300, of whom 100 for at least 1 year. The extension phases were finalised by September 2014 and the safety data from the extensions of the T2DM trials were submitted during the procedure and included additionally 1011 patients exposed to U300 for at least 1 year.   No safety concerns did arise from these data. Data for EFC12456 study (T1DM) were not yet available, and will be provided post-approval.

Hypoglycaemia rates with U300 were not higher than with Lantus. Most subjects who use Lantus have an evening injection. When this is compared to an injection with a similar amount of U300, this results for U300 in lower basal insulin levels during the night and higher basal insulin levels during the day. Accordingly,  for  U300  nocturnal  hypoglycaemia  events  were  somewhat  lower  and  daytime hypoglycaemia  events  were  higher  in  some  categories,  especially  in  combination  with  mealtime insulin. Most differences were small. The Applicant showed that mealtime insulin in combination with basal insulin contributes significantly to the increase in the number of daytime hypoglycaemia events. This was especially obvious in T1DM, with more hypoglycaemias in the U300 group. In T2DM the differences in hypoglycaemia were in favour of U300. CHMP agreed with the Applicant that mealtime insulin doses could have been further optimised, in particular in T1DM patients. The review of 'all hypoglycaemias' showed that, in the T1DM population, hypoglycaemia was reported by almost all patients.  This  is  in  line  with  data  from  other  studies  in  this  population.  Somewhat  more  severe hypoglycaemia events were reported with Lantus than with HOE901-U300. However, numbers are very small and thus no firm conclusions can be drawn. TEAEs were reported in 62.8% and 58.9% of U300 and Lantus treated patients respectively in T1DM studies, and in 57.3% and 53.7% of patients, respectively in T2DM studies. 5.1% of the U300 treated patients and 4.1% of the Lantus patients had an event of severe intensity; the most frequent in both groups being hypoglycaemia. A causal relation between events like nasopharyngitis (the most frequent AE) and PK/PD of insulin seems implausible. Rather, the difference between Lantus and U300 groups may be related to the open label design of the trials.

No safety signal was detected from the analysis of AEs of special interest, including injection site reactions,  hypersensitivity  reactions  and  cardiovascular  safety.  Also  analyses  of  serious  adverse events, deaths and discontinuations were unremarkable. The PK/PD data, however, evoked some concern  regarding  long-term  safety  with  regards  to  injection  site  reactions.  The  Applicant  has provided  adequate  data  explaining  the  apparent  difference  in  systemic  exposure.  These  data  in combination with the clinical safety data support keeping the current recommendation in the SmPC for rotation of the injection site.

Laboratory  tests  and  vital  signs  did  not  reveal  new  or  unexpected  safety  issues.  Body  weight increased more with Lantus than with U300, despite higher insulin use in the U300 group.

There is no difference in the insulin antibody response and in the clinical effects associated with the insulin antibody formation in the U300 and Lantus groups.

Based on the similarity between U300 and Lantus, no new analyses of interactions are deemed relevant.

## 2.6.2. Conclusions on the clinical safety

The safety profile of U300 is largely similar to that of Lantus and acceptable. Compared to Lantus the more stable basal insulin levels may lead to a reduction in hypoglycaemias in some situations.

<div style=\"page-break-after: always\"></div>

## 2.7. Pharmacovigilance

## Detailed description of the pharmacovigilance system

The Applicant has submitted a signed Summary of the MAH's Pharmacovigilance System (version 2.0, dated 12 June 2014). Provided that the Pharmacovigilance System Master File fully complies with the new legal requirements as set out in the Commission Implementing Regulation and as detailed in the GVP module, the CHMP considers the Summary acceptable.

## 2.8. Risk Management Plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 4.5 is acceptable. The PRAC advice is attached.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 4.5 with the following content:

## Safety concerns

Table 2.1 Summary of the Safety Concerns

| Summary of safety concerns   |                                                                                                                                                                                                                                                                                                                                                                                                       |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Hypoglycaemia Medication errors (insulin mix-ups) Injection site reactions Hypersensitivity reactions                                                                                                                                                                                                                                                                                                 |
| Important potential risks    | Malignancies Antigenicity Medication error (inappropriate dose injected, following needle blocked in absence of compliance with instructions for use) Medication error (unnecessary re-calculation of the units needed) Medication error (inappropriate use, ie, extraction of insulin from the pen using a syringe) Medication error (switching between 100U/mL and 300U/mL without dose adjustment) |
| Missing information          | Use in pregnancy (U300 only) Use in paediatric population (U300 only)                                                                                                                                                                                                                                                                                                                                 |

## Pharmacovigilance plan

Table 2.2: Ongoing and planned studies in the PhV development plan

<div style=\"page-break-after: always\"></div>

| Study/activity Type,titleand category (1-3)        | Objectives                                                                                                                 | Safety concerns addressed          | Status                    | Date for submissionof interimorfinal reports   |
|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|------------------------------------|---------------------------|------------------------------------------------|
| PASS:UKSoloStar Differentiation Study (Category 3) | Toevaluatetheeaseof differentiating betweenSoloStar pens containing different types ofinsulinwiththecurrentand new labels. | Medication errors (insulin mix-up) | Planned start 02-Feb-2015 | Final study report planned08-Jun-2015          |

PASS:Postauthorizationsafetystudy;UK:UnitedKingdom

*Category 1 are imposed activities considered key to the benefit risk of the product.

Category 2 are specific obligations

Category 3 are required additional PhV activity (to address specific safety concerns or to measure effectiveness of risk minimisation measures)

The PRAC, having considered the data submitted, was of the opinion that the proposed post-authorisation PhV development plan is sufficient to identify and characterise the risks of the product.

The PRAC also considered that routine PhV is sufficient to monitor the effectiveness of the risk minimisation measures.

## Risk minimisation measures

Table 2.4: Summary table of Risk Minimisation Measures

| Safety concern                     | Routine risk minimization activities                                                                                                                                                                                                                                                              | Additional risk minimization activities   |
|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| Important identified risks         | Important identified risks                                                                                                                                                                                                                                                                        | Important identified risks                |
| Hypoglycaemia                      | SmPC, package leaflet, prescription only medicine.                                                                                                                                                                                                                                                | None                                      |
| Medication errors (insulin mix-up) | SmPC, package leaflet/instructions for use, packaging, prescription only medicine. One single trade name per concentration available on the market at the same time: Lantus is the trade name for U100; Toujeo is the trade name for U300. High level of differentiation in colors and packaging. | None                                      |
| Injection site reactions           | SmPC, package leaflet, prescription only medicine.                                                                                                                                                                                                                                                | None                                      |
| Hypersensitivity reactions         | SmPC, package leaflet, prescription only medicine.                                                                                                                                                                                                                                                | None                                      |
| Important potential risks          | Important potential risks                                                                                                                                                                                                                                                                         | Important potential risks                 |
| Malignancies                       | Prescription only medicine.                                                                                                                                                                                                                                                                       | None                                      |
| Antigenicity                       | SmPC, package leaflet, prescription only medicine.                                                                                                                                                                                                                                                | None                                      |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                               | Routine risk minimization activities                                                                                                                                                                                                                              | Additional risk minimization activities                                                                                                      |
|------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Medication error (inappropriate dose injected, following needle blocked in absence of compliance with instructions for use). | SmPC, package leaflet/instructions for use, packaging, prescription only medicine.                                                                                                                                                                                | None                                                                                                                                         |
| Medication error (unnecessary re-calculation of the units needed)                                                            | SmPC, package leaflet/instructions for use, prescription only medicine.                                                                                                                                                                                           | None                                                                                                                                         |
| Medication error (inappropriate use, ie, extraction of insulin from the pen using a syringe)                                 | SmPC, package leaflet/instructions for use, prescription only medicine.                                                                                                                                                                                           | None                                                                                                                                         |
| Medication error (switching between 100U/mL and 300U/mL without dose adjustment)                                             | SmPC, package leaflet, prescription only medicine. One single trade name per concentration available on the market at the same time: Lantus is the trade name for U100; Toujeo is the trade name for U300. High level of differentiation in colors and packaging. | Before Toujeo launch: HCP educational material: HCP brochure Patient educational material: Patient brochure to patients treated with Toujeo. |
| Missing information                                                                                                          | Missing information                                                                                                                                                                                                                                               | Missing information                                                                                                                          |
| Use in pregnancy (U300 only)                                                                                                 | SmPC, package leaflet, prescription only medicine.                                                                                                                                                                                                                | None                                                                                                                                         |
| Use in paediatric population (U300 only)                                                                                     | SmPC, package leaflet, prescription only medicine.                                                                                                                                                                                                                | None                                                                                                                                         |

SmPC: Summary of Product Characteristics

The  PRAC,  having  considered  the  data  submitted,  was  of  the  opinion  that  the  proposed  risk minimisation  measures  are  sufficient  to  minimise  the  risks  of  the  product  in  the  proposed indication(s).

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 3. Benefit-Risk Balance

## Benefits

<div style=\"page-break-after: always\"></div>

## Beneficial effects

U300 in Toujeo is a new strength/potency of insulin glargine. It was proposed in a line extension to insulin glargine 100 U/mL (Optisulin). It has the same composition as the commercial formulation of insulin glargine 100 U/mL (Lantus, Optisulin) except for adjustment of 3 times the amount of active pharmaceutical ingredient and corresponding zinc content. The efficacy and safety of insulin glargine are well established.

Insulin glargine has the same metabolism after SC injection regardless of its source. However, the U300 and U100 formulations are not bio-equivalent. The difference between U300 and Lantus (U100) comes only from the PK/PD profiles of the 2 formulations as shown in the Phase 1 PK/PD clamp studies,  which  showed  a  flatter  and  more  prolonged  (up  to  36  hours)  profile  of  the  insulin concentration and glucose lowering activity of U300 compared with Lantus at the same doses. With this time-action profile, U300 was expected to provide a more constant 24-hour basal insulin supply when compared to Lantus).

<!-- image -->

*Glucoseinfusionrate

Figure 10 - TDR11626 - 36-hour mean smoothed glucose infusion rate profiles at steady state for 0.4 U/kg Lantus (dotted line) and 0.4 U/kg U300 (solid line)

Efficacy of U300 was investigated in studies including a broad range of adult patients with T1DM and T2DM using different established anti-hyperglycaemic treatment approaches, including basal insulin in combination with mealtime insulin or basal insulin in combination with non-insulin AHA in patients with T2DM.

Non-inferiority of U300 over Lantus on HbA1c change from baseline was shown in all Phase 3 studies with the upper bounds of the 95% CI below 0.185% which was well below the pre-specified margin of 0.4%.

The secondary endpoint of nocturnal severe and/or confirmed hypoglycaemia (SMPG ≤3.9 mmol/L (70 mg/dL)) during the night was in general similar between groups in T1DM and the 3 studies in T2DM, however, the percentages were lower in the U300 groups compared with the Lantus groups reaching statistical significance in the studies in insulin pre-treated patients with risk reductions of 21% (study EFC11628: 36.1 vs 46.1%) and 23% (study EFC11629: 21.6 vs 27.9%).

Data from the extension phases in the T2DM trials (12 months) showed that the effect on HbA1c is maintained over the 12 month period with only modest increase in insulin dose. The effect of U300 remains  comparable  to  that  of  Lantus  but  with  a  lower  rate  of  hypoglycaemia  (and  especially nocturnal hypoglycaemia) in insulin-experienced patients.

## Uncertainty in the knowledge about the beneficial effects

Exploratory data in 3 months extensions show that occasional deviations from precise 24hour dosing is expected to be safe. The trial was relatively short and no power calculation was provided, making the findings uncertain. On theoretical grounds, occasional flexibility is expected to be safe.

<div style=\"page-break-after: always\"></div>

Due to the higher concentration, the volume to be injected is smaller, which may be less painful.

## Risks

## Unfavourable effects

The safety evaluation was based on 1544 patients exposed to U300, of whom 100 were exposed for at least 1 year. The analysis focused on hypoglycaemias and injection site issues, which is appropriate given the large similarities to Lantus.

In  comparison to Lantus, hypoglycaemias occurred somewhat less frequently in most categories investigated.

U300 was well tolerated and had a general safety profile, including injection site reactions, similar to the well-established safety profile of Lantus. The evaluation of systemic hypersensitivity reactions and AIAs suggest an immunogenic potential similar to Lantus.

Data  on  immunogenicity  at  12  months  was  provided  with  the  submission  of  the  data  from  the extension phases for the pivotal T2DM studies that were finalised by September 2014. Antibodies against insulin were detected in similar proportions of patients in U300 and Lantus groups at 12 months.

In all pharmacokinetic studies U300 was administered subcutaneously by injection in the periumbilical area of the abdomen. The SmPC recommends injection in the abdomen wall, the deltoid or the thigh. Data  from  the  clinical  phase  3  studies  was  provided  which  support  keeping  the  current recommendation in the SmPC for rotation of the injection site.

## Uncertainty in the knowledge about the unfavourable effects

In order to obtain a similar effect on HbA1c, 10-18% higher doses of U300 than Lantus were given. The difference in dose between U300 and Lantus is consistent with the 17% lower 24-hour exposure of -U300 compared with Lantus at fixed, equal daily doses (0.4 U/kg) in steady-state conditions in the PK/PD study TDR11626.

The different pharmacokinetic and pharmacodynamic profiles of insulin glargine from Lantus and U300 are due to different absorption rates from the subcutaneous precipitate, the mechanism behind this difference remains unclear. Considering the lower systemic exposure also at steady state, it may be assumed that a higher proportion of U300 is either retained or degraded within the subcutaneous tissue which may be exposed to higher insulin levels than with Lantus. The Applicant has, however, provided adequate data explaining the apparent difference in systemic exposure.

In their discussion, the Applicant suggested that mealtime insulin doses as used by the participants in the trial were not optimal, based on patterns of hypoglycaemia, variability of glucose measurements and possibly increase in total use of insulin.  Data indeed suggest that mealtime insulin contributes to the incidence of hypoglycaemia. The difference between U300 and Lantus is especially obvious in T1DM,  with  more  hypoglycaemias  in  the  U300  group,  whereas  in  T2DM  the  differences  in hypoglycaemia were in favour of U300.

<div style=\"page-break-after: always\"></div>

## Benefit-risk balance

## Importance of favourable and unfavourable effects

In  many  aspects  U300  is  similar  to  Lantus.  There  is  extensive  experience  with  Lantus  and  the benefit/risk  of  Lantus  is  well-established.  The  similarity  with  Lantus  strongly  supported  the benefit/risk assessment.

The PK/PD differences, resulting in a flatter basal insulin curve, could be considered a theoretical advantage. However, the clinical trials did not show major clinical advantages of this flatter profile.  In some patients, however,  a reduction in hypoglycaemias may be important, and thus a  valuable additional therapeutic option.

The reduction in injection volume could be of importance especially for patients who require large amounts of insulin. However, the limitation to 80 units per injection requires these patients to use still more than one injection, to some extent negating the most obvious advantage.

The average increased dose of insulin up to 18% is a theoretical disadvantage when a switch is made from  100  U/ml  (Lantus)  to  U300.  It  is  consistent  with  the  lower  systemic  exposure.  It  has consequences for patients who switch from U300 to 100 U/ml insulin glargine as a dose reduction of 20% with subsequent titration may be needed. The extended residence time of U300 insulin glargine did not result in clinically relevant differences in anti-insulin antibody titers.

Although the pre-specified non-inferiority margin of 0.4% is considered as too wide the actual upper limit was 0.185%, which is well below the more desired margin of 0.3%.

U300  is  not  simply  interchangeable  with  other  long-acting  insulins,  including  100  U/ml  insulin glargine. Importantly, when switching between insulin glargine 100 U/ml and U300, different doses may be needed to achieve target ranges for plasma glucose levels giving rise to a potential risk of medication error. This risk is addressed both in advice given in the SmPC and as an additional risk minimisation measure in the form of educational material (brochure) for health care professional and patient.

## Benefit-risk balance

The benefit-risk balance of insulin glargine 300 U/ml is positive.

## Discussion on the benefit-risk balance

Insulin glargine U300 has flatter PK/PD characteristics than Lantus and is not bioequivalent with insulin glargine 100 U/ml necessitating adaptation of the dose when a switch is made. After dose titration U300 has demonstrated comparable efficacy, safety and tolerability to Lantus in a broad population  of  patients  with  T1DM  and  T2DM  with  different  pre-treatment  regimens  and  dose requirements of insulin.

For T2DM there was a reduced risk for hypoglycaemia. In T1DM the only advantage is the reduction in injection volume. For patients who require more than 80 units of basal insulin, the volume but not the number of injections can be reduced.

## Conclusion

The overall B/R of Toujeo, insulin glargine 300 units/ml solution for injection in a pre-filled pen is positive.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Final Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the risk/benefit balance of Toujeo 300 units/ml in the treatment of diabetes mellitus in adults is favourable and therefore recommends the granting of the extension of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

## Conditions and requirements of the Marketing Authorisation

## · Periodic Safety Update Reports

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) ) provided for under Article 107c(7) of Directive 2001/83/EC and  published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The MAH shall perform the required  pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.

## · Additional risk minimisation measures

Prior to launch of Toujeo 300 units/ml in each Member State the Marketing Authorisation Holder (MAH) must agree the content and format of the educational programme, including communication media, distribution modalities, and any other aspects, with the National Competent Authority.

The  MAH  shall  ensure  that  in  each  Member  State  where  Toujeo  300  units/ml  is  marketed,  all healthcare professionals (HCPs) who are expected to prescribe or dispense Toujeo 300 units/ml, as well as all patients or their carers who are expected to use Toujeo 300 units/ml, are provided with educational material to address the risk(s) of Medication error (switching between 100 units/ml and 300 units/ml without dose adjustment).

The educational materials for healthcare professionals shall contain the following key elements:

- -That insulin glargine 100 units/ml and insulin glargine 300 units/ml (Toujeo 300 units/ml) are not bioequivalent and are therefore not interchangeable without dose adjustment.

<div style=\"page-break-after: always\"></div>

- -That dose adjustment is needed when patients are switched from one to the other strength:
- -After titration, on average a 10-18% higher basal insulin dose are needed to achieve target ranges for plasma glucose levels when using the 300 units/ml formulation compared to the 100 units/ml formulation.
- -Switching from the 300 units/ml to the 100 units/ml concentration results in an increased risk of hypoglycaemic events, mainly in the first week after the switch. To reduce the risk of hypoglycaemia, patients who are changing their basal insulin regimen from an insulin regimen with once daily Toujeo 300 units/ml (insulin glargine 300 units/ml) to a once daily regimen with insulin glargine 100 units/ml should reduce their dose by 20%;
- -When switching from a treatment regimen with an intermediate or long-acting insulin product to a regimen with Toujeo 300 units/ml, a change of the dose of the basal insulin may be required and the concomitant anti-hyperglycaemic treatment may need to be adjusted. Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter;
- -Patients need to be instructed that insulin glargine 100 units/ml products and Toujeo 300 units/ml are not interchangeable and dose adjustments need to be made;
- -Blood glucose monitoring by patients is needed during the switch and the initial weeks thereafter;
- -Reporting of medication errors or any side effects.

The educational material for patients and/or carers to address the risk(s) of Medication error (switching between 100 units/ml and 300 units/ml without dose adjustment) shall contain the following key elements:

- -That insulin glargine 100 units/ml and insulin glargine 300 units/ml (Toujeo 300 units/ml) are not bioequivalent and are therefore not interchangeable without dose adjustment.
- -That the switch from one insulin therapy to another should only be done when prescribed by their healthcare provider;
- -That the dose newly recommended by their healthcare provider should always be followed;
- -That blood glucose need to be closely monitored during the switch and the initial weeks thereafter;
- -That they should consult their healthcare provider for further information;
- -Reporting of medication errors or any side effects.

The target audience and the modalities for distribution of all of these materials are to be agreed at Member State Level. The MAH shall agree the final text and the context of the educational material for HCPs and patients together with a communication plan, with the National Competent Authority in each Member State prior to launch of the medicinal product.

In addition, CHMP recommends the variation(s) to the terms of the Marketing Authorisation, concerning the following change:

| Variation requested   | Variation requested                                                                             | Type   | Annex(es) affected   |
|-----------------------|-------------------------------------------------------------------------------------------------|--------|----------------------|
| A.2.a                 | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs | IAin   | I, IIIA, IIIB and A  |

To vary the invented name from Optisulin to Toujeo.